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The processes that regulate Rotavirus replication are not fully understood and the lack of a 
reverse genetic approach represent an obstacle for the investigations in Rotavirus biology.  
Viroplasms are cytoplasmic structures that form soon after infection, and constitute the site 
of virus replication. Structural proteins like the viral RNA-dependent RNA -polymerase 
VP1, the capping enzyme VP3, the scaffolding protein VP2,and the middle layer VP6 
localize in viroplasms; in addition, also the non-structural proteins NSP5 and NSP2 have 
been demonstrated to be essential components for viroplasm formation. Following the 
characterization of the interaction between NSP5 and VP1, we characterized the 
relationships between NSP5 and the structural protein VP2.  
In this work, interaction of NSP5 with VP2 was investigated by coexpression of the two 
proteins in uninfected cells, which resulted in a strong hyperphosphorylation of NSP5 and 
in the formation of viroplasm like structures (VLS). The behaviour of NSP5 in the presence 
of VP2 is very similar to that induced by NSP2 and already described (1), (60). Therefore, 
a comparison between the phosphorylation degree of NSP5 and VLS formation induced 
either by VP2 or by NSP2 was conducted. 
In both cases VLS formation was shown to assemble independently of the phosphorylation 
degree of NSP5, and to recruit the viroplasm-resident proteins VP1. However, VP6 (the 
protein forming the middle layer of the virion) was shown to be recruited only into VLS 
induced by VP2 (VLS(VP2i)), while it  remains organized in tubular structures when 
VLSinduced by NSP2 (VLS(NSP2i)) were formed. Attempts to coimmunoprecipitate NSP5 
and VP2 failed both from infected and co-transfected cells. However, promising 
preliminary results were obtained with a recently isolated monoclonal Ab specific for 
NSP5. 
Altogether, these data showed that two different viral proteins induced the same kind of 
modifications in NSP5, suggesting that these modifications may have a fundamental role 
for virus replication. Moreover, these data suggest that NSP5 plays a key role in 
architectural assembly of viroplasms and in recruitment of the other viroplasmic proteins. 
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1 INTRODUCTION (1) 
 
In the 1960s Rotavirus was discovered in animals, and in 1973 was first described in 
humans, when electron microscopy images reveal its presence in duodenal biopsies of 
children with acute gastroenteritis (19). Subsequently it was recognized as the most 
important cause of severe, dehydrating gastroenteritis in infant and young children 
worldwide. About 600.000 children die every year from Rotavirus, with more than 80% of 
all rotavirus related deaths occurring in resource-poor countries in south Asia and sub-
Saharan Africa. Rotavirus related deaths represent approximately 5% of all deaths in 
children younger than 5 years of age worldwide. Furthermore, recent studies indicate that 
rotavirus causes approximately 39% of childhood diarrhea hospitalizations worldwide. The 
burden of rotavirus infection is not limited to the less-developed countries. Studies from the 
western European found that 50% of cases of gastroenteritis in children younger than 5 
years old that were hospitalized were caused by Rotavirus infection, and, moreover, that 
these infections caused 230 deaths per year. In the United States Rotavirus is estimated 
to cause 20-60 deaths, and 55.000-70.000 hospitalizations per years, with very high health 
and social costs consequences (75). 
According to all these statistical studies on Rotavirus infection, an effective vaccine 
program is necessary. Fortunately, following initials problems with the first attempts to 
develop a vaccine, in 2006 two new Rotavirus vaccine were licensed in the United States, 
the Europe Union and in many countries in Central and South America. The effectiveness 
of these two vaccines is well documented and still under investigation, in particular 
postmarketing surveillance studies are monitoring the impact of vaccine on different 
circulating strains of rotavirus, according to geographic distribution and selection pressure 
(75). 
Rotavirus biology has been extensively studied in these past decades, and some infection 
mecchanisms have been elucidated, however much need to be learned in Rotavirus 
replication. In particular the goal of a reverse genetic system would answer to different 
questions related to rotavirus replication and to the role of different viral proteins during 
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1.1 VIRUS CLASSIFICATION 
Rotavirus is a non-envelope double stranded RNA virus that belong to the family of 
Reoviridae. The term Rotavirus derived from latin word rota, which means wheel, 
according to the distinctive morphologic appearance at electron microscopic analysis (58). 
The viral particle is large (1000 Å) and complex, it consists of three concentric protein 
layers (outer, intermediate, inner layer) surrounding the viral genome of 11 double strand 
RNA segments. The genome segments encode for 6 structural proteins (viral proteins, 
VPs VP1-4, VP6-7), that make up the virus particles, and 5 (or 6, depending on the strain) 
non structural viral proteins (NSPs, NSP1-5, NSP6) (58).  
Rotaviruses are classified according to antigenic specificity. They are classified in groups, 
viruses of the same group share cross-reacting antigens serologically detected using 
monoclonal and polyclonal antibodies against VP6 (intermediate layer protein). Groups A-
E have been clearly identified, two more groups F,G are likely to exist. VP6 mediates also 
subgroups specificity according to the exclusive reactivity of two VP6 specific monoclonal 
antibodies (subgroup I, and subgroup II). 
The structural protein VP7 is the main component of outer layer, and it is associated with 
VP4, a structural protein that forms spikes that emerge from the VP7 shell. This particular 
organization induces neutralizing antibody responses that are the basis for the binary 
classification in serotypes mapping VP4, or VP7, and genotypes by sequence comparison, 
within each group. Serotypes determined by the glycoprotein VP7 are termed G (which 
stands for glycoprotein) and those defined by VP4 are named P (which stands for 
protease-sensitive protein, which is the case for VP4). For VP7 classification, 
neutralization assays and sequencing yeld to concordant results, so viruses are refer to 
their G serotype alone (G1, G2, G3 and so forth). On the contrary, for VP4 classification, 
serotypes do not correspond to genotypes and a dual system for P typing is used. P 
serotype are referred to by their serotype number (P1, P2, P3 ecc) while P genotypes are 
denoted in brackets (P[1], P[2] ecc). P genotyping is the most widely used method, since it 
is difficult to standardize VP4 neutralization assays. Currently, 19G and 24[P] types are 
known.(57, 58, 75). 
Recently, it has been proposed a rotavirus classification system for all the rotavirus genes 
that recognizes phylogenetic relationships and defines genotypes based on percentage 
identity cutoff values for each of the genes, which may have followed separate evolutionary 
paths. Such a classification system could be an important tool to elucidate how rotaviruses 
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evolve over time, to identify reassortment events and gene constellations shared by human 
and animal rotaviruses.(122) 
 
1.2 VIRION STRUCTURE 
The morphology of the complete rotavirus infective particle is peculiar, and by electron 
microscopy analysis it is possible to observe three types of particles in the cytoplasm of 
infected cells. The first type of particle is a triple-layered particle (TLP) that is the complete 
infective particle of about 100 nm in diameter and present a triple-layerd icosahedral 
protein capsid composed of an outer layer, an intermediate layer, and a inner core layer. 
The second type is the double-layered particle (DLP) formed when the outer layer of the 
TLP is missing, while the third type is the single-layered particle (or core) composed only 
by the innermost layer and seen infrequently, it lacks the genome and aggregates in the 
cytoplasm with other single-layerd particles (160) (210). 
A particular characteristic of the virus structure is the presence of 132 large channels that 
extend over the two shells and link the outer surface with the inner core. Three types of 
channels (type I-III) can be distinguished based on their position and size (160). 
The viral genome is packaged inside the inner core together with two viral proteins 
essential for viral transcription and replication: the viral RNA-dependent RNA-polymerase 
VP1 and the capping enzyme VP3 (140).  
Herein a detailed description of virus structure is reported: 
The outermost layer :  the outer layer is mainly composed by the structural protein VP7 
that is uniformly distributed and forms a smooth surface from which sixty spikes of VP4 
hemagglutinin protein extend. VP7 is organized in trimers, with a total number of 780 VP7  
molecules forming the outer shell organized in a T=13l (levo) icosahedral surface. The 
VP4 spikes is multi-domained with a radial length of about 200Å, and extend about 120Å 
from the surface of the virus. It interacts with two molecules of VP7 by extending inwards 
about 80Å into the virion outer layer, and inside it appears that VP4 interacts with six VP6 
molecules that surround type II channel (209). The interaction between VP4-VP7 and VP4-
VP6 implies that VP4 has a relevant role in maintaining the precise geometric organization 
between outer and middle capsids (210) (Fig.1A).  
 
The intermediate layer : VP6 is the only component of the intermediate layer. 760 
molecules of VP6 are arranged in trimers and localized in the local threefold axis of the 
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T=13 icosahedral lattice. VP6 trimers lie below VP7 trimers, so that the aqueous channel 
in the two T=13 layers are in register, and above the inner layer of VP2 (160). The VP6 
molecule has two domains: the distal eight-stranded -sheet domain core makes contact 
with the VP7 layer, and the lower -elical domain that makes contact with the inner VP2 
layer. The interacting surfaces (VP6-VP7 and VP6-VP2) expose the most conserved 
residues of VP6, suggesting that VP6 may play a major role in providing structural integrity 
to the rotavirus capsid. However, the lateral interactions between trimers that form the 
T=13 icosahedral organization, are not sufficient per sè to allow the closed shell. On the 
contrary, VP2 is able to form native like icosahedral shell, suggesting that VP2 layer 
provides a proper scaffold for the assembly of VP6 trimer into a T=13 icosahedral 
organization (210) (Fig.1A). 
 
The innermost layer : the single layerd particle posses a T=1 symmetry and is composed 
of 120 VP2 molecules, arranged in dimers that surround the viral genome. VP2 protein 
interacts with both VP6 of the middle layer and the RNA genome, through the N-terminal 
residues that have RNA binding ability. N-terminal residues of VP2 are also involved in the 
anchoring to the inside surface of the VP2 layer, at the vertices of the icosahedral 
structure, heterodimer of RNA-dependent RNA-polymerase (RdRp) VP1 and capping 
enzyme VP3 (159). The RNA genome is well organized inside the core, as well. In 
particular the 25% of genome made internal dodecahedral structure in which the RNA 
double helices, interact closely with VP2 and are packed around the transcription 
complexes located at the vertices of the icosahedral structure. (Fig1B) (89) 
 
The aqueous channels : in the mature infective particle there are three types of channels 
classified on the basis of positions and size. There are twelve type I channels located in 
the five-fold axes, sixty channels of type II at the six-coordinated position surrounding the 
fivefold axes, and sixty type III channels on the six-coordinated positions around the 
icosahedral three-fold axes. All three channels type are about 140Å in depth, and differ in 
width since type II and III reach 55Å in width at the outer surface of the virus, while type I 
channels are narrower (about 40Å) at the outer surface of the virus. In entering the viral 
particles, these channels constraints before to reach the maximum width, which is close to 
the surface of the inner shell. These channels are involved in importing the metabolites 
required for RNA transcription, and in particular type I channel in exporting the viral mRNA 
transcripts into the cytosol of the cells for subsequent viral replication processes (89). 





Figure 1: Rotavirus structure determined by cryo-EM. A) Cut-away view of the rotavirus TLP showing the outer layer 
(VP7 in yellow and VP4 in red), the middle layer (VP6 in green) and the inner layer (VP2 in blu). B) Cross-section of a 
rotavirus particle. The various protein components are colored as indicated in A). VP1 and VP3, the polymerase and 
mRNA capping enzyme, respectively, are anchored to the inside of the VP2 layer at the five-fold. White arrows show 
where the N-terminal arms of the outer-layer protein, VP7, clamp onto the underlying VP6. surrounding the enzymes VP1 
and VP3 (in red), which (From Chen et al. PNAS 2009). 
 
1.3 GENOME STRUCTURE AND ORGANIZATION 
The viral genome consists of 11 segments of double stranded RNA, that range in size from 
0.7 to 3.1 kB, and is enclosed inside the inner core of the virus. The viral segments are 
thought to be organized in the core with a dodecahedral symmetry: one copy of each 
segment interacts with one replication complex constituted by one molecule of RdRp VP1 
and one of capping enzyme VP3 (159) (49).  
The sequences from different rotavirus strains show common features in the structure of 
each segments (58): 
 Segments are A+U rich (58% to 67%). 
 5’-methylated cap sequences m7GpppG(m)GPy, uncapped minus strand lacking a -
phosphate. 
 An open reading frame (ORF) that encodes the protein product of the gene, flanked 
by untranslated ragions (UTRs). 
 A set of conserved consensus sequences (CS) at the 5’-3’ UTRs.  
 The last four to five nucleotides of the 3’CS[(U)GACC] can function as translation 
enhancer.  
 There is no polyadenylation signal at the 3’-end of the mRNA segments. 
A B
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The 5’ and 3’ UTRs of the 11 genome segments show considerable variation in length and 
sequence, this suggest that they are needed for their own translation and packaging. In 
contrast the UTRs of homologous segments are highly conserved among viruses 
belonging to the same group, in some cases more than the sequence of the ORF (142) 
(144). 
In the case of group A rotavirus, that is the most important in term of human morbidity and 
mortality, the (+)strand RNAs of genome segments typically end with 5’CS, 5’–GGC(U/A)7-
3’, and the 3’CS, 5’-UGUGACC-3’ (49). 
Computer modelling proposed that base-pairing in cis between 5’ and 3’ regions of mRNA, 
leads to the formation of panhandle structure from which the  3’CC extends in an un-paired 
tail (142),(34),(33). This stable structure allows the recognition by the viral RdRp that 
interacts with the 3’-CC and induces the formation of (–) strand initiation complex 
(145),(144). Indeed, the 3’-terminal CC have been shown to be crucial for the formation of 
the initiation complex of RNA replication (30),(32). 
The 3’CS not only includes sequences that promote genome replication but also contains 
a determinant sequence required for efficient translation of rotavirus (+)RNAs. In particular 
the last four nucleotide of 3’CS [(U)GACC] are recognised by a dimer of the non-structural 
protein NSP3 (155),(154), that in turn is recognise by the eukaryotic translation initiation 
factor, eIF4GI (152),(151). This however, has been described below (see page 22). 
Sequences enhancing replication are localized also in the 5’CS of the genome segments 
(145); however attempts to identify 5’-sequences recognised by the RdRp VP1 have been 
unsuccessful. It cannot be excluded that the 5’-recognition signals interact with VP1 or the 
core protein VP2, despite evidences from replication studies that the synthesis of (-)RNA 
depends on the interactions with viral protein of the replicase complex with both ends of 
viral segment (197). (Fig. 2)  
The most interesting, and still obscure, aspect of rotavirus genome organization is related 
to the mechanisms that control replication and packaging of the 11 segments. Indeed the 
11 segments should share similar cis-acting signals to be recognise and replicated by the 
same polymerase; moreover each segment should have a unique sequence signal in 
order to be distinguished from one another during the packaging. The packaging of the 11 
dsRNA segments is mediated by a deep interaction between RNA and viral proteins. The 
viral proteins that participate in the encapsidation of the viral genome are still under 
identification. Obviously an important role is played by VP1, VP3 and VP2, but involvement 
of non-structural proteins is not to excluded (126), (58).  






Figure 2: Schematic representation of a group A rotavirus plus-strand RNA. The conserved sequences at the 5’ 
and 3’ ends are indicated. Both sequences were shown to be essential for the formation of the minus-strand initiation 
complex. They are predicted to stably base-pair forming a panhandle structure. The dinucleotide GG indicated in purple 
is conserved within all groups of rotaviruses and the second G was shown to be essential for specific recognition by the 
polymerase VP1. Another recognition signal for VP1 is at the 3’UTR. Both signals are underlined. The sequence 
indicated in blue is a translation enhancer. 
 
1.4 VIRAL PROTEIN 
Although new functions for the different rotaviral proteins are continuously identified, their 
assignment with the 11 genome segments has been well established. The Rotavirus 
genome encodes for 6 structural proteins, that make up the viral particles, and 6 non-
structural proteins, with exception of some strains that have 5 non-structural proteins, that 
are produced during the infection to maintain infective status.  
The proteins of SA11, a simian strain, have been studied more thoroughly, since it was 
completed first and for this reason it is considered the strain of reference. The migration 
order/pattern of RNA segments could differ among different strain. 
In figure 3 is reported the protein assignment to the different RNA segments of SA11 
strain: RNA segments 1, 2, 3 encode for the core structural proteins VP1, VP2, and VP3; 
segment 6 encodes the middle layer viral protein VP6; segments 4 and 9 produce the 
outer layer proteins VP4, and VP7, respectively. The non-structural proteins NSP1, NSP2, 
NSP3, NSP4, are encoded respectively by segment 5, 8, 7, 10; while segment 11 encodes 














Figure 3: Gel PAGE of the 11 dsRNA 
segments of Roatvirus SA11. Genome 
segments are indicated on the left and the 




Table 1 summerizes and describes all Rotavirus proteins with their functions and 
properties.  
 












(125005) Inner capsid, 5-fold axis
RNA-dependent RNA polymerase ; Part of minimal replication complex ;Virus specific 





Inner capsid structural protein;Non-specific ss & dsRNA-binding activity;





(98120) Inner capsid, 5-fold axis
Guanylyltransferase ;Methyltransferase Basic Protein ;Part of virion transcription 





(86782) Outer capsid spike
VP4 Dimers form outer capsid spike;Interacts with VP6 ;Virus infectivity enhanced by 
trypsin cleavage of VP4 into VP5* and VP8* ;Hemagglutinin;Cell attachment protein 
;P-type neutralization antigen ;VP5* permeabilizes membranes ,Crystal structure of 










Associates with cytoskeleton;Extensive sequence diversity between strains 
Two conserved cysteine-rich zinc-finger motifs;Virus specific 5’-mRNA binding





Major virion protein ;Middle capsid structural protein;Homotrimeric 4o structure 






Homodimer ;Virus-specific 3’- mRNA binding ;Binds eIF4G1 and circularizes mRNA 
on initiation complex;Involved in translational regulation and host shut-off ;Crystal 






Non-specific ssRNA-binding ;Accumulates in viroplasm ;Involved in viroplasm
formation with NSP5 ;NTPase activity ;Helix destabilization activity ;Functional 
octamer ;Binds NSP5 and VP1;Regulates NSP5 autophosphorylation ;Crystal 




[7368) Outer capsid glycoprotein
Outer capsid structural glycoprotein;G-type neutralization antigen ;N-linked high 
mannose glycosylation and trimming ;RER transmembrane protein, cleaved signal 





Enterotoxin ;Receptor for budding of double-layer particle through ER membrane 
RER transmembrane glycoprotein ;Ca++/  Sr++ binding site ;N-linked high mannose 




Interacts with VP2, NSP2 and NSP6;Homomultimerizes;O-linked glycosylation
(Hyper-) Phosphorylated ;Autocatalytic kinase activity  enhanced by NSP2 interaction
Non-specific ssRNA binding 
NSP6 92(11012) Nonstructural Product of second, out-of-frame ORF ;Interacts with NSP5 ;Localizes to viroplasm
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In the follow paragraphs, the viral proteins are described more in detail starting from the 
structural proteins that form the viral particle, in particular from the proteins inside the core 
in contact with the viral genome, towards those forming the middle and the outer layer. 
Subsequently the non-structural proteins are taken in consideration, classified in those 
involved in viral replication and those with different role in viral morphogenesis. 
 
1.4.1 STRUCTURAL PROTEINS 
The core:  
VP1 
VP1 is the viral RNA dependent RNA polymerase encoded by segment 1, and it functions 
as both, the transcriptase for mRNA synthesis, and the replicase for minus-strand RNA 
synthesis to generate genomic dsRNA.  
VP1 crystal structure has been recently resolved, revealing that it is a compact protein of 
about 70 Å in diameter. Three distinct domains were identified: an N-teminal domain (aa 1-
332); a polymerase domain consisting in finger, palm, and thumb subdomains (aa 333-
778) and a C-terminal “bracelet” domain (aa 779-1089) (118) (Fig.4). 
N and C-terminal domains surround most of the polymerase domain creating a sort of 
cage with a large hollow center.  
The polymerase domain has the six canonical motif A-F that are also present in RdRp of 
other viruses like reovirus λ3 (187), bacteriophage φ6 P2 (25), hepatitis C virus NS5B (3). 
The palm subdomain consists of three helices that support the four-stranded antiparallel -
sheet and includes the conserved residues of the active site.  
The finger subdomain comprises one side of the template entry tunnel, and has a three 
dimensional arrangement that is different of that observed for reovirus polymerase λ3. The 
thumb subdomain consist of a -strand followed by three -helices, a loop at the tip of 
thumb interacts with the tip of finger domain enclosing the catalytic site on the palm of the 
polymerase domain, and maintaining VP1 in a closed conformation (118). 
The closed conformation is reinforced by the N-terminal domain that covers one side of the 
active domain, while C-terminal domain is situated around the exit tunnel for the dsRNA 
product of replication and for the minus RNA template of transcription. In particular 
aa1072-1089 form a -helical plug that extend into the template tunnel and reduces its 
diameter, so it is necessary to remove the plug for the exit of dsRNA (118). 




Figure 4: Structure of the RdRp VP1. A)Ribbon diagram of the entire polypeptide chain. B) The fingers, palm, and 
thumb subdomains of the polymerase in blue, red, and green, respectively. C)The N-terminal domain is in yellow. D) the 
C-terminal bracelet domain, in pink; the C-terminal plug, in cyan. (118) 
 
VP1 polymerase (separated by gradient centrifugation from the other components of open 
cores VP2 and VP3), when incubated alone with plus strand RNA does not show any 
replicase activity, indicating that the enzyme alone is an inactive form of the viral RdRp. 
However, when VP1 is incubated with (+)RNA and the core protein VP2, the synthesis of 
dsRNA activity takes place, proving that VP2 induces the conversion to the active form of 
VP1 (136). The ratio between VP1 and VP2 is also critical to obtain the maximal replicase 
activity. Stoichiometric analysis have demonstrated that the optimal ratio VP1:VP2 is 1:10 
which is the ratio present at the vertices of rotavirus core. This suggests that not only the 
presence of VP2 is required to have an active polymerase but also that VP1 has to be 
collocated into a precise structure that is the pentamer unit of the core (141).  
Electrophoretic mobility shift assays have shown that VP1 has a strong affinity for viral 
(+)RNAs due to the recognition of sequence signals located near the 3-end of RNAs.  
According to these assays it has been proposed a multistep interaction between the 
polymerase and (+)strand RNA: VP1 recognises the UGUGA sequence at 3’CS of (+)RNA 
in a VP2-independent manner, then VP1/+RNA complex interacts with VP2, (involving its 
N-terminal domain) that induces a conformational change on VP1 leading to the interaction 
with 3’CC portion to form the initiation complex. This model however does not take in 
consideration the requirement of VP2 also during the elongation step of (-)RNA synthesis. 
In addition, VP1 also interacts with other protein and in particular with the virus non-
structural protein NSP5 and NSP2. (see NSP5 paragraph, page 25) 
B DC
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Interaction with NSP2 has been demonstrated by co-immunoprecipitation assays from 
infected and trancfected cells (96). 
 
VP3 
VP3 is the structural protein encoded by genome segment 3. It is the minor component of 
the virion core, there are 11-12 molecules per particle, and several studies provided 
evidences that VP3 is the viral guanylyltransferase, responsible for the capping of viral 
mRNAs. The protein has the intrinsic ability to bind GTP molecule in the absence of other 
viral proteins (31). Moreover, it has been demonstrated that VP3 has specific ability to bind 
ssRNA but no dsRNA, and also its 5’ capping activity was also shown to be non specific 
(138). VP3 interacts with the N-terminal of VP2 together with VP1 and the RNA segment, 
and is an essential components of trascriptase complex, but not of the replicase one, since 
baculovirus expressed core like particles composed only by VP1 and VP2, still possess 
replicase activity (141). 
In addition to the capping function, VP3 seems to have another distinct role in the 
formation of replication intermediates, revealed by the analysis of mutants with a ts lesion 
in VP3. Thus it is supposed that VP3 would increase the rate of VP1-VP2 complexes 
assembly into replicase particles (201),(141). 
 
VP2 
The structural protein VP2 is the main component of the inner core of the virus. The core is 
made up by 120 copies of VP2, with two molecules of VP2, named VP2A and VP2B, in the 
icosaedral asymmetric unit. A recent CryoEM analysis for the identification of secondary 
structures revealed the presence of 28 distinct -helices and four -sheet, where the -
helices are well distributed in the structure, while three of the four -sheet are located in 
the lower part of the protein. VP2 shares common features in secondary structure with 
other viral inner core proteins like blutoungue VP3 (95). One characteristic feature of 
Rotavirus VP2 is helix 1, located at the the N-terminus, that is not present among other 
reovirus inner capsid proteins, and that extends towards the fivefold vertex and crosses 
over to an adjacent VP2 molecule. At the end of helix 1, another helix (helix 0) can be 
seen to cross underneath VP2, towards the fivefold vertex where it may interact with the 
transcription enzyme complex. However the resolution of this analysis does not permit to 
assign the helix to one or the other molecule of the dimer. Moreover interaction between 
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VP2 and VP6 layer has been resolved. Since there is a symmetry mismatch between VP2 
and VP6 layers, different interactions between VP6 trimers and VP2 dimers have been 
described. In particular, the VP6 trimer that surround type I channel near the fivefold axes 
contacts the apical domain of both VP2A and VP2B; the VP6 trimer located at the 
threefold axes and near to type three channel makes contact only with VP2B; and other 
three VP6 trimers that surround the type II channels contact VP2A and/or VP2B. All these 
interactions strongly stabilize the double layer particle (112) (Fig.5). 
 
Figure 5: VP2 pentamer (A) VP2A (pink) and VP2B 
(light green) subunits in the icosahedral asymmetric unit 
are shown. The VP6 trimers that sit atop VP2 subunits 
are indicated by triangles. The VP6 residues, as 
deduced from fitting of the VP6 crystal structure, that 
interact with VP2 








By analsysis of baculovirus-expressed recombinant proteins, it has been demonstrated 
that N-terminus of VP2 is required for the binding of VP1 and VP3, however, the synthesis 
of rotavirus dsRNA in vitro is sufficiently supported by particles formed by VP1 and VP2 
(141). The N-terminal domain of VP2, contains also the RNA-binding domain and binds 
ssRNA more efficiently than dsRNA. This difference would have an important role during 
transcription, allowing the dsRNA genome able to move and to be read from VP1. 
Moreover, the low affinity of VP2 for dsRNA reveals that VP2 does not have a dominant 
role in the packaging of viral genome and involvement of other viral protein occurs (105). 
The VP2 N-terminal domain has also a structural role (as already describe): it contains the 
-helix1 that stabilizes the VP2 dimer allowing the pentamer organization (112).  
A weak interaction between VP2 and NSP5 has been reported in both mammalian infected 
cells and in transfected insect cells (18). The description of the interaction between NSP5 
and VP2 will be discussed in this thesis. 
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The middle layer:  
VP6 
VP6 is the most abundant protein of the viral particle. It is the main constituent of the 
intermediate layer of the triple layerd particle, in particular 780 molecules of VP6, 
organized in trimers surround the VP2 core with a icosahedral symmetry. VP6 integrates 
two principal functions of the virus: cell entry and transcription since it interacts with both, 
the components of the outer layer and with VP2, the core of the virus.  
VP6 has two domains: an eight-stranded -sheet domain that interacts with VP7 layer, and 
a cluster of -helices that make contacts with the inner VP2 layer. The trimers of VP6 
interact laterally to form the icosahedral structure and this contacts involved charged 
residues. The interacting surface with the other components of the triple layer particle 
involves conserved residues of VP6, the contacts with VP2 and VP7 involves principally 
hydrophobic residues. Although VP6 have the capacity to form trimers, stabilized by a Zn 
ion, it does not have the information to organize the different trimers into a closed shell. 
Indeed, when expressed alone VP6 easily forms helical tubes in the cytosol. So, the 
correct assembly of the middle layer is driven by the core, since VP2 alone has all the 
information to form native icosahedral shell around which VP6 trimers organize (Fig.5) 
(89).  
Earlier biochemical studies revealed that none of the component of the DLPs are able to 
transcribe alone the viral genome, and that VP6, althought does not have any enzymatic 
activity, is essential for endogenous transcription. This hypothesis was confirmed using 
mutants, with an extra charge in the VP6-VP2 interface, that does not rescue the 
transcriptase activity of the reconstituted DLPs (29). Moreover, it has been observed that 
interfering with the conformational changes near the VP6-VP2 interface using monoclonal 
antibody (MAb) against VP6, affects viral transcription (192). A conserved -hairpin motif 
of VP6 extends inside a type I channel, used by the newly transcribed mRNA to exit the 
DLPs, and may play a role in the translocation of the mRNA. This suggests that the 
dynamics of VP6 itself and in the VP2-interface have an important role in mRNA viral 
transcription. 
During rotavirus replication, VP6 is found in viroplasms, that are electrondense structures 
that form soon after infection and are the putative site of viral replication and core 
assembly. VP6 has active role in virus assembly, probably through the interaction with 
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NSP4, which may facilitate association to core particles, to form DLPs, during the exit of 
core particles from viroplasm (117).  
The outer layer: 
 VP7 
VP7 is the main component of the outermost layer of rotavirus particles. It is a glycoprotein 
of about 38 KDa, that forms a smooth capsid where VP4 spikes associate. The shell has 
760 copies of VP7 organized in 260 trimers with an icosahedral symmetry. The trimers are 
stabilized by two Ca2+ ions, bound at each subunit interface. The core of each subunit 
folds into two compact domains, a Rossmann fold domain (domain I) and a jelly-roll  
sandwich (domain II), with disordered N and C-terminal arms. The arms extend away from 
the compact core; the N-terminal arm moves towards the centre along the surface of VP6 
subunit, so that the three arms of the VP7 trimer grip the VP6 trimer (Fig.1), and it is also 
involved intra-trimer contacts. The C-terminal arm of one subunit interacts with its 
counterpart of the other subunit, but most of its contacts appear to be within its trimer of 
origin (4, 35).  
VP7 is involved in the entry of the virus into the cell by modulating VP4 rearrangements 
during attachment and penetration of the viral particle. While the appropriate levels of 
calcium help in maintaining the structural integrity of the VP7 layer, low calcium 
concentrations trigger VP7 conformational changes and subsequent dissociation of VP7 
trimers (51). Since VP7 shell stably locks the spikes in the assembled virion, VP7 trimers 
dissociation would precede VP5* rearrangements, in order to promote virus penetration 
into the host cell . 
According to measurement by cryo-microscopy the VP4 spikes located inwards the type II 
channels, have a diameter of 70Å, that fits more with the diameter of type II channel at the 
surface of VP6 layer (78Å) respect to that of VP7 layer (54-58Å). This suggest that, during 
the assembly of the virus, the spikes should first anchor to the VP6 layer about at the type 
II channel and then VP7 trimers would subsequently arrange above VP6 trimers to form 
stable triple layer particle (112). 
VP7 has been identify as the viral protein that interacts with integrins. In particular, after 
the initial binding mediated by VP4 with sialic acid and integrin 21, VP7 is prompted to 
interacts with X2 and v3 integrins, and mediates the entry of the virus probably 
through an endocytic pathway (73). The low calcium concentration inside the endocytes 
may favour VP7 trimer dissociation and subsequent uncoating of TLPs to release DLPs. 
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During Rotavirus infection VP7 is localized in the ER where the virus morphogenesis is 
completed. It is found in the transient enveloped particle that the DLPs acquire in the 
budding process into the ER, together with NSP4 and VP4 (117). Silencing of VP7 induces 
accumulation of enveloped particles in the ER, a phenotype similar to depletion of calcium, 
suggesting that in order to displace the transient membrane surrounding the DLP, VP7 
needs to trimerize (123). 
 
VP4 
VP4 is encoded by segment 4, and is one of the two constituents of the outermost layer. It 
has an important role in virus attachment and entry into the host cell. Association of two or 
three, molecules of VP4 forms spikes that protrude from the smooth VP7 shell, and are 
located at the level of type II channels.  
VP4 spikes are characterized by a globular domain that forms the head of the spike, and a 
central domain that forms the central body of the spike. Moreover, the spikes are anchored 
to a globular base that has been demonstrated to be part of VP4, and is linked to the 
central bodies with an elongated bridging domain (158). 
In order to induce the attachment and penetration into the host cell VP4 needs to be 
cleaved by trypsin. The cleavage products are the globular domain (VP8*) that is involved 
in virus attachment, and the central body (VP5*) that is thought to mediate cellular 
penetration. Both the cleavage products remain associated to the viral particles.  
Recently cryo-EM analysis gave evidence that spikes have both dimeric and trimeric 
structures. 
VP5* is a well-ordered homotrimer with a C-terminal -helical triple coiled-coil, and a N-
terminal globular domain. Each globular domain packs in a groove between the -helices 
of the other two subunits. The globular domain of VP5* have a core of eight stranded anti-
parallel -sandwich, with two functional important -hairpin: one stabilizes the globular 
structure, while the other is involved in the rotavirus binding to the 21 integrins (52). 
VP8* is the head of VP4 protein, and is attached to the central body by about 25 amino 
acidic residues non structurally defined. However, hydrophobic interaction between VP5* 
and VP8* are present, as well. The central structural feature of VP8* domain is an 11-
stranded anti-parallel -sandwich formed from a five-stranded -sheet, and a six-stranded 
-sheet with an interrupted top strand. The domain contained other structural elements 
like: intersheet loop containing a short -helix, a longer -helix at the c-terminus, and a -
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ribbon. All these elements with a dense hydrophobic core between major structural 
elements suggest a rigid structure that does not undergo structural rearrangements during 
virus entry. Between the two -sheets lies the sialic acid bindig site, since rotavirus have a 
sialic acid-dependent mechanism to enter the host cell (53). 
The spikes extend inward into the type II channels making contacts with VP7 trimers , and 
are anchored to the globular base located between the VP7 and VP6 layers. The base 
present a strong threefold symmetry with both -helices and -sheets secondary 
structures, and make symmetrical contacts with three trimers of VP6 (112). 
Image reconstruction from electron cryomicroscopy of rotavirus particle have provided 
evidence that VP4 is subjected to a series of rearrangements, upon trypsin treatment, that 
allow the entry of the virus into the host cell. Before the processing by trypsin, the spikes 
are flexible structure visible by cryo-EM. Following trypsinization VP4 spikes are stabilized 
inducing a disorder-to-order transition, not shown for other viruses. The hypothesis is that, 
following trypsinization, they assume a dimeric appearance leaving the third subunit 
flexible, which, following an unknown triggering event, folds back to the dimer forming the 
trimeric structure and promoting cell membrane penetration and virus entry. VP8* is 












Figure 6: Structure of VP4 spike. A) Fitted VP8* and VP5*-t secondary structures are shown in the cryoEM density 
map of one of the dimeric subunits of the VP4 spike. The polypeptide chain is colored from the N (blue) to C (red) 
terminus. (112). B) Models of two VP4 conformations. (a)Two subunits form the spike visible in electron cryomicroscopy 
image reconstructions of trypsin-primed virions. A third subunit is flexible. VP8* is gray, the VP5* antigen domain is green 
bean-shape, with a red membrane interaction region and a yellow GH loop, the foot is blue, as is a protruding region that 
rearranges into the coiled-coil. Following trypsinization two of three spike dimerize living the third subunit flexible. (b)The 
putative post-membrane penetration state. Unknown trigger events induce VP8* released; the yellow parts of each 
subunit have joined in a -annulus; the -helical triple coiled-coil has zipped up; and the VP5* antigen domain has folded 
back. The models were produced by Digizyme, Inc. (211) 
After the initial contact, which is mediated by VP8*, a second interaction with integrin 21 
occurs. This interaction is mediated by the integrin binding motif DGE present in the -
hairpin motif in the globular core of the VP5*. Moreover, VP5* is likely to be involved in 
binding to integrins 41 and 47 through its peptide sequence YGL (72, 74). Additional 
interactions in a post-attachment step, involving also VP7, occur and bind heat shock 
protein 70 (Hsc70) and other integrins v3 and x2 (76). 
The role of VP4 during viral morphogenesis remains unclear. VP4 has been found at the 
plasma membrane associated to microtubules, and also detected in filamentous arrays. 
Infected cells treated with siRNA against gene4 still form viral particles, suggesting that 
VP4 is not essential for virus assembly or release of DLPs from the ER. More interestingly, 
the use of siRNA against gene 4 allowed to detect two different pools of newly synthetized 
VP4 inside the infected cells: one pool that rapidly associates with rafts at the plasma 
membrane and a second that associated with viral particle at the ER (45). 
Within VP4 and in particular the N-terminal VP8* cleavage product, it has been identified a 
conserved TNFR-associated factor (TRAF) binding motif, that permits to bind TRAFs, a 
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ligands of Tumor Necrosis factor (TNF), and NF-B transcription factor . This permit VP4 to 
direct NF-B activation and the cellular response to viral invasion (106). 
 
1.4.2 NON-STRUCTURAL PROTEINS 
Essential role in virus replication cycle: 
NSP2 
NSP2 is protein of about 35KDa encoded by segment 8 of SA11 Rotavirus genome. 
Crystallographic analysis showed that the monomer consists of two domains, and it is 
organized in tetramer, that self-interact head-to-head to form a donut-shaped octamer with 
a central hole of about 35Å and deep grooves lined by basic residues at the periphery. 
NSP2 octamer possesses multiple activities: it binds ssRNA non-specifically and 
cooperatively, it has helix-destabilizing activity that is Mg2+ and ATP-independent (190); it 
has an associated Mg2+-dependent nucleoside-triphosphate phosphoidrolase (NTPase) 
activity and hydrolizes all four NTPs to NDP and Pi (188). Interestingly the NTPase activity 
of NSP2 is associated to NSP2 phoshorylation transiently expresses in vivo. Since no 
phosphorylated NSP2 is found in infected cells, the phosphate group generated from 
hydrolysis of NTPs would rapidly transferred from NSP2 to another viral protein or 
removed by cellular phospahatases (191). The NSP2 monomer has two distinct domains 
(C-terminal, N-terminal domain) separated by a deep cleft involved in the biding and 
hydrolysis of NTPs. The C-terminal domain has a prominent twisted anti-parallel -sheet 
flanked by -helices that exhibits a HIT (histidine triad)-like motif, that is common among 
nucleotidyl hydrolases (90). In NSP2 the three histidine and a cluster of basic residues at 
the base of the cleft are probably involved in NTP binding and hydrolysis. In particular 
H225 was proposed as the catalytic residue of NSP2 since mutants H225A failed to 
promote dsRNA synthesis, without affecting viroplasm formation and the octameric 
structure of NSP2. This suggests that the triposphate activity is localized in the HIT motif 
and is involved in viral genome replication (104) (189) (Fig 7). 




Figure 7: NSP2 octamer. A) and B), ribbon representation of the NSP2 octamer superimposed on a space-filling model. 
The 25-Å-deep cleft between the C- and N-terminal domains of one NSP2 monomer (green) oriented along 4-fold (A) 
and 2-fold (B) axes is indicated. Three histidines and a cluster basic residues at the base of the cleft are probably 
involved in NTP binding and hydrolisis.(200) 
The N-terminal domain of NSP2 is mainly composed of -helices and it is possible to 
distinguish two sub-domains separated by a 24-residues basic loop. This loop lines the 
grooves that form on the surface of the octamer and, based to the concentration of 
charged residues at this level, they are supposed to be the site of ssRNA binding (191). At 
the same time, the loop exposed the electropositive residues at the entrance of the cleft 
that contains the HIT-like motif. The close proximity of grooves and clefts, allows the 5’-
triphosphate end of the ssRNA, bound to the groove, to accommodate in the cleft where 
the HIT-like motif directs the cleavage of the - phosphoanhyidride bond at the 5’end of 
ssRNA. Thus, NSP2 protein shows an additional activity that is the RNA triphosphatase 
activity (RTPase) that utilizes the same HIT-like motif of the NTPase activity producing 
indistinguishable phosphorylated intermediates (200). 
The binding of ssRNA, the helix-destabilizing activity, and the NTPase activity suggest that 
NSP2 might function as a motor that uses the energy derived from NTP hydrolysis to drive 
rotavirus dsRNA replication and packaging. In fact, in vivo complementation experiments 
revealed that the synthesis of dsRNA does not proceed without the hydrolysis of NTPs, 
despite formation of viroplasms. Thus, once the sub-cellular sites for replication and virus 
assembly form, NTPase activity of NSP2 takes place. It is been proposed that binding of 
nucleic to the cleft of the protein induces a structural rearrangements of NSP2 octameric 
structure, from a relaxed conformation to a more compact one, involving the ssRNA 
binding groove that allows the interaction with the 5’-phosphate of mRNA, switching from 
NTPase to RTPase activity, and  to initiate of viral replication (189),(200). 
The localization of NSP2 in viroplasms, where the replication and the packaging take 
place, is not surprising since it accumulates in a environment that contains the substrates 
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for both NTPase and RTPase activities. In particular, in the presence of RNA substrates, 
as in viroplasms, the RTPase activity would be anticipated inducing the switch from 
NTPase to RTPase that is an activity directly link with genome replication, traslocation and 
packaging. Early studies demonstrated the interaction of NSP2 with the viral RdRp VP1, 
VP2 and with partially replicated RNA, suggesting the active role of this protein in viral 
replication. This was further confirmed using siRNA specific for NSP2, that causes a 
complete inhibition in viroplasms formation, viral protein production and viral genome 
replication (180). 
Interestingly, experiments preformed in transfected cells, revelead that NSP2 interacts with 
NSP5, leading to the formation of structures that resemble viroplasms of infected cells, 
named viroplasms like structures (VLS) where both proteins co-localize (60). This 
interaction has been demonstrated also with co-immunoprecipitation assays from both 
infected and co-trasfected cells. Moreover NSP2 has been demonstrated to induce NSP5 
hyperphosphorylation, however VLS formation and NSP5 hyperphosphorylation appear 
not related events (1). However, part of this aspect is discussed in this thesis. 
NSP5 
NSP5 is encoded by the segment 11 of Rotavirus genome. It is a protein of 196-198aa 
with a high content of serine (21%) and threonine (4.5%). The protein is produced soon 
after the viral infection and initially was described as a protein of 26 kDa. Further studies 
showed that it is subjected to different post-translational modifications that involved both 
O-glicosylation and hyperphosphorylation, that, following Western blot analysis, is possible 
to separate into different isoform with two main bands at 26 and 28 kDa and a series of 
higher molecular weight bands spanning from 30 to 34 kDa. 
Cytoplasmic O-glycosylation occurs by the addition of O-linked monosaccharide residues 
of N-acetylgluocosamine (O-GlcNAc) to serine or threonine residues of cytoplasmic or 
nuclear proteins. In particular O-GlcNAc of NSP5 occurs in both the 26 and 28 kDa forms 
of the protein, since N-acetylglucosaminitol was released from both isoforms following -
elimination (67). The higher molecular weight isoforms showed almost no glycosylation. 
Indeed, in infected cells both the isoforms are labelled with [3H]glucosamine that is 
released upon -elimination, indicating that the 26 kDa isoform is not the first product of 
gene 11, and the protein is subjected to O-GlcNAc soon after its translation. This suggests 
that the O-Glcycosilation event would protect NSP5 from degradation and, since NSP5 is 
subjected to phosphorylation, it could also regulate the phosphorylation events (67).  
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The hyperphosphorilation events, involving NSP5, are not well clarified and still under 
investigation. Western blot analysis of extracts of infected cells treated with phospatases 
shows a disappearance of the higher molecular weight bands and the accumulation of the 
band at 26 kDa, confirming that the isoforms at higher molecular weight are due to 
hyperphosphorylation events during Rotavirus infection (2). 
However the band at 26 kDa is still phosphorylated indicating that some of the 
phosphorylation sites are resistant to phosphatase treatment. The phosphorylation 
involved residues of serine and threonine as demonstrated by partial acid hydrolysis of 
NSP5 and a two-dimensional thin-layer electrophoresis of the obtained phospho-
aminoacid (2). (Fig.8) 
 
 
Figure 8: Hyperphosphorylation of NSP5 induced by NSP2. Anti-NSP5 Western immunoblot of cellular extracts of 
MA104 cellstransfected with pT7v-NSP5 or co-transfected with pT7v-NSP5 and pT7v-NSP2, as indicated. Where 
indicated, k-Ppase treatment of the extract was performed beforePAGE. Open and closed arrowheads indicate the NSP5 
26 kDa precursor and phosphorylated forms, respectively (1). 
NSP5 is able to multimerize, and the multimerization involved the C-terminal domain of the 
protein that have a predicted -helical structure, since NSP5 deletion mutants lacking the 
last 10aa, or the last 18aa, are not able to multimerize (195).  
Several studies report that NSP5 has a low level of autokinase activity (56), that in any 
case is not sufficient to produce the higher molecular weight isoforms of the protein. In 
particular, a Mg2+-dependent triphosphatase activity of NSP5 has been identified and the 
N-terminal or C-terminal, or both, of NSP5 influence this activity. The triphospatase activity 
lead to the formation of -Pi products that could be released as free -Pi, or used to 
produce low-level of autophosphorylated protein as detected by in vitro phosphorylation 
assays in the presence of [-32P] ATP (2), (12). These data suggest that other viral and/or 
cellular protein as phosphatases or kinases, would be necessary to obtain the 
hyperphosphorylated form of NSP5. 
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The NSP5 hyperphosphorylation has been proposed to be up-regulated by NSP2, an 
hypothesis supported by different observations: the in vivo hyperphosphorylation of NSP5 
when it is co-expressed with NSP2 in uninfected cells (1); and the in vitro 
hyperphosphorylation when purified recombinant NSP5 and NSP2 are incubated in a 
phosphorylation assay. Moreover, it has been demonstrated a physical interaction 
between NSP5 and NSP2 by co-immunoprecipitation assays from both infected and co-
trasfected cells. This interaction involves the N-terminal region of NSP5, and it is 
reinforced when both proteins are bound to RNA. This is suggested by UV treatment 
experiments, that allows RNA to crosslink to NSP2 (96) conferring a conformation that 
facilitate the interaction with NSP5 (1).  
Recent studies have proved that NSP5 dimerized (in particular residues 66-188 are 
sufficient to drive the dimerization) and four dimers are able to interact with one NSP2 
octamer, near the grooves, to form a stable complex detectable by cryoelectron 
microscopy (91). The mechanism that drive the hyperphosphorylation of NSP5 mediated 
by NSP2 is not known. One possibility is that the interaction between the two proteins 
induce conformational changes in NSP5 dimer that induce the activation of its (auto)-
kinase activity. Alternatively, the fact that the dimer binds the groove of the NSP2 octamer, 
near its catalytic cleft, raised the hypothesis that the NTPase/NDP kinase activities of 
NSP2 could provide the phosphate moieties for NSP5 low (auto)-phophorilation (195) 
(202). This, however was not shown to be the case since NSP2 mutants that are NTPase 
defective induce NSP5 hyperphosphorylation (28). 
Attempts to map the regions involved in the hyperphosphorylation of NSP5 led to the 
identification of Ser67 as the residue responsible for initiation event of 
hyperphosphorylation. In particular, phosphorylation of this residue, more likely due to a 
cellular kinase, is the first step of a hierarchical process that leads to NSP5 
hyperphosphorylation. Moreover it has been observed that Ser67 is localized in a 
consensus region for casein kinase I  (CK1) phosphorylation. Indeed, in vitro 
phosphorylation assays with recombinant CK1, show phosphorylation of NSP5 wt, but no 
phosphorylation for a mutant NSP5, in which Ser 67 in mutated into Ala. (54). 
The involvement of cellular CK1 in NSP5 hyperphosphorylation has been investigated 
using a small interference RNA specific for CKI. In particular the role of this kinase has 
been studied in the contest of the infection and co-expression of NSP5 and NSP2. In  both 
cases, silencing of CK1 affected NSP5 hyperphosphorylation (26). 
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NSP5 has shown to be localized in viroplasms during rotavirus infection. More 
interestingly, recombinant NSP5 expressed in cells together with NSP2 induce the 
formation of particular structures resembling viroplasm of infected cells and for this reason 
called viroplasm like structure VLS (60). NSP5 and NSP2 have been found co-localized 
into VLS, and, although the interactions between NSP566-188 and NSP2 has been 
characterized, the arrangements of the complex NSP5 dimer-NSP2 octamer to form VLS 
have not been identified, probably due to the lacking of NSP5 C-terminal region. However, 
it is has been proposed that C-terminal region of NSP5 in one NSP5-NSP2 complex may 
operate as a multimerizing domain, interacting with the C-terminal region of another NSP5-
NSP2 complex. Since other reports show that also the N-terminal domain of NSP5 is 
involved (127), it is possible that a multi-step mechanism involving different regions of 
NSP5 controls NSP2-NSP5  interaction within VLS (195).(Fig 9)  
 
Figure 9: VLS formation. Confocal immunofluorescence microscopy of cells co-expressing NSP2 and NSP5. (a) MA104 
cells, either infected with rotavirus SA11 or co-transfected with NSP2 and NSP5 as indicated, were reacted 
simultaneously with anti-NSP2 (green) and anti-NSP5 (red). The rightmost panel is a superimposition of the two 
independently acquired images. 
Several evidences showed that hyperphosphorylation of NSP5 is not related to VLS 
formation: i) NSP5 mutants with Ser67 mutated into alanine, that are not phosphorylated 
when expressed with NSP2, still form VLS (54); ii) in vivo inhibition of phosphatases in 
cells transfected with an NSP5 encoding plasmid results in a fully phosphorylated NSP5, 
but not in VLS formation (20) ; iii) an siRNA against CK1, the kinase involved in the 
phosphorylation of serine 67, inhibits NSP5 hyperphosphorylation, but not viroplasm 
formation (26). This observations are presented in results1 of this thesis. 
Silencing the NSP5 expression in infected cells, with specific siRNA, abolishes viroplasms 
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Moreover, knocking down NSP5 in infected cells inhibits the accumulation of other viral 
proteins. Indeed the lack of viroplasms, as consequence of silencing NSP5, determines 
the inhibition of the assembly of new DLPs and the production of mRNA as a consequence 
of the secondary transcription. It has also been observed an inhibition of replication, 
revealing the relevant role of NSP5 in viral dsRNA production (27). This role was also 
supported by co-immunoprecipitation assays from infected and trasfected cells that 
showed that NSP5 strongly interacts with viral polymerase VP1. In particular, the last 48aa 
of NSP5 are involved in the interaction with VP1, and since the C-terminal region of NSP5 
is also involved in dimerization, it is possible that a dimeric NSP5 is required for the 
association to VP1, with the binding region located just up-stream of the C-terminal tail. 
Moreover, this interaction is not weakened by the interaction of NSP5 with NSP2, since all 
three protein are co-immunoprecipitated in transfected cells and in particular they co-
localized in VLS (6). On the contrary, VP1 impaired the ability of NSP2 to induce NSP5 
hyperphosphorylation, probably sequestering NSP5, or blocking its conformational 
changing. 
All the information collected about NSP5 features and functions in infected cells, provide 
new highlights to the important role of NSP5 during Rotavirus infection. 
NSP4 
The product of gene 10 is the non-structural protein NSP4, an ER-resident glycosylated 
protein that has been identified as the viral enterotoxin protein (216). The first protein 
product is a 20kDa protein, that upon glycosylation in the ER, becomes a polypepetide of 
about 28kDa.  
NSP4 has two main domain: the N-terminal one that is anchored to the membrane of ER 
with three hydrophobic domains, and the C-terminal region, corresponding to the majority 
of the protein, that is oriented to the cytosol and exhibits all known NSP4 biological 
functions (44). 
NSP4 has been extensively studied for its important role in virus morphogenesis and 
because it was first shown to be an enterotoxin that cause many symptoms of the viral 
infection (216). 
A distinctive feature of NSP4 is its role as a receptor for DLP assembled into the 
viroplasms. About 20aa of the C-terminal region appear important for the binding of DLPs 
and their subsequent budding into the ER lumen (88). The receptor role of NSP4 is 
supported by the lower levels of TLP accumulated in cells treated with siRNA against 
NSP4 (117). 
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However knocking down NSP4 expression not only decreases the formation of triple 
layered particles as expected, but affects other Rotavirus activities: it induces increased 
levels of plus-strand RNAs, suggesting that NSP4 can be hypothesized to act as a 
feedback inhibitor in the infected cell and to signal to the viral transcription system, when 
adequate plus-strand RNAs have been generated to allow productive infection (181). 
Moreover, NSP4 silencing does not affect the synthesis of the other viral proteins, normal 
amount of viral proteins are synthesized, however it induces failure of viroplasms 
maturation since NSP4 silenced cells show small viroplasms. Thus, the effect of the lack of 
NSP4 on viroplasms is not associated to a low amount of viroplasmic proteins, but it is 
likely to a defect on the traslocation of viroplasmic protein to the viroplasms. In particular a 
redistribution of VP2 and VP6 has been observed in NSP4 silenced infected cells: VP2 is 
more diffused in the cytoplasm rather than concentrated around viroplasms, and also VP6, 
is redistributed from viroplasms to fibers. This redistribution is thought to be mediated by 
the interaction of NSP4 C-terminal with VP6. Upon these observations, NSP4 is thought to 
create a cytoplasmic environment that promote the association of the different structural or 
non-structural proteins to form viroplasms (117).  
Besides VP6, NSP4 has been found in oligomeric complexes with VP7 and VP4 in 
enveloped particles. The association of VP4, NSP4, and VP7 may represent sites on the 
endoplasmic reticulum membrane that participate in the budding of the DLPs into the 
lumen of the ER, where maturation to TLPs occurs (120). 
The enterotoxin property of NSP4 has been associated to a 66aa cleavage product of 
NSP4 (NSP4112-175), that is secreted from infected cells early post infection. The trafficking 
pathway that lead to the secretion of NSP4 peptide has been indentified as a nonclassical 
vesicular transport that bypasses the Golgi apparatus and involves the microtubule 
network, since treatment with nocodazole and cytochalasin D, but not with brefaldin A, 
impaired its secretion. The production of the enterotoxin is due to protease activity, 
however the proteases responsible for the cleavage of NSP4 have not been yet identified 
(216). 
The released cleavage product is available to bind to a putative receptor on the 
neighboring secretory cells to trigger the signal pathway that results in diarrhea (11),(131). 
Surface Plasmon resonance (SPR) associated to mass spectrometry identified two distinct 
functional domains on NSP4. In particular the NSP4114-130 domain binds to the MIDAS 
motif on integrin I domain, involved in the binding of divalent cation, and the second 
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region, NSP4131-140, interacts with other un-identified domain of 21 or other surface 
molecules (179). 
NSP4 was also found to be associated with cellular proteins: calnexin, that needs a 
glycosylated form of NSP4 for binding (125); caveolin, that induces destabilization of the 
plasma membrane and promotes secretion of NSP4 peptide (enterotoxin) (124, 134, 185); 
and tubulin that interferes with the transport of vesicles to the plasma membrane (207). 
At least three pools of intracellular NSP4 exist in rotavirus infected cells: 1) NSP4 localized 
in the ER plasma membrane, to drive DLPs internalization into ER; 2) a minor pool in the 
ERGIC compartment that may be recycled back to the ER or use for a non-classical 
secretion of NSP4 peptides into the medium of infected cells; 3) NSP4 distributed in 
cytoplasmic structure associated with autophagosomal marker LC3 and viroplasms. The 
third pool appears in infected cells at 6h post infection, and it has been hypothesize that 
the association LC3 autophagosomes-NSP4 prevents the fusion of autophagosomes with 
lysosomes, which would affect virus replication (17).   
Controversial role in virus replication cycle: 
NSP3 
NSP3 is the product of rotavirus gene 7, and it is a protein of about 35 kDa. Like NSP1, 
NSP3 has been found co-purified in cell-fractions containing cytoscheletal matrix. Indeed 
in IF analysis it has a diffuse to filamentous cytoplasmic distribution .  
Crystallographic analysis revealed that NSP3 is organized in asymmetric homodimers, and 
each monomer is mainly composed of -helices. The N-terminal has three -helices, while 
the C-terminal includes both -helices and -sheet. Although the two monomers are 
identical in their secondary structure composition, they differ for their spatial positioning of 
N- and C-terminal, these lead to an asymmetry of the whole molecule (48). Poncet et al. 
demonstrated that monomers and multimeric species of NSP3 interact with 3’ end of 
rotavirus mRNAs. Enzymatic sequencing of the RNA segments recognised by NSP3 
revealed that the very last sequence UGACC of viral mRNA is the one bound to NSP3. 
Further analysis showed that only the last four nucleotide (GACC) are necessary for NSP3 
recognition of viral mRNAs (155). The structural analysis demonstrated that the RNA 
binding doimain is localized at the N-terminal half of the monomer and in the homodimer 
the N-terminal are arranged in order to form a closed basic tunnel that preclude the 
possible recognition of internal GACC sequences (48). Extensive contacts between the 
two monomers and with the mRNA explain the high stability of the complex RNA-NSP3. 
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The evidences on the role of NSP3 in rotavirus infection were first highlighted with 
experiments of two hybrid screening systems, that identified NSP3 interactions with the 
cellular protein eIF4GI. This observation was also confirmed in vivo during rotavirus 
infection, by co-immunoprecipitation experiments (152).  
eIF4GI is an eukaryotic translation initiation factor that usually interact with the poly-A 
binding protein (PABP), which recognises poly-A cellular mRNAs, and promotes synthesis 
of cellular proteins (110). The eIF4GI/PABP interaction involves the carboxy-terminal 
domain of eIF4GI, the same region involved in interaction with NSP3. Thus, it has been 
proposed that during infection NSP3 interacts with the C-terminal domain of eIF4GI, 
preventing association with PABP therefore affecting the cellular protein synthesis and 
dislocating the translation machinery towards non-polyadenylated viral mRNA (151, 152). 
Initially, the model, that propose NSP3 as a substitute factor for PABP to enhance 
translation of rotaviral mRNAs, while shutting off cellular protein synthesis, was widely 
accepted, supported by different experimental evidences. Even thought the interaction of 
the N-terminal domain of NSP3 with the 3’-end of a viral mRNA and of its C-terminal 
domain with eIF4GI have been clearly established, there are no clear evidences that these 
interactions occur simultaneously inducing circularization of the viral mRNA, favouring its 
translation (as it has been proposed by Piron et al.). In fact, recently observations of cells 
treated with an siRNA specific for NSP3 go against this model. Indeed, the synthesis of 
viral protein is not affected when the expression of NSP3 is knocking down, suggesting 
that binding of NSP3 to the viral mRNA is not necessary for its translation. Moreover, an 
increased level of viral mRNA and dsRNA has been found in NSP3 silenced cells, 
suggesting that, rather than promoting translation, NSP3 binds mRNAs to protect them 
from degradation and/or to keep a pool of mRNA available for translation. This results also 
indicates that it is not required for virus replication. However, the use of siRNA against 
NSP3 did confirm a role for NSP3 in shutting off cell protein synthesis since standard virus 
infected cells have an increased shut off of cellular protein synthesis with respect to cells 
treated with siRNA specific for NSP3. The studies with siRNA specific for NSP3  allow to 
proposed a modified model where the eIF4GF interaction domain and RNA binding 
domain of NSP3 have independent different functions. The binding of eIF4GI is 
responsible for affecting the synthesis of cellular proteins as it has previously suggest, 
while the binding of the RNA might have a role in protecting the mRNA from degradation 
or from VP1 polymerase binding to ensure a pool of mRNA available for translation (128).  
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Non essential for virus replication:  
NSP1 
NSP1 is the product of segment 5, and is 55 kDa protein that accumulates in the 
cytoplasm of infected cells. Among all different rotavirus strains, NSP1 has a conserved 
cystein-rich region and is involved in specific mRNA binding, since mutants lacking this 
region do not conserve this feature.  
The distribution of NSP1 in infected cells is rather diffuse with slightly punctated and 
filamentous pattern consistent with results from cellular fractionation studies, indicating 
that some of the protein is associated to the cytoskeleton. The recruitment of mRNA to the 
cytoskeleton may only require transient interactions of NSP1 with the cytoskeleton and 
thus may explain why significant amounts of this protein are found both in the soluble and 
cytoskeletal fractions of infected cells. A possible role of NSP1 bound to the cytoskeleton 
may be to move mRNAs to the viroplasm where other RNA binding viral proteins 
accumulate to promote viral dsRNA synthesis and formation of new DLPs (82).  
NSP1 is not an essential protein for viral replication, since rotavirus mutants with C-
truncated forms of NSP1 are still able to replicate efficiently in infected cells (143). 
Moreover, infected cells treated with siRNAs against NSP1 actively support rotavirus 
replication (180). However, NSP1 silenced virus has a “very small plaque” phenotype 
suggesting that NSP1 may be involved in modulate cell immune response to viral infection. 
Indeed, it has been demonstrated that NSP1  interacts with Interferon Regulatory Factor 3 
(IRF3) both in vitro and in vivo (70). IRF-3 is a 427-amino-acid transcription factor that is 
constitutively expressed in all cell types. IRF-3 resides latently in the cytoplasm, and upon 
activation is phosphorylated, dimerizes, and translocates to the nucleus, where it 
complexes with transcription coactivators such as CBP/p300 to induce stimulation the of 
interferon (IFN) response genes (10). It has been described that rotavirus NSP1 C-
terminal deletion mutants have the ability to trigger IRF3 translocation to the nucleus and 
the expression of IFN, while Rotavirus with wild type NSP1 suppresses these 
mechanisms, indicating that the primary effect of NSP1 is to antagonize the immune cell 
response. NSP1 suppression of IFN response is not only due to binding IRF3 monomer 
and preventing its dimerization and traslocation, but is an inducer of the proteasome-
dependent degradation of IRF3 (13). Recently, it has been demonstrated that NSP1 
promotes proteasomal degradation of other IRF family members like IRF5 and IRF7, in 
this way NSP1 induce downregulation of proinflammatory cytokines, and type I interferon 
expression respectively (81),(9). However, the regulation of IRF3 amount is virus-strain 
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and cell-type specific (177). NSP1 of the porcine strain OSU is not able to induce 
proteasome-mediated degradation of IRF3, however it affects IFN expression. It has 
been recently demonstrated that OSU NSP1 represses induction of IFN by subverting the 
activation of NFB  transcription factor in MA104 cells. Indeed, it mediates the 
proteasomal degradation of -TrCP, a protein of the SCFTrCP E3 ligase complex, that 
regulates the degradation of IB, that is stabilized and inhibits NFB activation towards 
IFN genes (68). Thus NSP1 represents a broad-spectrum antagonist of immune cells 
response (14). 
It has been proposed a putative function for NSP1 as an E3 ubiquitin-protein ligase, 
according to data on sequence analysis. Indeed, one of the prominent characteristic of 
NSP1 sequence is the conserved Cys-rich region at the N-terminus of the protein. This 
sequence fits with RING finger domains that are present in E3 ubiquitin-protein ligases, 
which promote transfer of ubiquitin, conjugated to enzyme E2, to the specific protein. 
Since it has been identified a proteasome degradation susceptibility of NSP1 that can be 
prevented by unidentified rotavirus protein(s) or viral mRNA, it is speculated that the 
presence of RING finger motif provides a means for self-ubiquitinilation (149). Mechanisms 
by which NSP1 functions in the ubiquitin-dependent proteasome system are still under 
investigation. 
NSP6 
NSP6 is a small protein of about 11kDa encoded by the alternative open reading frame of 
segment 11. It is not clear the function of this protein in the replicative cycle of Rotavirus, 
since in some strains it is not produced. However, it is thought to have a regulatory role 
during the infection. It seems to localize in viroplasms and to interact with the C-terminal 
region of NSP5 to form an heterocomplex. This interaction however, in infected cells has 
not been demonstrated, probably due to the low level of expression of NSP6 during 
infection, but it has been clearly characterized in vitro by two hybrid system and by in vivo 
expression of recombinant NSP5 and NSP6 (195). 
Pulse–chase studies showed that, in contrast to other viral proteins like NSP5 that 
following post-translational modifications are stable, NSP6 has a high rate of turnover with 
the vast majority of the protein synthesized in a 5 h, pulsed with 35S, being degraded after 
a 2 h chase period. Filter binding assays showed that, in common with NSP5 and most of 
the other proteins found in the viroplasm, NSP6 has an affinity for RNA, however it has a 
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broad nucleic acid binding capacity which does not exhibit any detectable sequence 
specificity (163). 
 
1.5 ROTAVIRUS REPLICATIVE CYCLE 
1.5.1 OVERVIEW 
The general features of the rotavirus replicative cycle, based on studies in cultures of 
monkey kidney cells are: 
 Replication of the virus is totally cytoplasmatic; 
 DLPs are transcriptionally active producing mRNAs; 
 Transcripts function both as a source of viral proteins and as template for synthesis 
of (-)strand to form the genomic dsRNA (replication); 
 The replication machinery is totally viral; the cells do not contain enzymes to 
replicate dsRNA. Yet cell proteins could also be involved for instance in viroplasms 
formation; 
 dsRNA synthesis and initial steps of assembly take place in specific cytoplasmic 
structures called viroplasms that formed soon after infection; 
 No dsRNA, nor (-)ssRNA are found in the cytoplasm of infected cells; 
 Subviral particles DLPs form within viroplasms and bud into the ER to complete 
their maturation; 
 Levels of intracellular calcium are important for controlling virus assembly and 
integrity. 
New insight about viral replication are coming from studies in polarized intestinal epithelial 
cells, or polarized differentiated enterocytes. In polarized intestinal cells, virus entry may 
occur mainly through the apical membrane, or even the basolateral one depending on the 
virus strain. In differentiated enterocytes the rotavirus infection alters different functions 
like cellular protein trafficking, cytosckeleton, and tight junctions, and finally the virus is 
released by a non-conventional vesicular transport that does not induce extensive 
cytophathic effect (58). 
Several information collected nowadays lead to draw a general description of rotavirus 
cycle. 
The entry of Rotavirus into the host cell is characterized by different interactions between 
the proteins of the outer layer, VP4 and VP7, with components of the cellular membrane. 
After the entry, Ca2+ concentration in the cytoplasm determine the disassociation of VP7 
 ___________________________________________________________ Introduction (1) 
37 
 
trimers, with the consequent disassembly of the outer layer capsid. The TLPs become 
transcriptionally active DLPs that start producing viral mRNA (primary transcription). The 
mRNA is extruded in the cytoplasm of the cells through type I channels and this has two 
main functions: to be translated to produce viral proteins, and to serve as a template for 
the synthesis of viral dsRNA (virus replication). After a critical amount of viral proteins 
accumulate in the cytosol, some of them are involved in the formation of viroplasms. It is 
within viroplasms that genome replication and new DLPs assembly occur. Newly formed 
DLPs, however, are transcriptionally active (secondary transcription) and produce mRNAs 
for the maintainment of the production of viral protein during the infective cycle. DLPs from 
viroplasms bud into the endoplasmic reticulum through the interaction with NSP4, where 
they acquire a transient envelope subsequently replaced by the assembly of VP7-VP4 
outer layer. TLPs are released either by cell lysis or by a non-classical, Golgi-independent, 
vesicular transport involving interaction with lipid “rafts” near the plasma membrane and in 
this case resulting in extensive cytopathic effect (58). (Fig.10)  
 
 
Figure 10: Schematic rappresentation of Rotavirus replicative cycle. 
 




The initial step of rotavirus infection is the binding of the virus to the membrane of the host 
cell.  
The demonstration that the neuroaminidase (NA) treatment of red blood cells inhibits the 
attachment of Rotavirus on the cell surface indicated that sialic acid (SA) has an important 
role in virus binding. However, studies on rotavirus entry into the host cells reveal that the 
infectivity of many animal and human strains of rotavirus are not affected by the treatment 
with NA, and for this reason were named NA-resistant strains. Nevertheless this does not 
mean that these strains do not need SA to bind to the cell membrane. Indeed some NA–
resistant strains are thought to bind to some internal NA-insensitive SA moieties on 
glycolipids or to modified SA-moieties on oligosaccharide structure on the cell surface (37). 
The SA binding domain is collocated in the VP8* cleavage product of the spike protein 
VP4, in particular between the two -sheet of the -sandwich, similar to that found in 
galectins, a family of sugar-binding proteins. X-ray crystallographic structures of both NA-
sensitive and resistant strain confirm the occurrence of this interaction (53). 
 
1.5.3 PENETRATION AND UNCOATING 
The initial interaction with SA is generally followed by specific interaction with several other 
cell surface molecules as integrins and the heat shock cognate protein hsc70 (116) (5) 
(115) . 
The initial interaction of VP8* with SA moieties is thought to induce conformational 
changes that favour the interaction of the VP5* cleavage product with integrin 21 
through its DGE sequence (73). Subsequently a series of post-attachment interactions that 
involve VP5* and VP7 take place: 
1) VP5* interacts with heat shock cognate protein 70 (hsc70) that could induce a 
conformational changes in the virus particle to help the virus enter the cell (76);  
2) VP7 interacts with V3 and X2 in an early stage of virus interaction (73) (77);  
3) VP5* and VP7 interact with integrins 41 and 47 (72);  
4) Ganglioside GM1 and GM3 have been suggested to play a role as possible 
receptors (79),(166); 
5) infectious particles also associate with lipid rafts on cell membrane during early 
interactions (78),(5) (85); 
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The mechanism by which Rotavirus is internalized in infected cells is still under 
investigation, and till now two different models of viral particles entry have been proposed: 
a) non-classical endocytosis; and b) direct membrane penetration. 
a) Early electron microscopy studies of rotavirus-infected cells suggested 
endocytosis as the virus internalization pathway, and suggested that uncoating 
might occur by the effect of acidification (146). However, rotavirus infectivity is 
not inhibited either by preventing the acidification of endosomes or by drugs that 
block the intracellular traffic of endocytic vesicles . 
However, since the model of a non classical endocytic-mediated entry is not to 
be excluded, it has been proposed that the solubilization of the outer layer would 
occur due to the low Ca2+ concentration within the endocytic particles (40). The 
low Ca2+ concentration would trigger conformational changes in the proteins of 
the outer capsid with their consequent solubilization. It has been observed that 
solubilized outer proteins are able to permeabilize cellular membranes. Thus 
disrupted VP4 and VP7 could permeabilize the vesicle's membrane to release 
the transcriptionally active double-layered particle into the cytosol (170). 
b) On the other hand, different observation support the model of direct penetration 
of the viral particle (94),(132). It has been demonstrated that depletion of 
cholesterol inhibits rotavirus infection and that a functional dynamin, a protein 
associated in processes that involve membrane dynamics, is necessary for 
rotavirus infection. Moreover, it has been recently reported that drugs and 
dominant-negative mutants that are known to impair clathrin- and caveolae-
mediated endocytosis did not affect rotavirus cell infection (171).  
Trypsin has been found associated to the outer capsid of the virus particles, and 
the hypothesis of the direct penetration would explain its role in rotavirus 
infection: VP7 and VP4 cleaved by trypsin would be capable to disrupt 
membranes and allow DLPs to gain access to the cytoplasm to begin the active 
transcription of the viral genome (169). 
Therefore, rotavirus cell entry is a coordinated, multistep process that is not entirely 
elucidated and involves sequential interactions with several ligands. The results of this 
process is the release of transcriptionally active DLPs in the cytosol of infected cells, for 
the initial production of viral mRNA. 
 
 ___________________________________________________________ Introduction (1) 
40 
 
1.5.4 TRANSCRITPION  
The transcription event consists in the production of positive sense RNAs from the dsRNA 
genome. It is possible to distinguish two events of transcription during rotavirus infection: 
primary transcription that occurs soon after the release of DLPs into the cytosol, and the 
secondary transcription performed by the newly synthesized DLPs within viroplasms. 
The trascriptase complex consists of the polymerase VP1 associated to the capping 
enzyme VP3, that is attached to the inner surface of the VP2 layer at the fivefold axes 
(159). None of the viral proteins, by itself, demonstrate transcription activity, so the 
structural integrity of DLPs is necessary for the transcription to occur. TLPs are not 
transcriptionally active, the uncoating is necessary to trigger the transcriptional activity of 
DLPs, an observation supported by both in vitro assays and by liposome-mediated 
transcription of DLPs into cells, that is sufficient to initiate the transcription of viral genome 
(15),(38) . 
In particular the whole process of transcription could be divided in three step: initiation, 
elongation, traslocation of the transcripts. 
In the initiation step, the end of the dsRNA must be partially unwound (the helicase 
responsible of this process has not been identified) and then nucleotide transfer and the 
capping of the transcript occur. Two types of shorter particle-bound capped oligonucleotide 
(5-7 nucleotide in length) result from a brief pause in the transcription before it proceeds to 
the synthesis of full-length transcripts. These shorter oligonucleotides have been found 
associated to both TLP and DLP, in particular that associated to the TLPs become full 
length transcripts only when the outer layer is removed and the TLP is converted to a DLP. 
This indicates that VP7 inhibits the step elongation. Since the same observation was 
obtained when DLPs are coated with a monoclonal Ab anti-VP6, this suggests that both 
mAb anti-VP6 and VP7 confer conformational change in the structural integrity of DLPs 
that prevent elongation of the transcripts (107). The DLP structure has a rigid organization 
to permit the transcription of the viral genome. Indeed, the trascriptase activity results 
impaired if the hydrophobic interaction between VP2 and the layer of VP6 is perturbed, or 
with VP6 mutant that are not able to properly fold with the viral core (29). Since the short 
oligos are formed in the TLPs as well, this indicate that TLP are not transcripionally 
incompetent, and that the site of initiation and capping are closed within the core (108). 
In vitro transcription studies have identified the different enzymatic activities of the 
transcriptase complex: trascriptase, nucleotide phosphohydrolase, guanyltransferase, and 
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methylase. Indeed viral mRNA are capped by the addition of m7GpppGm at the 5’ and do 
not contain poly-A tail. The process of capping proceeds in four step: 
1. Phospho-hydrolysis at the 5’ to remove the orthophosphate of the nascent 
mRNA 
2. Attachment of guanine nucleotide to the 5’end 
3. Attachment of a methyl group to the N7 position of the G cap 
4. Attachment of a second methyl group 
Two of the four enzymatic activities are supported by the VP3 that is the methyl/guanyl 
transferase (31),(114),(138, 153). Since the template is a dsRNA, a helicase activity has 
been thought to be required to unwind the template, but that enzymatic property has so far 
not been demonstrated for any of the viral structural proteins.  
Cryoelectron microscopy of in vitro transcription assays indicates that full-length transcripts 
are released through the type I channel, located at the fivefold axes of the icosahedral 
structure. Several mRNAs are released simultaneously from the same active particles, 
confirming that the transcription of the 11 segments occur simultaneously and in continuos 
(183). The mechanisms that allow repeated cycles of transcription remain unknown (109). 
Viral mRNAs are extruded in the cytoplasm where are engaged by the cellular translation 
machinery to produce viral proteins, but viral mRNAs must also become available as 
templates for the replication of viral genome. This however takes place in viroplasms and 
not in the cytosol. 
 
1.5.5 TRANSLATION 
The viral protein synthesis is supported by the cellular translation machinery, that 
recognise capped and poly-adenilated mRNA. Since the viral mRNA is capped but non-
polyadenilated, it is not recognisable by the poly(A) binding protein (PABP) and collocated 
in the right position of the initiation complex of translation. However the 3’ end of viral 
mRNA presents the most conserved sequence, among all 11 segments, thus proposed 
that is recognised by the non-structural viral protein NSP3 (as describe before in page 32) 
(155).  
Other viral proteins are involved in translation of viral mRNA: VP2 NSP2 and NSP5 
seemed to be involved in inducing the phosphorylation status of the translation factor 
eIF2, inhibiting in this way cellular protein synthesis, silencing the expression of each 
viral protein induce phosphorylation of eIF2 switching on cellular protein synthesis (129).  
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1.5.6 REPLICATION and PACKAGING 
Several studies have defined the steps of viral replication and packaging using replication 
intermediates (RIs) purified from infected cells.  
Kinetic studies revealed that positive and negative strand RNAs are present at 3 hours 
post infection and increasing between 9 and 12 hours, when the maximum level is reached 
(184). 
Electron-dense cytoplasmic inclusions, termed viroplasms, function as sites of genome 
packaging and replication in the infected cell. Since in these structure localize both 
structural viral proteins, found in single shelled particles and DLP (VP1, VP2, VP3, VP6) 
and non-structural proteins NSP2 and NSP5, it is reasonable to assume that these protein 
have a role in virus replication and packaging (64). In vitro studies, however, revealed that 
VP1 and VP2 are the minimal proteins required for replication of mRNA but they are not 
sufficient to drive dsRNA packaging, suggesting the other proteins within viroplasms may 
have this role (141). 
Different studies, both in vitro and in vivo, provide information about the mechanism of 
replication and the role of the different proteins.   
Early analysis of replication intermediate (RI), recovered from infected cells, and revealed 
that the initial step of replication involves the interaction of VP1 and VP3 with (+)RNA to 
form pre-core RIs, and a second step involves the interaction with VP2 core to form core 
RIs that contain the full 11 (+)RNAs . Only the core RIs have replicase activity suggesting 
that the viral polymerase VP1 exists in an inactive form that the interaction with VP2 
converts into an active one (141) (214). This was also confirmed using mutants that 
expressed a defective form of VP2 unable to assemble RIs with replicase activity (121). 
The intermediate layer of VP6 associates with the core RI to form DLP, that maintain the 
capacity to produce dsRNA (139),(64). Treatment of purified RIs with RNAse specific for 
ssRNA destroys their ability to synthesize dsRNA, while the treatment of in vitro replicating 
RIs with RNAase specific for dsRNA does not degrade the dsRNA produced. These 
observation suggest that positive ssRNAs move from the external into the RIs where they 
are replicated and they are protected from dsRNAase degradation (139) (137). Taken 
together all these observations suggest that packaging of (+)strand RNA and its replication 
are two related events that depend on the presence of the core protein VP2. The presence 
of VP2 ensures to gather the dsRNAs into the core, and to protect them from the dsRNA-
dependent immune cell response. It has been observed that the packaging precedes the 
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replication events, and it does not finish before the initiation of replication, suggesting that 
the packaging signal must be present on the (+)RNAs and not in the dsRNA (142) (144). 
NSP5 and NSP2 are components of RIs with replicase activity, and this is not surprising 
since the replication occurs within viroplasm. These proteins are able to bind to RNA and 
to the structural components of the RI (140).  
In vitro replication assays performed with open cores were also a useful tool to study 
Rotavirus replication. Incubation of Rotavirus cores with low ionic strength buffers results 
in the disruption of the cores (open cores) and release of dsRNA . The polymerase of the 
open cores maintains its activity and was highly processive continuing the replication for 
hours, exclusively in the presence of VP2. Indeed, purified VP1 from open cores system 
does not show replicase activity, even incubated with (+)RNA. The open cores system was 
utilized to identify the cis-acting signals in (+)RNA. In particular it has been observed that 
open cores incubated with even small amount of salt have the synthesis of dsRNA 
impaired (32). The sensitivity to salt concentration is associated to the formation of 
initiation complex, since once it is formed, with a preincubation of RIs components without 
salt, the dsRNA synthesis occurs even at high salt concentration. In particular the 
formation of initiation complex required GTP, Mg2+, (+)RNA, VP1, VP2, where the 
presence of Mg2+is essential for the formation of the initiation complex (196). Through this 
method and RNA containing mutantions it has been possible to locate the regions and 
structures of RNA necessary for viral replication. Three region have been found to be 
important: 
 The first signal is the 3’ consensus sequence (3’CS) 5’-UGUGACC-3’. It is a very 
conserved sequence among viruses of the same group, indicating its importance in 
replication. In particular the 5’-UGUGA-3’ sequence seems like to form a 
polymerase recognition signal, while the last two nucleotide CC-3’ are of primary 
importance for initiation of replication. In addition, the 3’CS signal must be single 
strand to function efficiently as replication signal (196). 
 The second region lies upstream the 3’CS at the 3’ UTR of the viral mRNA; and 
seem to have an enhancing role on replication (145).  
 The third region is located at the 5’ UTR and has been demonstrated to stimulate 
RNA replication (197) 
Based on the location of the cis-acting sequences and computer modelling, it is 
hypothesized that the ends of the mRNA would interact in cis to form panhandle structure 
that promote the synthesis of dsRNA. Moreover, the predicted secondary structure present 
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some loop structure at the 3’ and 5’ of the mRNA that different among the 11 segments 
and would have role in packaging and assortment (145, 197),(144).  
Using siRNA specific for different viral proteins, it was possible to characterize the role of 
the different viral proteins in viral replication. Affecting the expression of proteins not 
involved in virus replication, such as NSP1 and VP7, with siRNA against gene 5 and 9, it 
was observed that the synthesis of dsRNA segments was not affected. This confirm the 
presence of two pools of mRNA, one susceptible to siRNA treatment with a cytosolic 
localization and another, used as a tamplate of dsRNA, protected from siRNA recognition, 
more probably localized within viroplasms (180). 
The role of VP1 and VP2 during replication has been widely demonstrated using in vitro 
systems. Additionally, the nonstructural proteins NSP5 and NSP2 have an important role 
in forming viroplasms, but they do not seem to be essential for the replicase activity. They 
might increase or regulate the replication process or have a role in genome packaging.  
Although the role of the enzymatic activities of NSP2 (NTPase, RTPase, NDP kinase) is 
still unclear, it has been proposed that NSP2 acts as a molecular motor providing the 
energy deriving from hydrolysis of NTPs for genome replication and/or packaging and 
maintaining a pool of nucleotides in viroplasms for RNA synthesis and for processes 
requiring ATP (i.e. transcription or RNA packaging). Interestingly, an inhibitory role for 
NSP2 in the formation of the replication initiation complexes has been demonstrated in in 
vitro assays with recombinant VP1 and VP2. In detail, NSP2 was shown to interfere not 
with the binding of VP1 to the template, but with the function of VP2, possibly as a result of 
competition for RNA binding (188),(90) (96). 
The role of NSP5 in viral replication is even more obscure than that of NSP2. Indeed, 
different studies demonstrates the relations of NSP5 with different components of 
replication complex: 
 NSP5 interacts with NSP2 forming VLS in cytoplasm of transfected cells. 
Moreover, it competes with NSP2 in RNA binding, suggesting a regulatory role for 
NSP2-RNA interaction (60), (91). 
 NSP5 interacts with VP2, functions as a physical adapter between NSP2 and VP2 
(18). 
  NSP5 strongly interacts with VP1 both in infected cells and in transfected cells in 
absence of other viral proteins (6). 
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All these observations, linked to the fact the NSP5 is indispensable for viroplasms 
formation, where replication occurs, suggest that, besides a structural role, it would have a 
more regulatory functions during viral replication. 
The genome packaging is a selective mechanisms that lead to the encapsidation of 
equimolar genome segments within the core of the virus. The mechanism is still under 
investigation but different models have been proposed (142): 
 The pre-core precursor complex: based on the characterization of replication 
intermediates the model proposes the organization and assembly of VP2 core 
protein around a nucleation site formed by the RdRp VP1, viral mRNA and VP3.  
 Empty core precursor complex: based on the capacity of the capsid proteins to 
self assemble into VLPs it has been proposed that viral mRNA would be 
inserted in these cores. 
 Encapsidation coincident with capsid assembly: this model is based on 
structural data, in which has been described that each VP1-VP3-mRNA 
complex is associated to a pentamer of VP2. Thus, each pentamer is 
associated to a specific mRNA, interactions between the different mRNAs 
would drive the assembly of the icosahedral structure, and the interaction 
between the different pentamers would confer conformational changes in the 
core lattice that activate the VP1 polymerase. 
Further studies are needed to clarify which model is correct and if and how they may need 
to be modified. In particular none of these model take in concideration the strong 
interaction between NSP5 and VP1 (6). 
 
1.5.7 VIRUS ASSEMBLY AND RELEASE 
The virus morphogenesis is a process still under investigation since it differs from other 
members of Reovirus family, and from other viruses. The particular feature of the 
morphogenesis in Rotavirus system is that subviral particles, formed inside the viroplasm, 
bud through the membrane of the ER, acquiring a transient envelope, that is soon 
replaced by proteins that constitute the outer layer of the mature viral particle. Once the 
TLPs are formed, they are release from the cells with different mechanisms depending on 
cells type (58). 
Both biochemical and morphological data support the idea that viroplasms are the site of 
virus replication and DLPs formation, since several proteins thought to be involved in viral 
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replication (NSP2, NSP5, NSP6) and structural elements of transcriptionally active DLPs 
(VP1, VP2, VP6) are found localized in these structures (140),. Moreover, structural 
protein VP4 was found distributed in the close periphery of viroplasms and outside the ER. 
The first step of virus morphogenesis occurs inside the viroplasms where viral structural 
proteins VP1 and VP3 interact with the 11 segments and pentamers of VP2 to form the 
core of the virus (140),(144). Subsequently, DLPs acquire the intermediate layer of VP6. 
VP6 is known to localize in the viroplasms in a distribution quite similar to that of NSP5 
and NSP2. The assembly of the intermediate layer is thought to occur during the exit of the 
particle from the viroplasms. Since it has been observed that silencing of NSP4 impaired 
DLPs formation and VP6 distribution, it has been hypothesized that NSP4 interacts with 
unassembled VP6 driving its collocation in viroplasms, and consequently the formation of 
DLPs (181),(117). 
Once DLPs are formed, the C-terminal region of NSP4 functions as a intracellular receptor 
on ER membranes and mediates the budding of newly formed DLPs into the ER by 
binding VP6. NSP4 does not need glycosylation to bind the DLPs and interacts with VP4 in 
the cytosolic side and VP7 in the ER lumen to form a heterotrimer with  an unknown 
function (7),(8), (16). 
The last steps of virus morphogenesis occur in the ER. The budding into the ER confers to 
the DLP a transient lipid envelope that is removed by VP7. Although VP4 and NSP4 were 
shown to have membrane destabilizing activity, the main role in removing the transient 
envelope is played by VP7, as demonstrated by siRNA experiments targeting VP7 mRNA. 
(117). It has been shown that this process is dependent on Ca2+ concentration since cells 
treated with thapsigargin or the calcium ionophore A23187, which decrease the Ca2+ 
concentration into the ER, virus morphogenensis is blocked at the stage of the enveloped 
particle (123), (156). VP7 trimer are stabilized by Ca2+ ions binding at the interface of the 
monomers, and trimerization is dependent on Ca2+ concentration (123),(157). Thus, it has 
been proposed that soon after budding of DLPs into the ER, VP7 that is embedded in the 
transiently enveloped layer surrounding DLP together with NSP4, VP4, assembles into 
trimers, with a process that is Ca2+ dependent, excludes the lipid enveloped from the 
virion, and associates with VP6 trimers (117). This model does not rule out that NSP4, as 
well as cellular protein, would be needed in this process (117). 
The  final step of virus morphogenesis is the association of VP4 spikes. Timing and 
location of VP4 assembly in infected cells is controversial. 
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Studies in non-polarized endothelial MA104 cells, suggest that VP4 binds DLPs before or 
during VP7 assembly in the ER. Evidences support the model of VP4 assembly to VP7 
coated cores in the ER: immunoelectron microscopy analysis localizes VP4 in the 
cytoplasm between viroplasms and ER (147), immunofluorescence and biochemical 
analysis reveal VP4 localized in transient enveloped particles together with NSP4 
(66),(120); cells treated with siRNA specific for VP4 accumulate spikeless particles in the 
ER (43),(41).  
On the other hand, using one monoclonal antibody specific for VP4 in polarized intestinal 
epithelial Caco-2 cells, a pool of VP4 was detected in lipid rafts, suggesting the hypothesis 
that, in this cells, VP4 assembles after VP7 while the VP7 coated particle are transported 
from the ER to the cell surface within extrareticular compartments. (46),(42).  
In vitro recoating experiments of DLP with recombinant outer proteins introduced the 
hypothesis that VP4 assembly precedes VP7 assembly in vivo. According to this model 
VP4 transiently oligomerize and bind weakly to the DLP, VP7 goes to Ca2+–dependent 
trimerization and binds DLP tightly, locking VP4 in place. VP7 binding is independent from 
VP4 binding since triple layer spikeless particles are formed in cell treated with a siRNA 
specific of VP4 (198). This model is further supported by recent cryo-EM with 
subnanomolar resolution (112). 
The release of mature viral particles occur with the lysis of non-polarized cell, following 
alteration in the permeability of the plasma membrane of infected cells. Despite cell lysis, 
most DLP ad TLP remain associated with cellular debris, suggesting interaction of the 
particles with some structures within the cells like cytoskeleton or cell membrane lipids 
(58). 
Studies on Caco-2 gave different information about the release of mature viral particles. 
Caco-2 cells are human intestinal epithelial cells established from an adenocarcinoma 
that, after confluence, display many of the morphological and biochemical properties of 
mature enterocytes. These cells display an apical domain with a brush border and 
expression of intestinal hydrolases, and a basolateral domain (150). In this cell line release 
of virus has been demonstrated not to be mediated by cell lysis but by an atypical 
trafficking pathway bypassing the Golgi apparatus, that resembles more what happens in 
the natural rotavirus infection (92). In this mechanism, membrane raft microdomains are 
involved and in particular it has been demonstrated that VP4 is rapidly associated with 
these structures, and serve as a platform for the assembly of VP4 with the rest of the viral 
particle (172). Moreover VP4 located at the apical domain of Caco-2 cells creates 
 ___________________________________________________________ Introduction (1) 
48 
 
interaction with actin bodies, suggesting a role for raft and actin in Rotavirus final assembly 
and apical release (65).  
VP4 associated to rafts microdomain has been found also in non-differentiated kidney 
epithelial cells, MA104. In this cell line siRNA specific for gene4 induce accumulation of 
viral particle into ER and prevent the targeting of TLPs to rafts, suggesting  that in order to 
associate to raft viral particles need VP4 and its assembly with the viral particles occurs in 
the ER (41). Thus association of rotavirus particle into raft is a conserved process present 
in the two different polarized cells studied (45). 
The association of rotavirus particle with lipid raft through VP4, is probably due to the 
galectin-like motive present in VP8* (172). However how the rotavirus particle translocate 
to lipid rafts remain an open question. Evidences suggest that VP7 and NSP4 are possible 
candidates for rafts targeting. However, in cells transfected with siRNA specific for VP7, 
the association with lipid rafts does not result impaired (41). In contrast, in cells treated 
with siRNA specific for NSP4, the association of viral particles with rafts does not occur.  
Indeed NSP4 is involved in different events during virus morphogenesis and release like 
the budding of DLP into ER working as a intracellular receptor (7),(8), (16); the removal of 
the transient enveloped, event that involved the interaction with VP4 (193), and 
interestingly the blockage of the transport of vesicles from the ER-Golgi intermediate 
compartment to the Golgi by NSP4 has been reported (207).  
Generally the assembly of raft occur at the level of the Golgi apparatus, while the viral 
particles reach the apical surface with a non-conventional vesicular transport pathway, so 
it has been investigated at what level the association of lipid rafts with viral particle occurs. 
In the conventional secretion pathway the cargo proteins transit from the ER to the Golgi 
apparatus through a vesicle-mediated transport system that constitutes the so called ER-
Golgi intermediate compartment (ERGIC) and can be visualized by two marker proteins 
usually recycling among ER, ERGIC and Golgi: ERGIC-53 and -COP (207). Increasing 
evidence suggest participation of the ERGIC in rotavirus maturation:  
 NSP4, VP4 and VP7 were all found in ERGIC, since co-localization with ERGIC-53 
has been detected (41).  
 Overexpression of NSP4 in transfected cells as well as natural rotavirus infection 
changes the distribution of ERGIC-53 from a juxtanuclear vesicle-like pattern to a 
more dispersed one (41). 
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Upon these observations, it has then been proposed that at some stages organelles 
containing ERGIC-53 and rotavirus proteins exit the traditional secretory pathway and do 
not reach the cis-Golgi (41). 
The presence of rotavirus particles in ERGIC raises several questions to be addressed in 
future studies to investigate which transport pathways are directly involved in Rotavirus 
maturation and release.  
 
1.6 PATHOGENESIS AND IMMUNITY 
The pathogenesis of rotavirus has been investigate first using animal models. In this way it 
was possible to characterize the virus and to observe virus replication in different tissues in 
order to obtain information about the sites of infection and the immune response against it.  
Rotavirus infection can result in asymptomatic or symptomatic infections and the outcome 
of the infection is affected by both viral and host factors. The most prominent host factor 
that affects the clinical outcome of infection is age: neonates infected with Rotavirus rarely 
have symptomatic desease, due to the transplacental transfer of maternal antibodies. 
Between 3 months and 2 years of age the susceptibility of the infection increases, due to 
the reduced amount of maternal antibodies, causing severe Rotavirus induced desease. 
Rotavirus can also infect adults, but severe disease is uncommon (75). Diarrhea is the 
main clinical manifestation of rotavirus infection in infants and young children. The features 
that distinguish the viral diarreha from bacterial-induced one is that little inflammation or 
lesions are seen in infected intestine. 
The virulence of the virus is multigenic and would be associated with several of the 11 
genes of the genome, like gene 3,4,5,9, and 10, and the basis of the involvement of these 
gene is only partially understood. Through the use of virus reassortants, the correlation 
between virulence and viral protein has been characterized. In particular mutations of 
NSP4 have been associated with altered virus virulence supporting a role of NSP4 in viral 
pathogenesis (215). It has been described that NSP4 acts as an enterotoxin both at intra 
and extracellular level (50),(216). The intracellular expression of NSP4 causes a disruption 
of Ca2+ homeostasis and increase in Ca2+ permeability triggers several intracellular 
process such as disruption of cytoskeleton, inhibition of Na-solute co-transporter system, 
and lack of the expression of enzymes in the apical part of the cells necessary for 
digestion (194). Moreover a cleavage product, corresponding to residues 112 -175 is 
release from infected cells and has a paracrine effect on un-infected cells since it binds to 
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integrins proteins and triggers phospholipase C-inositol 1,3,5-triphosphate cascade that 
cause the release of Ca2+ from the ER (24) (179). 
Concluding disease pathogenesis is due to the virus-mediated destruction of absorptive 
enterocytes, virus-induced down regulation of the expression of absorptive enzymes, and 
alteration of the functional thigh junctions between enterocytes that lead to paracellular 
leakage (75). 
A role of the enteric nervous system (ENS) in  rotavirus diarrhea has been shown using 
drugs that are able to inhibits this pathway and that reveals to attenuate rotavirus induced 
diarrea in mice and children. NSP4 or other factors release from virus-infected cells would 
mediate this effect (119). 
Rotavirus infection is not limited to the intestine. Extraintestinal spread has been 
documented more that 45 years ago when virus was detected in multiple organs of mice. 
The clinical consequences of such systemic infection remains unclear (75). 
Studies on Rotavirus infection in both animals and human first showed the existence of the 
acquired immunity to the recurrent disease and also to a lesser extend re-infection after 
primary infection.  
Studies on mice showed that B cells were the primary determinant of protection from re-
infection after natural infection, whereas CD8+ T cells were responsible to shortening the 
course of primary infection. CD4+ T cells are involved in Rotavirus infection to mediate the 
active protection via interferon -dependent pathway. The regulatory T cells do not appear 
to modulate rotavirus infection, while lymphocyte homing is critical in regulating the 
rotavirus immunity and B cells trafficking to the intestine (75).  
The role of immune response in the rotavirus infected cell and the effect of IFN induced 
antiviral effect has been examined both in vivo and in vitro. Levels of INF type I and II 
increase in rotavirus infected animals and children (204). It has been shown that INF I and 
II are able to inhibit the infection of rotavirus in vitro, and in early studies in pig and cattle 
administration of IFN reduced rotavirus-associated diarrhea . Additionally, in vitro studies 
showed the link of Rotavirus infection to innate immunity, since Rotavirus NSP1 was 
demonstrated to regulate IFN response in infected cell by proteasome degradation of 
interferon regulatory factor 3 (IRF3) and 7 (IRF7), and inducing activation of nuclear factor-
B (68),(14).  
 




Attempts to develop a vaccine against human rotavirus began in the early 1980s. The first 
efforts used a Jennerian approach (in reference to Edward Jenner’s cow-pox vaccine 
against smallpox) and children were vaccinated against rotavirus that normally infect 
animals. An attenuated bovine strain was the first candidate that showed protection of 
calves from subsequent challenge with human rotavirus strain. Despite the high 
effectiveness in preventing diarrhea in Finnish children, it was less effective in African and 
Latin-American children. Thus, because of the failure in clinical trials in Africa this 
candidate was not pursued. Another candidate was a monovalent simian rotavirus strain 
that shows effectiveness in the preliminary trials but in a subsequent study it lost its 
efficacy. This failure was likely due to the differences between the serotypes oh this 
candidate and the  circulating rotavirus strains at that time. To circumvent serological 
problems a tetravalent vaccine, based on reassortant strains with serotypes (G1-G4), was 
developed. This vaccine called, RotaShield was evaluated in different countries and gave 
high results of efficacy. However, cases of intussusceptions occurred after the 
administration of the vaccine and RotaShield was judged not safe for routine use an was 
withdrawn from commercial manufactories (75). 
Recently, in 2006 two new rotavirus vaccines were licensed in USA in Europe and many 
countries in Central and South America: RotaTeq and Rotarix .  
Rotateq is a pentavalent bovine rotavirus strain (WC3)-based vaccine manufactured by 
Merk. In the first trials 70.000 infants were vaccinated and the vaccine showed highly 
efficacy  protection. Moreover the RotaTeq efficacy rates did not appear to be affected by 
breast-feeding and administration of the vaccine did not interfere with immune response 
induced by other vaccine. The important aspect is that no intussusception was associated 
with this vaccine (75). 
Rotarix is a live-attenuated human rotavirus vaccine. It was developed following multiple 
passages of human rotavirus strain in MA104 cells to achieve its attenuation, and the final 
product resulted in a very efficient vaccine. The molecular basis for the attenuation, as for 
the RotaTaq, are not known, but sequence comparison with wild-type parent could identify 
gene changes associated with attenuation. Recent reports showed that Rotarix does not 
interfere with other routine childhood vaccination (75). 
Several third generation vaccines are under development in case these vaccines do not 
overcome safety issues. Several groups are pursuing inactivated virus or recombinant 
virus-like particle approaches. Parental and intranasal immunization with recombinant 
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nonreplicating virus-like particle have been effective in animals and is going to reach 
phase I testing in human being (47). 
Vaccine safety in immunocompromised children are needed to be monitored, case of 
chronic infections occurs in babies with immunodeficiency that receive the vaccine before 
the disorder was diagnosed. (75) 
 
1.8 ROTAVIRUS REVERSE GENETIC 
The lack of a reverse genetic system applicable to Rotavirus, limits the investigation on 
rotavirus biology and on the role of the different viral proteins during infection. As 
described in the previous chapters, the observations collected till now are due to the use of 
different approaches: infection with reassortant viruses or ts mutants; expression of the 
viral proteins, alone or in different combination between each other, into mammalian and 
insect cells; in vitro replication/transcription assays; small interfering RNA (siRNA). In 
particular the last approach was most useful, till now, in order to identify the different 
functions of viral proteins during infection. 
However, the real approach that would revolutionize Rotavirus studies, would be a reverse 
genetic technique. In the past twenty years, especially since the first infectious clone of a 
negative-stranded RNA virus was reported in the mid-1990's, the reverse genetics 
systems have been available for nearly all the major human and animal RNA virus groups. 
There are mainly four external expression systems for construction of the RNA virus 
reverse genetics systems based on the kind of RNA viruses: 
1. in vitro RNA transcripts,  
2. RNA polymerase I-driven expression plasmids,  
3. RNA polymerase II-driven expression plasmids,  
4. modified vaccinia virus/T7 RNA polymerase-driven expression system.  
In particular, the viral nucleoprotein and polymerase proteins are required to assemble the 
viral ribonucleoprotein (RNP) complexes for the rescue of the negative-stranded RNA 
viruses (83). 
For the dsRNA viruses, among the family of Reoviridae, a successful reverse genetic 
approach has been developed for reovirus (10 segments) and bluetongue virus (12 
segments). In particular, for reovirus it has been used a plasmid-based reverse genetic 
approach. Each reovirus segment was engineered downstream to a T7 RNA polymerase 
promoter and a hepatitis delta virus ribozyme fused to the 3’ terminus. Following co-
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infection with an attenuated T7 RNA polymerase recombinant vaccinia virus and 
transfection of the ten plasmid DNAs, transcripts are expressed and, with the activity of the 
ribozyme, processed at the 3’ end generating an authentic viral genome. The virus is 
rescued from plaques. The accuracy of the process was confirmed with the identification of 
silent point mutations opportunely inserted into one of the segments (101).  
The original system applied to Bluetongue virus (BTV) is different, since it is based on the 
transfection of in vitro synthesized viral RNA transcripts. Two different approaches have 
been developed: mixture of authentic viral transcripts derived from DLPs and T7 
transcripts; or a complete set of T7 transcripts. These approaches take advantage on the 
discovery that the BTV transcripts are infectious once transfected on permissive cells (23). 
The recovery of authentic recombinant BTV was verified with the identification of 
mutantions opportunely inserted (22).  
Concerning Rotavirus a first approach of reverse genetic was developed by Taniguchi and 
involves transfectionof DNA plasmid encoding one segment under the contro of the T7 
polymerase and rybozime at the 3’end followed by infection with a recombinant vaccinia 
virus expressing T7 RNA polymerase and superinfection with a helper virus. In particular it 
was used a plasmid, encoding the sequence of VP4 a mAb with strong neutralizing activity 
against the helper virus P serotype. After several passages in the presence of the strong 
selective pressure of the mAb a recombinant rotavirus was obtained. However, this 
system is limited by the need of a helper virus and by strong selective pressure that make 
it  impossible for non-structural proteins or other VP non directly targetable.(102). 
The development of an improved reverse genetic approach for rotavirus remains a big 
challenge. It would be extremely useful to address several questions on the molecular 
biology still unresolved, and the mechanism of packaging, the reassortment of genome 
segments, the morphogenesis of the virus. Moreover, it would improve the design of 
vaccines and understand the mechanism that induce the immunity against different 
phenotypes. 
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2 MATERIAL AND METHODS 
2.1 Cell culture 
MA104 cells (embryonic African green monkey kidney cells) were grown as monolayers in 
Dulbecco's modified Eagle's medium (DMEM) containing 10% foetal calf serum (FCS) 
(Invitrogen), 2mM L-glutamine and 50µg/ml gentamicin (Invitrogen). 
MA104 cells stably transfected with an NSP5-EGFP fusion gene were obtained by calcium 
phosphate procedure as described previously (55) and cultured in DMEM complete 
medium supplemented with 500µg/ml geneticin (G-418, Invitrogen). 
For the experiment of Results2, the cells were treated with proteasome inhibitors MG132 
(SIGMA),or Bortezomib (Sellek), or Epoxomicin (SIGMA) at different time point post 
infection with different concentration as indicated. 
2.2 Virus propagation 
The simian SA11 (G3, P6[1]), and porcine OSU (G5, P97) strains of rotavirus were 
propagated in MA104 cells as described previously (59),(71). 
T7-recombinant vaccinia virus (strain vTF7.3) was propagated in HeLa cells as described 
by Fuerst et al. (63). 
Viral titres were determined by plaque assay (71) and with measurements of percentage of 
green cells with infection of NSP5-EGFP cells. 
2.3 Construction of plasmids 
pT7v-NSP5 was obtained as previously described (60). The NSP5 gene was derived from 
the OSU rotavirus strain (Genbank accession number: D00474). The VP1 and VP2 genes 
(X16830 and L33364, respectively) were cloned from extracts of SA11 rotavirus-infected 
cells: viral RNA was extracted from 500µl of cell supernatant after complete cytopathic 
effect (CPE) had been reached. The cDNA was obtained by reverse transcription, using 
random hexamers (Sigma) and MuLV reverse transcriptase (Applied Biosystem) (87). The 
final constructs in pcDNA3 coding for VP1 and VP2 has been obtain as reported in Arnoldi 
et al.(6). 
The constructs coding for the phosphorylation mutants of NSP5 pT7v-NSP5/S67A and 
pT7v-NSP5a were obtained as described by Eichwald et al. (54).  
The pT7v-NSP5 S42A mutant has been constructs by amplification of pT7v-NSP5 OSU. 
pT7v-NSP5 OSU was amplify by PCR with two set of primers (listed in table 1) carrying the 
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mutation. The two segments, NSP5 S42A I and II, were mix and amplified by PCR with 
specific primers to incorporate KpnI and BamHI restriction sites at the 5’and 3’ ends of the 
NSP5 gene, respectively. The fragments was clone KpnI/BamHI into pcDNA3. The same 
strategy and primers were used to obtain pT7v-NSP5-S42-67A and pT7v-NSP5a-S42A 
using as DNA tamplate the pT7v-NSP5 S67A and pT7v-NSP5a, respectively. 
To obtain pT7v-NSP5c, pT7v-NSP5 OSU was amplified with two set of primer listed in table 
2. The segments obtained are annealed and amplified with primers containing KpnI and 
BamHI restriction sites to cloned the amplicon into pcDNA3. pT7v-NSP5c was used as 
template DNA to construct pT7v-NSP5c S137-142A. Primers used for this cloning are 
listed in table 2. All the mutants were cloned in pcDNA3 KpnI/BamHI 
The pT7v-VP6 vector was obtained by cloning the VP6 gene (L33365) from SA11 
rotavirus-infected cells: the cDNA was obtained as described for VP1 and VP2 and the 
region spanning the open reading frame (ORF) of VP6 was amplified with primers VP6-for 
and VP6-rev listed in Table 2. The VP6 amplicon was cloned into the pGEM-T Easy 
vector, sequenced and cut with KpnI and EcoRV. It was then inserted into pT7v-d81-130 
3 vector previously digested with the same restriction enzymes in order to remove the 
insert Δ3 and allow the insertion of the VP6 amplicon. 
The siRNA against the cellular kinase CK1 was as previously described by Campagna et 
al. (26). 
The vector pcDNA3-HA-PP2A/C encoding the 35KDa catalytic subunit of PP2A was 
constructed by cloning an N-terminally HA-tagged cDNA encoding PP2A/C into plasmid 
pcDNA3, and was the kind gift of David Pim (148). 
 




Table 2: Primers used for the cloning of different NSP5 Ser mutants. 
 
2.4 Productions of antibody 
Anti-NSP5 and anti-NSP2 sera were produced by immunization of guinea pigs and mice 
(1, 6, 67). Anti-serum to VP2 was produced by immunization of guinea pigs and mice with 
the GST-tagged VP2/I protein fragment (amino acids 1-357). The protein was produced in 
the E. coli BL21 strain with a procedure similar to that used for histidine tagged VP1/I  but 
with the following modifications: cultures were induced with 1mM IPTG for 4 hours at 25°C; 
the bacterial pellet was washed with ice-cold STE (10mM TrisHCl pH8, 100mM NaCl, 
1mM EDTA pH8) and resuspended in STE supplemented with 0.1µg/µl lysozyme, 1X 
CLAP cocktail, 0.3-0.5% laurilsarcosine, and 2mM DTT for sonication; after addition of 1% 








S42A down 5’GACAACATGTATTTATTGAATGCTTCTGCATCTGGTGCAAT3’ S42A II
KpnIATG-NSP5 5’CGGGGTACCATGTCTCTCAGC3’
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Triton X-100 in STE, GST-VP2(I) was purified from bacterial lysates by affinity 
chromatography using GSTrap™ HP columns prepacked with Glutathione Sepharose™ 
High Performance medium (GE Healthcare) and was eluted under mild, nondenaturing 
conditions using reduced glutathione, following manufacturer’s instructions. Guinea pigs 
and mice were injected subcutaneously with 125µg and 40µg of protein, respectively, and 
boosted 3 times every 15 days (with 50µg and 40µg of protein, respectively). Sera of the 
immunized guinea pigs and mice were tested by Western blot on extracts of rotavirus-
infected and uninfected cells.  
2.5 Transient trasfction of MA104 cells 
T7 RNA polymerase expressed from a vaccinia virus recombinant (63) is used to increase 
the expression level of proteins encoded by the transfected genes engineered downstream 
the T7 promoter. Since the vaccinia virus replication cycle is cytoplasmatic, exogenous 
gene transcription and translation are coupled in the cytoplasm of the transfected cells. For 
transfection experiments confluent monolayers of MA104 cells in 6-well plates (Falcon) 
were infected with T7-recombinant vaccinia virus strain vTF7.3 (63) at a multiplicity of 
infection (MOI) of 20 and 1 hour later transfected with a maximum total of 3µg/well of 
plasmid DNA (1µg of each plasmid in cotransfections) using 5µl of Lipofectamine 2000 
(Invitrogen)/well and following the manufacturer’s instructions. Transfected cells were 
harvested at 18 hours post-transfection (p.t.). For transfection of siRNAs, approximately 
1.5 x 105 cells were transfected with 2µg of siRNAs in 1ml of serum free medium 
containing 5µl Transfectam reagent (Promega). After 6 hours at 37°C, cells were washed 
twice with serum free medium, incubated for additional 32-35 hours in medium 
supplemented with 10% foetal bovine serum (Invitrogen) and then infected with vaccinia 
virus and transfected as described above.  
2.6 Cellular lysis 
Lysates (corresponding to about 5x105 cells) were prepared in 100µl of TNN lysis buffer 
(100mM Tris-HCl pH8.0, 250mM NaCl, 0.5%NP40) at 4°C and were subsequently 
centrifuged at 2000g for 5 minutes at 4°C. Usually 10µl of supernatants were used in 
PAGE and Western immunoblot analyses, and 40-80µl were used for immunoprecipitation 
experiments. The pellets were washed 3 times with PBS (170mM NaCl, 10mM phosphate, 
3mM KCl, pH 7.4) and resuspended in 20µl of loading buffer for PAGE and Western blot 
analyses. 
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Alternatively lysis was performed with hot Laemmli buffer, 100 µl of Laemmli buffer were 
added to the cells and the lysate were sonicated for 30” and centrifuged. Finally, 5l of 
sample buffer with -mercaptoEtOH were added to 10 l of extract and loaded into a PA 
gel. 
2.7 Chemical DSP crosslinkig 
Dithiobis(succinimidylpropionate) (DSP) was purchased from Pierce. Monolayers of 
transfected cells were washed twice with PBS, overlaid with 1.5ml PBS containing 600µM 
DSP and incubated at 4°C for 30 minutes. After removing the reactant solution, the 
reaction was quenched twice with 2ml Tris Buffered Saline (TBS; 40mM TrisHCl pH8, 
150mM NaCl) for 3 minutes at 4°C. Cellular extracts were prepared in 100µl TNN buffer as 
described above. 
Cellular extracts were then prepared as described above.  
 
2.8 Real-Time PCR 
Total RNA from MA104 OSU infected cells untreated, or treated with Mg132 was extracted 
using phenol-cloroform exctraction, and reverse transcribed using specific primer for 
Rotavirus gene 11(5’-GACCGGTCACATAACTGGAGTGGGGA-3’). The cDNA was then 
used as a template for real-time PCR amplification to detect the expression levels rotavirus 
genes 11 (using SybrGreen® technology (Applied Biosystems) and specific primer sets 
(5’-GACCGGTCACATAACTGGAGTGGGGA-3’ and 
5’AGGTACCAATACGACTCACTATAGGGGGCTTTTAAAGCGCTACAG-3’). All the 
amplifications were performed on a 7000 ABI Prism Instrument (Applied Biosystems). 
 
2.9 Immunoprecipitation, PAGE and Western Immunoblot analysis 
Cellular extracts (usually 4/5 of the total extract, i.e. approx. 80µl) were 
immunoprecipitated for 2 hours at 4°C after addition of 1µl of undiluted antibody, 1µl of 
100mM PMSF, 50µl of 50% protein A-Sepharose CL-4B beads (Amersham Biosciences) 
in TNN buffer, and 20µl of TNN buffer. Beads were then washed four times with TNN 
buffer, once with PBS and resuspended in 20µl of loading buffer. Sample components 
were separated by SDS-PAGE (using the Precision Plus Protein Standards molecular 
markers, Bio-Rad) and after electrophoresis transferred to polyvinylidene difluoride 
membranes (Millipore). The membranes were incubated with the antibodies listed in Table 
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3. Signals were detected by using the enhanced chemiluminescence (ECL) system 
(Pierce). 
 

















Research NSP2 guinea pig 1: 3,000 O. Burrone 







VP2 mouse 1:5,000 O. Burrone 
SV5 mouse 1:10,000 O. Burrone 
p53 mouse 1:5,000 Santa Cruz 
Biotechnolog
IRF3 mouse 1:200 Santa Cruz 
Biotechnolog
Actin rabbit 1:500 Sigma 




GFP rabbit 1:1,000 Santa Cruz 
Biotechnolog
CK1 rabbit 1:2,000 Santa Cruz 
Biotechnolog
Table 3: List of antibody used in western blot analysis 
 
2.10  λ-Phosphatase treatment of immunoprecipitates 
70µl out of 100µl of a cellular extract obtained from transfection/infection of about 5x105 
cells were immunoprecipitated over night with anti-NSP5 serum and then divided in two 
aliquots to be incubated with or without 2μl of λ-phosphatase (400U/µl, BioLabs) in buffer 
for λ-phosphatase treatment (50mM Tris-HCl pH 7.5, 100mM NaCl, 0.1mM EGTA, 2mM 
DTT, 0.01% Brij 35) (BioLabs) supplemented by 2mM MnCl2. The reaction was incubated 
for 2 hours at 30C and was stopped with 10µl of PAGE loading buffer (40% glycerol, 6% 
SDS, 125mM Tris-HCl pH 6.8, 0.04% bromo phenol blue, 5% β-mercaptoethanol). 
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2.11  Indirect immunofluorescence mycroscopy 
For indirect immunofluorescence microscopy, cells were fixed in 3,7% paraformaldehyde 
in PBS for 10 minutes at room temperature. Cover slips were washed in PBS and blocked 
with 1% BSA in PBS for 30 minutes and incubated with primary antibody at room 
temperature. After three washing in PBS, slides were incubated either with another 
primary antibody for double staining or directly for 45 minutes with RITC- or FITC-
conjugated secondary antibodies. After three washings, nuclei were stained with Hoechst 
dye 2µg/ml for 10 min, washed and mounted with ProLong mounting medium (Molecular 
Probes). Samples were analysed by confocal microscopy (Axiovert; Carl Zeiss). The 
antibodies used in immunofluorescence are listed in Table 4. 
The quantitative immunofluorescence was performed directly on NSP5-EGFP cells plated 
on 96 multiwell plate, infected, fixed with paraformaldheyde 1.8%, and stained with 
Hoechst at different time post infection as indicated. 16 images for each well were 
acquired with a molecular devices ImageXpress high-content microscope and 
quantification of viroplasms was performed with MetaXpress software. 
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Table 4: List of antibody used for Immunofluorescence. 
 
2.12  DLPs CsCl purification 
Viral particles were purified from cell cultures after harvest at about 20 hours p.i. when 
almost complete CPE had been reached. Virus was pelleted by ultracentrifugation, the 
pellets extracted with Freon (trichloro-trifluoro-ethane, Sigma) and banded by equilibrium 
ultracentrifugation in CsCl gradient, essentially as described by Patton et al. (135). This 
allowed to obtain three well separated gradient bands containing empty particles (EPs), 
TLPs and DLPs. Empty particle, TLP and DLP suspensions were diluted in 20mM PIPES 
buffer pH6.6 containing 10mM CaCl2 and pelleted by ultracentrifugation at 110,000g for 1 
hour in a Beckman ultracentrifuge using an SW55 rotor. The pellets containing the 
different viral particles were resuspended in 35µl of water and used in in vitro transcription 
assays. 










NSP5 guinea pig 1:1,000 O. R. 
Burrone
guinea pig
RITC goat 1:200 KPL
NSP2 guinea pig 1:200 O. R. 
Burrone
Alexa 647 goat 1:1000
Molecular
Probes





















HA rat (monoclonal) 1:100 Roche rat FITC goat 1:200 KPL
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2.13  In vitro transcri ption assays 
DLPs purified with CsCl gradient centrifugation were incubated with transcription buffer 5x 
(Promega); DTT (3µM); ATP, CTP, GTP 3 µM, UTP 0,3 µM (Fermentas) and UTP-[-P32 ] 
(Perkin Elmer), 40U RNAsin (Promega), DMSO or MG132 50 µM (SIGMA). The 
transcription mix was incubated 3-4 hours at 42°C, ultracentrifuged with Airfuge 
ultracentrifuge (Beckman Coulter) at 40.000 r.p.m for 1 hour. Supernatants were treated 
with Proteinase K 1 µg/µl for 30 min. at 37°C, spotted on a PVDF membrane, previously 
treated with TCA 10%, and washed several time with TCA 10%. Membranes were 
acquired with Instant Imager instrument (Packard) and quantification of CPM was 
performed with Imager software.  
 
2.14  In vivo phosphorylation with 32P 
For in vivo phosphorylation assays, MA104 cells were infected, at 4 hours post infection 
were extensively washed and maintained with phosphate-free Dulbecco MEM (GIBCO) 
medium for one hour. The medium was adjust to 10 µg/ml with actinomicyn D, 50 µM of 
MG132, or DMSO, and 100 µCi of [32P]orthophosphate (Perkin Elmer) per ml, at 5 h.p.i. 
and the lysis of the cells was performed at 6 h.p.i. The cell were lysed with TNN buffer to 
separate the cytoplasmic exctract from nuclei the lysate were centrifuged at  low-speed. 
Supernatants were incubated for 30 min. with proteinase K (Invitrogen), and dsRNA was 
precipitated with phenol-cloroform and ethanol precipitation. Resuspeded dsRNA was 
electrophoresed in a 12% SDS-PAGE gel for 5 hours at 30mA. 





The characterization and description of the behavior of rotaviral structural and non-
structural proteins during virus infection is an important goal in rotavirus studies. Different 
studies have revealed the relevant role of the non-structural protein NSP5 and NSP2 in 
Rotavirus infection, since silencing the expression of either of these proteins affects 
viroplasms formation, virus replication and virion production (27, 180). Furthermore, 
previous studies in our laboratory have characterized the interaction of NSP5 with two 
different viral proteins: the non-structural protein NSP2 and the viral polymerase VP1. In 
this section we describe the interaction of NSP5 with the structural protein VP2, that is 
very similar to NSP2-NSP5 interaction, and we analyze the biochemical and morphological 
modifications of NSP5 induced by VP2 in comparison with those induced by NSP2. 
(Part of the results presented in this thesis were conducted in collaboration with Francesca 
Arnoldi and some experiments performed together.) 
 
3.1 VP2 induces NSP5 to form VLS  
Since the interaction between NSP5 and VP1 has been well characterized by Arnoldi et 
al., and VP1 and VP2 strongly interact to form the replication complex in vitro, we decided 
to better investigate the relation between NSP5 and VP2. Indeed, a weak interaction with 
NSP5 has been previously reported by co-immunoprecipitation of VP2 with an anti-NSP5 
antibody from virus-infected cells (18). More clearly the scaffolding protein VP2 has been 
shown to localize in viroplasms of infected cells. 
As shown by immunofluorescence analysis (Fig.11), NSP5 and VP2 expressed alone 
show a diffuse distribution in the cytoplasm of transfected cells, whereas cells co-
transfected with NSP5 and VP2, reveal the formation of structures similar to viroplasm like 
structure (VLS) that are induced by co-transfection of NSP5 and NSP2. NSP5 and VP2 in 
VLS seem to colocalize very tightly suggesting a possible biochemical/physical interaction 
between these two proteins. However we observed some differences: the structures 
induced by VP2 are less numerous, are not uniformly distributed, have the tendency to 
form clusters in the cytoplasm, and are apparently larger compared to VLS induced by 
NSP2 (Fig.11). Based on the morphological similarity with VLS induced by NSP2, we 
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named these structures VLS as well, and in particular we define VLS(NSP2i) the 
structures induced by NSP2, and VLS(VP2i) those induced by VP2.  
 
 
Figura 11: VLS formation. Immunofluorescence analysis of cells transfected with NSP5, NSP2, VP2 alone and co-
transfected with NSP5 and VP2 or NSP2. NSP5 forms VLS, in the presence of VP2 (left panel) or NSP2 (right panel), 
where they co-localize. NSP5 protein is shown in red, VP2 and NSP2 in green. 
 
Viroplasms formation teke place already at 3 hour post infection, and VP2 appears 
recruited in viroplasms since the very beginning of their formation. This is what happens 
also during VLS(VP2i)  formation, since in cells co-trasfected with NSP5 and VP2 these 
two proteins soon interact to form VLS(VP2i) (already at 6 hour post transfection) 
suggesting that this interaction is not mediated by other viral protein (Fig 12).  
 
 
Figure 12: Timing of VLS formation. Immunofluorescence analysis of MA104 cells at 6 hours post transfection with 
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3.2 VP2 induces NSP5 hyperphosphorylation 
In order to characterize NSP5-VP2 interaction we performed biochemical analysis in both 
infected and trasfected cells. Western blot of extracts of cells transfected with plasmids 
encoding NSP5 and VP2 show a significant increase on NSP5 hyperphosphorylation. 
When plasmid encoding the viral protein NSP5 is transfected alone in uninfected cells, a 
single band at 26KDa and a weaker band at 28 KDa are visible in western blot analysis 
(Fig.13 lane 4), while when co-expressed with VP2 the pattern of NSP5 post-translational 
modifications highly resembles that found in infected cells: a weak band of 26 KDa is still 
present together with a very strong one of 28KDa, and a series of higher molecular weight 







To confirm that the NSP5 modifications is due to an increased hyperphosporylation, we 
performed both in vitro and in vivo phospatase assays. Extracts immunoprecipited with 
anti-NSP5 serum were incubated with lambda-phospatase at 37°C for 30 minutes. 
Western blot analysis of NSP5 clearly revealed that the NSP5 profile was reduced to a 
band of 26 KDa in correspondence to the sample of cells co-transfected with NSP5 and 
VP2 (Fig.14A). 
To investigate the hyperphosphorilation induced by VP2 in vivo, NSP5 and VP2 were co-
transfected with a plasmid encoding the catalityc subunit of PP2A phosphatase, a 
serine/threonine phosphatase with a broad substrate specificity. The presence of PP2A 
phosphatase induced a decrease in NSP5 hyperphosphorylation, in particular the isoforms 
of higher molecular weight which seem to disappear, and an inversion of the relative 


















1 2 3 4 5
Figure 13: Hyperphosphorylation of NSP5 induced by 
VP2. Western blot analysis of extracts of MA104 cells 
infected with Rotavirus or transfected with NSP5 or/and VP2. 
The hyperphosphorylation of NSP5 induced by VP2 
resembles that observed during normal infection. 
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that NSP5 modifications induced by VP2 were the conseguence of hyperphosphorylation 
event. 
 
Figure 14: In vitro and in vivo phosphatase assays. A) Western blot analisys of NSP5 immunoprecipitated extracts, of 
MA104 cells transfected with NSP5 and NSP5, VP2. Immunoprecipitates are treated or not with λ-phosphatase before 
loading.  B) Western blot analysis of extracts of cells transfected with different combination of NSP5 and VP2, in the 
presence, or not, of the tagged catalytic subunit of PP2A phosphatase. The expression of the phosphatase change the 
pattern of NSP5 hyperphosphorylation induced by VP2. 
 
 
The cellular kinases involved in this process are still unknown. According to previous 
studies in our laboratory in which an involvement of the kinase CK1 on the initiation of 
NSP5 hyperphosphorylation during rotavirus infection was demonstrated (26), we 
investigated the possible involvement of this kinase on NSP5 hyperphosphorylation 
induced by VP2. For this purpose cells were transfected with an RNAi to specifically 
silence CK1, and then transfected with plasmids encoding NSP5 and VP2. As shown in 
figure 15, despite efficient silencing of CK1, NSP5 hyperphosphorylation induced by VP2 
was not impaired and the electrophoretic mobility of NSP5 was similar to that found in cells 
treated with an irrelevant siRNA (Fig.15). These observations suggest that the kinase 
CK1 is not involved in the NSP5 hyperphosphorylation induced by VP2 and other kinases 
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3.3 Mapping NSP5 hyperphosphorylation induced by VP2 
NSP5 is rich in serine and threonine residues, that are good targets for phosphorylation 
events. We constructed a series of serine mutants in order to characterize the main 
residues involved in the hyperphosphorylation induced by VP2. Previous studies in our 
laboratory attempted to identify the serine residues involved in NSP5 
hyperphosphorylation induced by NSP2, using both deletion mutants and Ser to Ala 
mutants in defined positions (54),(56). In particular NSP5 has been arbitrarily devided in 
five regions (1-4 and the tail T) and deletion mutants for all single regions have been 
constructed. These mutants were tested for their ability to be hyperphosphorilated in the 
presence of NSP2. From those studies, it was observed that the mutants lacking the 
region between residues 30-81 (region2) and the one lacking residues 131-181 (region 4) 
were not hyperphosphylated in vivo when expressed with NSP2. One particular residue 
(Ser67)  was identified as the responsible for the initiation of a hyperphosphorilation 
cascade induced by NSP2 (54). Some of these mutants were also tested in the VP2 
induced hyperphosphorylation. 
Figure 16 shows a schematic representation of the NSP5 serine mutants used in these 
experiments. 
Figure 15: Involvment of CK1 on NSP5 
hyperphosphorylation induced by VP2. 
Western blot analysis of cells transfected 
with NSP5 and VP2 and treated with a 
siRNA specific for CK1 or an irrelevant 
siRNA. Silencing the expression of CK1
does not impaired NSP5 
hyperphosphorylation induced by VP2. 




Figure 16: Schematic rappresentation of NSP5 Ser mutants. NSP5 has been arbitrarily devided in five regions (1-4 
and the tail T) and deletion mutants for all single regions have been constructed 
 
The first class of mutants we took into consideration was the one involving Ser67 residue, 
that is inserted in a serine rich motif. We analysed two different mutants: NSP5-S67A 
where the serine in position 67 was mutated into alanine preventing in this way NSP5  
hyperphosphorylation, and NSP5-S67D with Ser67 mutated into aspartic acid, and two 
other serines of the motif mutated into Asp, to mimic a phosphorylated serine, resembling 
in this way the phosphorylated protein (54). By WB analysis, NSP5-S67A, that is not 
phosphorylated when expressed alone, becomes only partially phosphorylated, in a clearly 
distinct way as compared to the wt protein, when co-expressed with VP2 (Fig.17 lane11). 
In particular the 26KDa isoform was the main band observed together with a weaker band 
of 28 KDa. This result confirms the important role of Ser67 in initiating 
hyperphosphorylation, but suggesting that other residues could also be involved in the 
initiation events induced by VP2. On the other hand, mutant NSP5-S67D was already 
phosphorylated when expressed alone (Fig.17 lane 9) and when co-expressed with VP2 
its phosphorylation profile increased producing a pattern similar to the wt protein in the 
presence of VP2 (Fig.17, lane 18). Together with serine 63 and serine 65, serine 67 forms 
one of the serine rich motif present in NSP5 that we named motif “a” (SDSAS). The mutant 
with all the serines in motif a mutated into alanine (named NSP5a) upon co-transfection 
with VP2 presented a pattern of phosphorylation very similar to mutant S67A, confirming 
the dominant role of serine 67 in promoting the formation of higher molecular weight NSP5 
isoforms (Fig.17, lane 12). These observations suggest that the mechanisms of initiation of 
NSP5 hyperphosphorylation are similar regardless the inducer of hyperphosphorylation is 
NSP2 or VP2. 
COOH1 2 3 4 T
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Following preliminary mass spectrometry analysis of different NSP5 isoforms from infected 
cells (F.Rossi graduation thesis), we observed that residue Ser42 was phosphorylated as 
well. To investigate the possible involvement of this residue in the hyperphosphorylation 
induced by VP2 we constructed Ser 42 to Ala mutant and analysed by western blot the 
effect of co-expression with VP2. As showed in figure 17 (lane13) the same pattern as the 
wild type protein co-expressed with VP2 was observed, so this mutant does not produce a 
particular phenotype, different from the wild type protein, when expressed with VP2 
suggesting that this residue is not critical for the initiation of hyperphosphorilation induced 
by VP2. Furthermore we constructed the double mutant NSP5 S42-67A and the quadruple 
mutant NSP5a-S42A, in order to investigate the role of Ser67 in the context of mutated 
Ser42. Both these mutant upon co-expression with VP2 showed a similar pattern: a strong 
band at 26KDa with a minor band at 28KDa. The insertion of S67A mutation into NSP5 
S42A mutant, promotes more accumulation of the 26KDa isoform respect to the 28 KDa 
one, and does not allow the appearance of higher molecular weight NSP5 isoforms (Fig17 
lanes 14,15). All these data confirm the dominant role of Ser67 in initiating NSP5 
hyperphosphorylation induced by VP2, as it happens for hyperphosphorylation induced by 
NSP2. 
Based on previous studies, we took into consideration another serine rich motif, named 
motif “c”, present in a particular acidic context (ADSDSEDYVLDDSDSDDG) located 
towards the C-terminal of NSP5 protein.( The region of NSP5 that we named tail does not 
contain any Ser residues.) The mutant with all the serine in motif c mutated into alanine, is 
indicated as NSP5c and it was tested for the ability to be hyperphosphorylated in the 
presence of VP2, as well. 
When NSP5c is co-expressed with VP2, it is hyperphosphorylated in a way similar to the 
wt protein, confirming that even if these mutated residues are involved in the 
hyperphosphorylation induced by VP2, they do not induce a change in NSP5 pattern (Fig 
17, lane 16). Furthermore we mutated two other serine residues (Ser 137, Ser 142) 
situated in the proximity of motif c, creating the mutant NSP5c S137/142A. It is important 
to note that in this way region 4 has all the serine mutated into alanine. Anyway, neither 
this mutant has its hyperposphorylation impaired when co-expressed with VP2 (Fig. 17 
lane 17). 
Taken together all these results, we can summarize that the phosphorylation of residues 
situated in region 4 of NSP5, are not involved in the initialization of NSP5 
hyperphosphorylation induced by VP2. In contrast mutants with serine 67 mutated into 
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alanine are the only ones that present impaired hyperphosphorylation when co-expressed 
with VP2, although we never observed a complete non-phosphorylated protein. Once 
more, this confirm the relevant role of Ser67 in the initialization of NSP5 hypersphorylation, 
and moreover that other serine residues could be involved in this event. 
 
 
Figure 17: Hyperphosphoryation NSP5 Ser mutants induced by VP2. Western blot analysis of extracts of cells 
transfected with NSP5 and NSP5 Ser mutants alone (left panel) or  in the presence of viral core protein VP2 (right panel). 
None of the NSP5 Ser mutants shows a complete non-phosphorylated phenotype, however mutants with Ser67 mutated 
into alanine show the more impaired phosphorylation confirming the important role of Ser67 in the initiation of 
hyperphosphorylation events. 
 
3.4 Correlation between NSP5 hyperphosphorylation and VLS  
As previously described, VP2 induces both VLS formation and NSP5 
hyperphosphorylation. Moreover, NSP2 was first seen to induce VLS when co-transfected 
with NSP5, and it was demonstrated that this event is independent from NSP5 
hyperphosphorylation induced by NSP2, using serine 67 mutants (54).  
We investigated the possible correlation between VLS formation and hyperohosphorylation 
induced both by VP2 and NSP2. For this purpose, we performed immunofluorescence 
assays to follow VLS formation when NSP5 hyperphosphorylation was impaired.  
Hereafter we indicate different methods we have used to impaired NSP5 
hyperphosphorylation.  
1. Since NSP5 hyperphosphorylation induced by VP2 is affected by the co-expression 
of the catalytic subunit of PP2A phosphatese (Fig 14), we characterized the effect 
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PP2A were co-expressed in uninfected cells, they both presented a diffuse 
distribution, while in the cytoplasm of cells co-transfected with NSP5,VP2 and 
PP2A, we observed the typical VLS formation. The same happens when we co-
transfected NSP5 and NSP2 with PP2A: we observed a reduction of NSP5 
hyperphosphorylation induced by NSP2 (Fig.18B) and, despite the inhibition of 
NSP5 hyperphosphorilation, in immunofluorescence assays we can still observed 
the typical formation of VLS (Fig.18C). This means that the reduction of NSP5 
hyperphosphorylation due to the presence of PP2A in both cases does not 
influence VLS formation. Alternatively since the inhibition of NSP5 
hyperphosphorylation by PP2A was not complete, it is possible that small amounts 
of phosphorylated NSP5 are sufficient to induce the formation of VLS.  
 
 
Figure 18: VLS formation and NSP5 hyperphosphorylation. B) Western blot analysis of extracts of cells transfected 
with NSP5 alone or co-trasfected with NSP2, in the presence, or not, of tagged catalytic subunit of PP2A phosphatase. 
A), C) Immunofluorescence analyisis of cells transfected with NSP5 alone (shown in red B) or in purple C)) or co-
transfected with NSP5 and VLS inducers  in the presence of tagged PP2A (shown in green in borh B) and C)). Despite 
the presence of the catalytic subunit of PP2A, there is still formation of VLS. 
 
2. We had observed, not without surprise, that the expression of the viral polymerase 
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VP2 (Fig.19A). This particular effect of VP1 polymerase is evident in the contest of 
NSP5 hyperphosphorylation induced by NSP2, as well. (Fig.19B), and is still under 
investigation. Since it has been demonstrated a strong interaction between NSP5 
and VP1 (6), it is possible that the polymerase sequesters NSP5 to the effect of 
cellular kinase and/or VP2 and NSP2. It has been demonstrated that co-transfection 
of NSP5 with VP1 leads to a diffuse distribution of both proteins. However, the co-
expression of NSP5 and VP1 with VP2 or NSP2, not only does not inhibit VLS 
formation, but induces recruitment of VP1 with a  clear co-localization in VLS 
together with NSP5 and VP2 or NSP2 (Fig.19D).  
 
Figure 19: VLS formation and NSP5 hyperphosphorylation. A), B) Western blot analysis of extracts of cells 
transfected with different combinations or rotavirus proteins NSP5, VP2, NSP2 and tag-VP1,as indicated. VP1 affects 
NSP5 hyperphosphorylation induced by both VP2 or NSP2.  C) D) Immunofluorescence analysis of cells transfected as 
indicated. VLS still form in the presence of VP1. Tag-VP1 is shown in green, VP2, NSP2 and NSP5 were labeled in red 
in C) and D) respectively. 
 
3. The different NSP5 serine mutants, previously analysed with impaired VP2 induced 
hyperphosphorylation, were tested for their ability to form VLS (VP2i). 
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capacity to form VLS (VP2i). In particular, all the mutants that present the mutation 
in Ser67, that in co-expression with VP2 presented a more affected 
hyperphosphorylation pattern with respect to the others, still formed VLS in the 
cytoplasm of cells co-transfected with VP2.(Fig.21A). According to the data 
obtained for hyperphosphorylation induced by VP2, we analysed whether the same 
serine mutants would affect NSP5 hyperphosphorilation induced by NSP2, and the 
formation of VLS(NSP2i). As shown in figure 20, NSP5 S67A, NSP5a an NSP5c 
are the only serine mutants that have their hyperphosphorylation impaired when co-
expressed with NSP2, as expected from previous studies (54). Whereas NSP5 
S42A , NSP5 S42/67A, and NSP5a-S42A mutants when co-trasfected with NSP2 
show the same pattern as they are co-transfected with VP2. Despite the different 
degree of hyperphosphorylation, all these mutants when express with NSP2 still 
form VLS(NSP2i). (Fig.21B) 
 
Figure 20: Hyperphosphorylation of Ser mutants induced by NSP2. Western blot analysis of NSP5 Ser mutants 
expressed with NSP2. As expected from previous data, only mutants with Ser67 mutated into alanine present a non-
phosphorylated pattern. In addition NSP5c appears not to be phosphorylated in the presence of NSP2. 
Anti-NSP5
Anti-NSP2
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Figure 21: VLS formation of NSP5 Ser mutants. Immunofluorescence analysis of different NSP5 Ser mutants 
expressed alone (left column) or in the presence of VLS inducers. All Ser NSP5 mutants form VLS when expressed with 
VP2 or NSP2. NSP5 is shown in red, VLS inducers are shown in green. 
Following these analyses, we can conclude that VLS(VP2i) and VLS(NSP2i) are similar, 
not only from a morphological point of view, but even they behave in the same way when 
subjected to treatments that impared NSP5 hyperphosphorylation, suggesting their 
independence from hyperphosphorylation degree of NSP5. In all the conditions analysed, 
NSP5 hyperphosphorylation was differently affected but we have not observed impaired 
VLS formation. This suggests that these two events are not strictly correlated. However we 
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hyperphosphorylation in all the examples described, and it is therefore still possible that a 
weak phosphorylation is sufficient to drive VLS formation. 
 
3.5 Towards viroplasms re-building:recruitment of different viral 
proteins into VLS 
Viroplasms formation during infection is an event not entirely elucidated. It is known that 
within these structures both structural (VP1, VP2, VP3, VP6) and non-structural proteins 
(NSP2, NSP5) localize, but the mechanism underlining recruitment of the different 
components for viroplams assembly and the single protein function inside viroplasms is 
still an open question. Following the observations presented till here, VLS represent, from 
a  morphological point of view, the more similar structures to viroplasms so far described. 
They could be consider as empty viroplasms in the sense that they would not contain the 
dsRNA viral genome. For this reason they could be studied as a valid model to investigate 
recruitment of viral proteins and viroplasm assembly, with the final aim to understand the 
role of different viral proteins within viroplasms, and to investigate the recruitment of viral 
mRNA, which in viroplasm functions as templates for the polymerase to produce the 
dsRNA of the viral progeny.  
Since we have identified two different types of VLS, produced by two different inducers 
NSP2 and VP2, we investigated whether there are differences between VLS(VP2i) and 
VLS(NSP2i) in their ability to recruit other viral proteins. For this analysis we used a stable 
cell line (MA104 NSP5-EGFP) expressing the fusion protein NSP5-EGFP. The 
fluorescence of NSP5-EGFP becomes visible clearly upon rotaviral infection, when NSP5-
EGFP, which has an otherwise diffuse distribution, concentrates in viroplasms (Fig.22A). 
We also tested this cell line for the ability to form VLS when co-transfected with one of the 
VLS-inducers. As shown in figure 22B, both VLS(NSP2i) and VLS(VP2i) are formed when 
either NSP2 or VP2 are expressed in the NSP5EGFP stable cell line. It is important to note 
that, although NSP5-EGFP protein is sufficient to form VLS when co-expressed with VLS 
inducers, in trasfection experiment it was preferable to co-transfect also the NSP5 wild 
type protein to improve the visualization and formation of VLS. 




Figure 22: NSP5-EGFP cell line. A) Immunofluorescence images of infected NSP5-EGFP cell line, the NSP5-EGFP 
protein stably expressed concentrates into viroplasm of infected cells. B) Immunofluorescence of NSP5-EGFP cells 
transfected with NSP5 alone or in the presence of VLS inducers. NSP5-EGFP protein concentrates into VLS. 
 
As expected, the two inducers, NSP2 and VP2 co-localized within VLS. Moreover, when 
both NSP2 and VP2 were co-transfected into the NSP5-EGFP cell line, VLS were formed 
with the co-localization of the three components. This indicate that both NSP2 and VP2 
collaborate in VLS formation, and that neither of the two inducers inhibits the recruitment 
of the other into VLS (Fig.23). 
We have already demonstrated that tag-VP1 is recruited in VLS (NSP2i), co-localizing with 
NSP5 and NSP2 (6). Previous data showed that the same happens when tag-VP1 is co-
expressed with NSP5 and VP2 in VLS(VP2i), despite the inhibitory effect upon NSP5 
hyperphosphorilation induced by NSP2 and VP2 (as shown previously in Fig.19) Figure 23 
shows the co-localization of tag-VP1 in both VLS(VP2i) and VLS(NSP2i). 
Since the middle layer protein VP6 localizes in viroplasms during infection, we investigated 
whether it was also recruited into VLS. It has been demonstrated that VP6 forms tubular 
structures when trasfected in cells (89) and this particular distribution is maintained when 
VP6 is co-expressed with NSP5. While, following co-transfection with NSP5 and VP2 (in 
NSP5-EGFP stable cell line) VP6 changes its tubular organization and it gets recruited into 
VLS(VP2i) (Fig.23). We analyse the distribution of VP6 in cells expressing NSP2 and 
NSP5, as well, and, differently from VLS(VP2i), VP6 remains organized in tubular structure 
and was not recruited into VLS(NSP2i) which were nevertheless formed (Fig.23). This is 
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not surprising since VP2 and VP6 physically interact to form DLPs and this interaction 
would be also present within VLS (VP2i), while no interaction has been described between 
NSP2 and VP6. This suggests that the structural protein VP2 is the driving force that lead 
to the recruitment of VP6 into VLS.   
 
 
Figure 23: Recruitment of viral proteins into VLS. Immunofluorescence analysis of NSP5-EGFP cell line transfected 
with different combinations of viral proteins as indicated. NSP5-EGFP is shown in green, NSP2 in purple (left panel), VP2 
in blu (right panel), tag-VP1 and VP6 are shown in red in both panels. 
 
The immunofluorescence assays described indicated a complex macromolecular 
association among the different viral proteins within VLS. For this reason we wanted to 
verify these associations carring out co-immunoprecipatation experiments. 
The interaction between NSP5 and NSP2 in infected cells is well documented in 
experiments of immmunoprecipitation with anti-NSP5 serum. (1) 
The strong interaction between NSP5 and VP1 has been well described by Arnoldi et al. In 
some cases, in particular when using a polyclonal anti-NSP5 serum, co-
immunoprecipitation of NSP5 and VP1 from co-transfected cell extracts was obtained only 
when cells were previously treated with the chemical crosslinker DSP. 
Immuniprecipitations performed on extracts cells co-transfected with NSP5 and VP2 




NSP5 VP2 mergeNSP5 NSP2 merge
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in spite of good expression levels of both proteins, and regardless of the pretreatment with 
or without DSP crosslinker (Fig.24). As expected from control experiments from extracts of 
infected cells with anti-NSP5 serum did not succeed to co-immunoprecipitate VP2, even 
following DSP treatment (only NSP2 and VP1 are co-immunprecipitated in these 
conditions (not shown)) (6)(6). 
 
 
Figure 24: Interaction between NSP5 and VP2. Western blot analysis of immunoprecipitated extracts with both NSP5 
serum and VP2 serum. Cells were infected or transfected with NSP5 and/or VP2, and treated, or not, with chemical 
crossliker DSP. Even the treatment with DSP does not elicit the co-immunoprecipitation of the two proteins. 
 
The failure in our attempts of coimmunoprecipitating viroplasmic proteins might be due to 
methodological limitation such as lysis conditions, extraction, or most likely, the type of 
antibody used for immunoprecipation. For these reasons, we also performed co-
immunoprecipitations with monoclonal antibodies against NSP5 recently isolated in our 
laboratory. One out of five monoclonal antibodies tested (mAb 1B7) gave promising results 
in co-immunoprepitating NSP5 with other viral proteins present in VLS, without any 
chemical crosslinking. 
As shown in figure 25B, tag-VP1 is well co-immunoprecipitated, when co-trasfected with 
NSP5, (lane 17) and also when co-expressed with different combinations of NSP5 and 
VP2/NSP2/VP6 in comparable amount.  
This antibody, however, does not have the same efficiency to co-immunoprecipitate VP2. 
Indeed only a faint band of immunoprecipitated VP2 is visible in correspondence of NSP5-
VP2 co-trasfected cells (Fig.25B, lane 15). The co-expression of VP6 together with NSP5 
and VP2 substantially increases the amount of VP2 protein co-immunoprecipitated, 
WB: anti-VP2
WB: anti-NSP5
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suggesting that VP6 stabilizes VLS and the interaction between NSP5 and VP2 (Fig.25B 
lane 20). Importantly, we have excluded the possible unspecific interactions of VP6 
trimers, or VP2-VP6 empty particles, with 1B7 antibody (not shown).  
On the contrary, the co-expression of tag-VP1 with NSP5 and VP2 has the opposite effect. 
Indeed while an efficient immunoprecipitation of tag-VP1 takes place we can hardly 
appreciate the band corresponding to VP2 when all three proteins are co-expressed 
(fig.25B lane 19). This observation is in part consistent with the inhibitory effect of tag-VP1 
on NSP5 hyperposphorylation induced by VP2, due to the strong interaction between 
NSP5 and the viral polymerase VP1. The dominant role of NSP5-VP1 interaction was also 
evident in the sample in which all the other viroplasmic components in different 
combination (VP2/NSP2/VP6) were also expressed (Fig.25B lane 25). 
With respect to NSP2, its co-immunoprecipitation with mAb 1B7, was not very effective. 
Only a low amount of NSP2 was co-immunoprecipated when co-trasfected with NSP5 
(Fig.25B lane 16). The amount of co-immunoprecipitated NSP2 does not change whether 
it is express with tag-VP1, but it shows a slight increase when express together with NSP5 
and VP6 (Fig.25B lane 21-22). 
 
 
Figure 25: Interactions between VLS components. Western blot analysis of extracts (A) and immunoprecipitated (B) 
with mAb 1B7, of cells transfected with NSP5 and different combination of viral proteins. 
We  cannot exclude that the epitope, recognized by mAb 1B7, corresponds to the region of 
interaction between NSP5 and NSP2 or VP2 and, for this reason, 1B7 would have a 
dissociating function for these protein. However, it is clear that VP1 strongly interacts with 
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stabilized the interaction of NSP5 with both NSP2 and VP2, suggesting that one of the role 
of VP6 protein within viroplasms would be to stabilize the entire structure and to strongly 
associate all viroplasmic components. 
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4 DISCUSSION (1)  
 
During Rotavirus infection the replication of viral genome occurs within viroplasms. In 
these structures different viral proteins converge to support viral replication and virus 
assembly. In particular, the localization of the two structural protein sufficient to support 
viral replication VP1 and VP2 has been demonstrated (141), and also of the two non-
structural proteins NSP2 and NSP5, although their function at this level has not been 
completely characterized. NSP2 and NSP5, transiently transfected in the absence of other 
viral proteins, form cytoplasmic structures, similar to viroplasms, named VLS where they 
both localized (60). Moreover, the interaction between NSP5, NSP2 and VP1 has been 
recently described (6). 
In this work we wanted to characterized the relationship between NSP5 and the structural 
protein VP2, comparing it with the very similar one of NSP5 and NSP2. The involvement 
and the influence of other viral proteins in these interactions have also been taken in 
consideration to better characterized the distribution and connection between the different 
viral proteins during infection.   
We first observed that VLS formation takes place when NSP5 is co-expressed with the 
structural protein VP2, as well, and that, even in this case, both proteins localize in these 
structures. VLS formation in the presence of VP2 occurs soon after transfection, indicating 
that as soon as the proteins form they interact to form VLS (fig.12). Since the behavior of 
NSP5 in the presence of VP2 is very similar to that observed in the presence of NSP2 
(60), we named the VLS formed by VP2 VLS(VP2i), where “i” stand form induced, and that 
formed by NSP2, VLS(NSP2i). Although the two type of VLS are very similar there are 
some differences regarding the dimension and distribution of these structures: VLS(VP2i) 
are larger respect to that formed by the interaction with NSP2, and they tend to cluster in a 
perinuclear localization while VLS(NSP2i) are diffused into the cytosol of transfected cells 
(fig.11).  
These observations are particularly interesting in the context of NSP5 post-translational 
modifications. It has been demonstrated that NSP5 is hyperphosphorylated in infected 
cells (2), and when co-expressed with NSP2 in the absence of other viral proteins, NSP5 
results hyperphosphorylated conferring to NSP2 a regulating role on NSP5 
hyperphosphorylation (1). Recent results have shown that hyperphosphorylation of NSP5 
occurs when it is expressed with VP2, as well (fig.13) (6). We further characterized this 
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modification. In particular, the hyperphosphorylation induced by VP2 resembles more the 
one observed in Rotavirus infected cells, since it gives arise to isoforms of higher 
molecular weight respect to that induced by NSP2. We confirm that the nature of this 
modification is hyperphosphorylation with treatment of the NSP5 immunoprecipitated 
extracts of transfected cells with lambda phosphatase, that converts the higher isoforms to 
the lower one at 26 kDa (fig.14). Moreover, the co-expression with the catalytical subunit 
of PP2A-phospatase contributes in part to reduce the hyperphosphorylion of NSP5 
induced by VP2 in vivo, since we still observe the isoform at 28 kDa, even at low amount 
(fig.14). This is not the case of NSP2, indeed the co-expression of PP2A with NSP5 and 
NSP2  provokes an almost total de-phosphorylation of NSP5 that shows a pattern similar 
to the NSP5 expressed alone (fig.18). As it appears from the pattern shown in Western 
blot analysis, the two types of induced modifications are different and are differently 
sensitive to phosphatase treatment. 
It has been demonstrated, with surprise, that VP1 co-expressed with NSP2 and NSP5 
affects the up-regulation of NSP5 hyperposphorylation induced by NSP2. Indeed, NSP5 
strongly interacts with VP1 and this interaction is not affected by the presence of NSP2, 
furthermore it seems to enhance VP1-NSP2 interaction. The region of interaction between 
NSP5 and VP1 has been mapped just upstream of the C-terminal tail, and since this 
region is involved in dimerization of NSP5, it is probable that dimers of NSP5 interact with 
VP1 (6). However by cryoEM analysis, it was demonstrated that four dimers of NSP5 
interact with an octamer of NSP2, and that region proximal to the C-terminus of NSP5 are 
involved in this interaction. Thus, it is reasonable to suppose that the strong interaction 
between NSP5 and VP1 would interfere with the interaction of NSP2, dissecting, in this 
way, the up-regulation of the hyperphosphorylation of NSP5 induced by NSP2 (fig.19). 
Moreover, these observations suggest a possible coordinative role of NSP5 between 
NSP2 and VP1 interaction, that has already been proposed (96).  
Upon this observations, and the interaction between VP1 and VP2 in forming the minimal 
replicase complex (141), we investigate if VP1 expression interferes with the NSP5 
hyperphosphorylation induced by VP2. The pattern of hyperhosphorylation of NSP5 
induced by VP2 changes in the presence of VP1, with the appearance of the 26 kDa 
isoform, and the inversion of the ratio between the 28 kDa and 26 kDa isoforms (fig.19). 
However, while it was possible to map the region of interaction between NSP5 and VP1 by 
co-immunoprecipitation experiments with anti NSP5 serum (6), the same approach was 
not useful to demonstrate the putative interaction between NSP5 and VP2, since we do 
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not succeed in the co-immunoprecipitation of VP2 with NSP5 in both infected and 
trasfected cells, and to map the NSP5 region(s) of interaction between them. In any case, 
it is evident that the strong interaction of NSP5 with VP1 interferes with the NSP5 
hyperphosphorylation induced by VP2, as well (Fig 19). 
NSP5 is a 198-aa protein with an high content of Ser, Thr residues that are good targets 
for the addition of phosphate groups. In order to identify the Ser residues involved in the 
hyperphosphorylation induced by VP2 we tested a series of Ser mutants. The first group 
that we take in consideration was that involving the Ser67 since they were already 
characterized by Eichwald et al. for their ability to get phosphorylated. Ser67 is inserted in 
a Ser rich motif (SDSAS named motif “a”) and was identified as the one responsible for the 
initiation of the NSP5 hyperphosphorylation. The point mutant has the Ser67 mutated into 
Ala (S67A) and it does not get phosphorylated in the presence of an activator of 
phosphorylation, while the mutant Ser67Asp (S67D), that mimics the phosphorylated 
protein, is sufficient alone to activate NSP5 hyperphosphorylation (54). In the presence of 
VP2, both S67A and NSP5a (whit all the Ser in motif “a” mutated into Ala) shows a low 
degree of phosphorylation: it is possible to appreciate a very weak band of 28 kDa band, 
but the main isoform expressed is the lower one of 26 kDa (fig.17 lane 11,12). Thus, the 
NSP5 hyperphospohorylation induced by VP2 is partially inhibited when S67 is mutated 
indicating that S67 maintains its important role in initiating the hyperphosphorilation event 
also when induced by VP2. This is important because it indicates that the basic 
mechanism by which NSP5 hyperphsophorylation is triggered is common with the one 
occurring during virus infection. However, since we have still a low degree of 
hyperphosphorylation, we can conclude that there are other important NSP5 residues 
involved in its hyperphosphorylation. The mutant NSP5-S67D alone, which mimics the 
hyperphosphorylated protein (54), is regardless still sensitive to the effect  triggered by 
VP2 (fig.17.lane 9-18)  
The second group of mutants analyzed was the S42 mutants. Preliminary mass 
spectrometry analysis of NSP5 isoforms obtained from infected cell, revealed the clear 
presence of a phosphate group at the level of S42 (F.Rossi graduation thesis data). Upon 
these evidences we constructed the mutant NSP5-S42A, and we combined this mutation 
with the S67A mutant to obtain the double mutant NSP5-S42/67A and NSP5a-S42A. 
NSP5-S42A in the presence of VP2 behaves as the wild type protein with the 
accumulation of the 28 kDa isoform, suggesting that this residues is not significant in 
NSP5 hyperphosphorylation induced by VP2 (Fig.17 lane 13). On the other hand, both the 
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double mutant NSP5-S42/67A and the quadruple one NSP5a-S42A show a change in the 
phenotype expressed in the presence of VP2 with respect to the wild type protein, that is 
an accumulation of 26 kDa isoform and a weak band at 28kDa (Fig.17 lane 14,15). This 
results confirm the critical role of S67 in the initiation of the hyperphosphorylation of NSP5, 
since all the mutants containing the Ser 67 mutated into an Ala show a phenotype that 
promotes the accumulation of the 26 kDa isoform with respect to the 28 kDa one.  
In our studies on NSP5 hyperphosphorylation, another Ser rich motif 
(ADSDSEDYVLDDSDSDDG), located towards the C-terminal of NSP5 protein and named 
motif “c”, was studied. A mutants with all the serine in motif c mutated into alanine, NSP5c, 
and a second mutant, that present all the serine of region 4 mutated into alanine (the tail 
does not contain Ser residues) and named NSP5c-S137/142A, was expressed together 
with VP2. Both these mutants showed an unchanged pattern of phosphorylation compared 
to the wild type protein (fig.17, lane 16,17), suggesting that neither motif c, nor all the 
serine in region 4 are critical in providing residues for the generation of the isoforms with 
lower mobility in the presence of VP2.  
This analysis with all NSP5 Ser mutants does not identify fundamental residues or motif in 
NSP5 protein that, once mutated, inhibits completely the hyperposphorylation induced by 
VP2, but we did confirm the role of S67 in initiating the phosphorylation cascade event as 
it happens when induced by NSP2. However, in this latter case the role of S67 is more 
critical respect to the that observed hyperphosphorylation induced by VP2. An important 
differences reside in region 4. Indeed, NSP5c together with NSP2 shows a phenotype 
similar to that of S67A, indicating that, the motif c does plays, in this case, an important 
role (fig.20 lanes 10,11,16). Since a big portion of NSP5, between residues 66-188, is able 
to bind to the groove of NSP2, as revealed by cryoEM microscopy (91), it could be 
supposed that the phosphate groups present in S67 and in motif c, would be an important 
signal in triggering the NSP5 hyperphosphorilation induced by NSP2. 
Moreover, since the NSP5 hyperphosphorylation induced by NSP2 is more sensitive to the 
treatment with phosphatase, and to the mutation of certain Ser residues respect to that 
induced by VP2, we can argue that the two type of induced hyperphosphorylation are 
different and maybe complementary. It also suggests that the reduction in PAGE mobility 
of hyperphosphorylated isoforms can be obtained involving different residues. 
According to the studies performed by Campagna et al. on CK1 kinase involved in NSP5 
hyperphosphorylation in infected cells (26), we investigate if it is also involved in initiating 
NSP5 hyperphosphorylation induced by VP2. Treatment with siRNA specific for CK1 in 
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cells transfected with NSP5 and VP2 did not impaired the hyperphosphorylation mediated 
by VP2. Thus CK1 appears not to be involved in the mechanism of VP2 induced NSP5 
hyperphosphorylation (fig.15). indicating that other kinases can efficiently participate and 
suggesting that the process is not tightly controlled , since alternative kinases can have 
similar consequences. 
VP2 and NSP2 are able to induce both VLS formation and NSP5 hyperophosphorylation, 
however the two events are not necessarily correlated. Indeed, in all the cases analyzed in 
which NSP5 hyperphosphorylation results impaired (co-trasfection with PP2A, or with VP1, 
or NSP5 Ser mutants), we still observe formation of VLS in the cytosol of cells co-
transfected with NSP5 and VP2, or NSP2 (fig.18, 19, 21). In particular, in the presence of 
VP1 polymerase, we still observe VLS formation, despite impaired NSP5 phosphorylation, 
and VP1 recruitment (fig.19) in these structures. In addition, all NSP5 Ser mutants, that we 
analyzed for their ability to get hyperphosphorylated, form VLS when express with NSP2 
or VP2, even those that show a more affected hyperphosphorylation with NSP2 (Fig.21). 
However, in the case of co-expression with VP2, none of the NSP5 Ser mutants has a 
completely abolished phosphorylation. It is possible that a basal phosphorylation status is 
sufficient to drive the formation of VLS. However, this appears not to be the case since the 
NSP5 S67D mutant that is already phosphorylated when expressed alone, has a diffuse 
distribution in the cytosol of transfected cells, and only upon co-transfection with VP2 or 
NSP2 the rearrangement into VLS occurs (Fig 21). This is a very strong evidence that it is 
not the hyperphosphorylation status that leads to the formation of VLS, but rather the 
particular interaction with NSP2, (probably through dimerization), or with VP2 that regulate 
VLS formation.  
To better characterize the two types of VLS, we investigate their ability to recruit other viral 
proteins. We first analyzed the recruitment of both NSP2 and VP2 into VLS. VLS inducers 
collaborate in the arrangement of VLS, they do not interfere between each other in the 
formation of these structures and they both co-localized there. As already discussed VP1 
polymerase is recruited in both VLS(NSP2i) and (VP2i), and its recruitment is likely to be 
due to the strong interaction with NSP5 (fig.23). Moreover, NSP2 and VP2 have been 
demonstrated to interact with VP1, interactions that have functional roles during viral 
replication to synthesized the dsRNA genome (141), (96). Therefore, the localization of 
VP1 into VLS is not surprising and indicates that these structures may be considered as 
valid models of viroplasms. 
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This interpretation is consistent with the results obtained with VP6, which was clearly 
recruited into VLS with a very distinct distribution compared to when it was expressed 
alone (that showed formation of tubular structures (trimers) in the cytosol) (89). This 
change was particularly evident in VLS(VP2i), most likely because of the interaction with 
the core protein VP2. In contrast, VP6 does not localize into VLS(NSP2i) and remains 
organized in filamentous structure into the cytoplasm of transfected cells (fig.23). This 
observation is interesting since first reveals that VLS are not simple aggregate/random 
structures able to recruit whatever viral protein, but they represent, at least from a 
structural point of view, a real intermediate structure of viroplasms. It is, in this context, 
very interesting to characterize in the future VLS from a functional point of view, 
considering recruitment of viral RNA and formation of DLPs. 
In contrast to the deep description of the interaction between NSP5, NSP2 and VP1, in 
both infected and transfected cells by Arnoldi et al., we failed in all our attempts to 
demonstrate a direct physical interaction between NSP5 and VP2, which was suggested 
by the co-localization of these proteins into VLS. Immunoprecipitation experiments of 
extracts of transfected cells with NSP5 and VP2, and of infected cells, with anti-NSP5 and 
anti-VP2 sera, did not succeed in co-immunoprecipitating the two proteins, even with DSP 
crosslinking. Moreover, neither the co-expression of NSP5, VP2 with NSP2 or VP1 triggers 
the interaction between NSP5 and VP2 (data not shown). The failure of co-
immunoprecipitating NSP5 and VP2 was probably due to methodological limitations such 
as lysis condition or, most likely, the high-affinity hyperimmune polyclonal antibody used 
for the immunoprecipitation, that gives already evidences of dissociating activity (6). In 
fact, recently, in our laboratory a series of monoclonal Ab (mAb) specific for NSP5 have 
been isolated (G.Petris graduation thesis), that were tested for their ability to 
immunoprecipitate NSP5 with other viroplasmic components from both infected and co-
trasfected cells. All the mAb isolated were able to recognize and immunoprecipitate NSP5 
from infected cells (not shown), however only one mAb, named 1B7, gave promising 
results in co-immunoprecipitation of other viroplasmic components (Fig.25). The first 
attempts of immunoprecipitation assays with mAb 1B7 confirmed the strong interaction of 
VP1 with NSP5, since the polymerase immunoprecipitates without the necessity of 
chemical crosslinking (Fig 25B, lanes 17, 19, 21, 23, 25). 
MAb 1B7, however, was not able to efficiently co-immunoprecipitate neither NSP2 nor 
VP2, unless VP6 was also present. It is possible that the epitope recognize by 1B7 
overlaps with the region of interaction of the two viral proteins (fig.25 lanes 15, 16) with a 
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consequent dissociating activity. However, in the presence of VP6 both proteins could be 
co-immunoprecipitate with 1B7.(fig.25 lanes 20, 22) suggesting that VP6 probably through 
its strong interaction with VP2 stabilizes the structure of VLS(VP2i). On the contrary, VP6 
is not recruited into VLS(NSP2i) and remains organized in tubular structure, a result 
somehow expected since there is not a protein able to drive its localization (VP6 does not 
interact with NSP2 nor with NSP5). However, VLS (NSP2i), was observed in some cases, 
aligned along VP6 tubes, suggesting a possible interaction between this two structures, 
that could explain the increased amount of co-immunoprecipiteted NSP2, when VP6 was 
also expressed. 
NSP5, NSP2, VP2 and VP1,together with VP3 are the components of replication 
intermediates with replicase activity (RI). However, the temporal order that lead to the 
interaction of these proteins with viral mRNA and the consequent formation of RI is still 
under investigation. 
Upon these observations, we could suppose a possible mechanism of viroplasms 
assembly during Rotavirus infection. Soon after virus penetration and uncoating, the 
synthesis of viral proteins take place. According to the characterization of RI from infected 
cells (64), VP1 and VP3 precede the other RI proteins in the interaction with mRNA. 
Moreover, the interaction between NSP5-VP1 (originally described by Arnoldi et al. and 
also briefly described in this thesis) indicates that these proteins interacts independently 
from other viral proteins. Thus, it is allowed to assume that NSP5 interacts with VP1 that is 
already in contact with VP3 and the viral mRNA.  
It is difficult to describe the sequence of interaction of NSP2 and VP2 on NSP5-VP1-VP3-
mRNA complex from our observations. Indeed there are no evidences in favour of a 
particular preference in the association with NSP2 before VP2 or viceversa. I would 
therefore propose two alternative situations: 
1. In this scenario,NSP2 first bind to the non-replicative NSP5-VP1-VP3-mRNA 
complex through its interactions with both NSP5 and VP1 (1), (91), (96), leading to 
the formation of an intermediate precursor of a viroplasm similar to VLS(NSP2i). 
This structure would protect the pre-replicase complex, and would probably be 
linked to upregulation of NSP5 hyperphosphorylation, for an as yet obscure 
function. Thus, in order to allow the association of VP2 to render the RI competent 
for the replication of viral RNA, the rearrangement of NSP2 is needed, since NSP2 
interferes with VP2 binding to ssRNA and initiation of replication would be inhibited 
(203). This process were probably reflected in the structural changes that we 
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observed going from the small VLS(NSP2i), to the large VLS formed with both 
NSP2 and VP2.   
2. Alternatively, VP2 binds first to the NSP5-VP1-VP3-mRNA complex. This 
interaction would be possible through VP2 binding to VP1 (141) that has already 
been demonstrated. In this case, (also suggested by Vende et al. (203)), VP2 
interacts with the non-replicative RI, forming an intermediate similar to VLS(VP2i), 
making the precursor replicative-competent, and inducing also NSP5 
hyperphosphorylation. Subsequent binding of NSP2 would contribute to the 
assembly of the viroplasm and the actual initiation of dsRNA synthesis. 
In both cases the association of VP6 occurs as last event, and only when VP2 is recruited 
into viroplasms. The presence of VP6 allows the formation of DLPs, that because of this 
become transcriptionally active (29), and bud from the viroplasms through the ER for virus 
morphogenesis. 
The role of NSP5 hyperphosphorylation upon Rotavirus infection is still obscure, it is 
possible that it might influence the polymerase activities, as it has been shown for 
phosphoprotein that regulate the polymerase of negative-strand RNA virus (84),(174).  
Further experiments will validate one of the two proposed models, in order to assign a role 
to NSP5 in viral replication and as the organizer of viroplasms assembly and functionality. 





The ubiquitin–protesome system (UPS) is important for almost every aspect of cellular 
functions. Viruses, on their hand, prevalently depend on host machinery for replication, 
therefore it is not surprising that viruses manipulate the UPS at many levels to enhance 
viral replication. 
In this study we characterized the effect of the proteasome inhibition on Rotavirus 
infection. We observed that addition of proteasome inhibitor MG132 in infected cells 
induces a strong decrease in the amount of structural and non structural viral protein 
production. Kinetics studies revealed that inhibition of proteasome activity strongly affects 
viral proteins accumulation when added at early time point post infection (from 1 hour till 5 
hour post infection). Moreover, absorption in the presence of proteasome inhibitors does 
not affect penetration and, probably, uncoating of the virus. Furthermore, the inhibition is 
dependent on the concentration of the different proteasome inhibitors utilized. Quantitative 
RT-PCR from infected cells showed that in MG132 treated cells the level of viral RNA is 
also largely reduced, respect to the DMSO-treated cells, indicating that the effect of 
protesome inhibition involved also viral processes that produce RNA like transcription or 
replication. 
In transfection experiments, proteasome inhibition did not affect the expression of viral 
proteins like NSP5, NSP2, and VP2, either when expressed alone or in different 
combination. Moreover, both the hyperphosphorylation of NSP5 and the VLS formation 
induced by VP2 or NSP2, did not change in the presence of MG132. 
We have excluded a direct effect of the inhibitor MG132 on the VP1 polymerase activities 
(transcriptase and repicase activities). In in vitro transcription assay in the presence of 
MG132, we did not observe any variation in the amount of transcribed mRNA; in vivo 32P 
labeling of replicated dsRNA in infected cells, when the replicase activity of VP1 is at 
maximal level, showed no effect on dsRNA production in the presence of proteasome 
inhibitor. 
NSP1 is the only known Rotaviral protein related to UPS, since it induces proteasomal-
mediated degradation of IRF3 factor in order to inhibit IFN response. In this regard, we 
observed that the amounts of IRF3 are not related to the strong impairment of Rotavirus 
infection that occurs when proteaseome is inhibited. 
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In addition to the biochemical analyses, we assessed the effect of MG132 by 
immunofluorescence assays. We looked at viroplasms formation and, consistently with the 
biochemical data, we observed that MG132 added during the early phases of infection 
does reduce viroplasms formation and growth in an early phase of viroplasms assembly
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5 INTRODUCTION (2) 
 
Different cellular functions are finely regulated by the ubiquitin-proteasome system (UPS). 
This is not only a machinery used for the degradation of misfolded proteins, but is also a 
regulatory system of several cellular processes like gene transcription, signal transduction, 
apoptosis, DNA repair. Upon viral infection, several cellular functions are subjected to 
adaptations driven by the viruses for their own advantage or as a response of the cell 
against them. These adaptations evidently involve the UPS machinery, and viruses have 
developed means to use this regulatory complex to permit their replication. 
In the follows paragraphs, it is described the UP system and some of the methods used by 
viruses to exploit it to enhance their replication, as it is the case for Rotavirus. 
 
5.1 The Proteasome  
The proteasome is a complex molecular machinery involved in protein degradation within 
the cells. The process consists in recognition of the opportunely ubiquitinated substrates, 
unfolding, de-ubiquitination, and traslocation of the substrate into a narrow channel, that is 
the proteolytic core of the machinery, where the proteins are hydrolyzed.  
Structurally, the proteasome consists of two main complexes: the 20S proteolytic core 
(core particle CP) and the 19S regulatory particle (RP), together these subunits form the 
26S proteasome. The association of the RP with the CP induces the activation of the 
proteolitical activity of the proteasome (62). 
The 20S complex is made up of  and  subunits organized in rings: two rings of 7 
subunits are separated by two stacked rings of 7 subunits, with a symmetry 7777. A 
narrow channel runs through the centre of these structures where the hydrolysis of the 
substrates takes place, due to the proteolytic activity of the  subunits (93). 
The 19S regulatory complex is been subdivided into two assemblies, the base, proximal to 
the CP, and the lid, distal from the CP. However, the whole RP subunit carries out a lot of 
functions (62): 
 It recognizes polyubiquitinated particles, 
 It cleaves the polyuquitin chains to obtain ubiquitin monomers (de-ubiquitination 
activity) 
 It binds to the 20S complex inducing the opening of the narrow channel 
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 It functions as a chaperone for the unfolding of the substrates and their traslocation 
into the proteolytic core for the degradation. 
5.1.1 The core particle (CP) 
The proteolytic core of the proteasome has 28 subunits arranged into four 
heteroheptameric rings. The external rings are made up of 7 -type subunits, while the two 
internal ones are composed by 7 -type subunits (199) (Fig 26).  
The inner rings contains the enzymatic activity of the machinery, in particular three of the 
seven subunits present the proteolytic active sites: 1, 2, and 5. These subunit belongs 
to the N-terminal nucleophile (Ntn) hydrolase family with an unusual, single-residue active 
site, the N-terminal threonine. Each sites is able to cleave a broad range of peptide 
sequence: in particular 1 prefers to cleave on the C-terminal side of acidic residues, 2 
cleaves after Arg and Lys residues, tryptic cleavage, and 5 cleaves after hydrophobic 
residues. For these differences in the cleavage, the sites of the subunits are classified as 
caspase-like site for 1, trypsin-like for 2 and chymotrypsin-like for 5. However, this 
classification is approximate since the cleavage specificity is not determined by the amino 
acid at the N-terminus of the cleaved bond. The combination of several active site, even 
with a low specificity, in a very narrow space, for an unfolded proteins with all the peptide 
bonds exposed guarantees its complete hydrolysis after the passage into the core particle.  
In the inactive state the core particle has its channel closed by a well defined network 
made up by the N-terminus of the -type subunits of the external ring. The activation of the 
core particle needs the disruption of this network, and this process is regulated by the 
association of the RP. At the interface of the -subunits, a structural pocket is formed, thus 
a series of seven pockets are exposed to the RP-facing surface of the -ring that are the 
binding site for RP. The binding of RP induces the opening of the CP channel, that results 
in register with the RP channel, where the substrates need to translocate before reaching 
the CP. The substrate translocation channel is very constricted even when it is in the open 
conformation. This prevents the spurious degradation of cytoplasmic proteins and, 
furthermore, it imposes the substrates to reach the channel in an unfolded conformation, 
that facilitates the rapid hydrolysis of the protein within the CP. The unfolding activity is 
supposed to be mediated by the ATPases subunits of the RP complex (62). 
The interaction between the C-termini of RP with the -pockets is sufficient to open the CP 
channel, and this is due to a sequence specificity. Indeed a hydrophobic residue followed 
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by a tyrosine and an unspecific C-terminal residue, HbYX motif, is able to open the gate 
(182).   
In addition to the RP HbYX motif, another protein has been characterized to induce the 
activation of CP, the heteromeric 28 proteasome activator (PA28). Differently from RP, 
PA28 lacks the ATPases activity and the capacity to bind the ubiquitinated substrates, 
however it is able to bind to the CP cylinder and to open the channel. The mechanism was 
well described through studies on the PA28 homolog from trypanosomes, PA26. In 
particular, the PA26 C-terminal -strand-like structure inserts into the -pockets of the CP. 
This insertion brings an internal sequence of the PA26, known as activator loop, to interact 
sterically with the Pro17 loop of the -subunit. Seven PA28 proteins interact 
simultaneously with the seven pockets of the -ring, in this way the seven Pro17 loops 
move and cannot maintain the ordered state of the closed channel (205). 
 
 
Figure 26: Core Particle. A) Medial section of the CP: it is organized in four heptameric rings of subunits. Two external 
rings of α-subunits and two internal rings of -subunits.(left figure). B) Top view of the 20S subunit: dark blu color indicate 
the 7 α-pockets of the α-ring where regulatory particle and PA26 bind to open the channel.  The channel is closed. 
 
5.1.2 The regulatory particle (RP) 
The base 
The base consist of 10 subunits: six ATPases, that belong to the ATPases-associated-
with-different-cellular-activities (AAA) family (also referred as Rpt, following the 
nomenclature for yeast); two scaffolding proteins Rpn1, Rpn2; and two ubiquitin receptors 
Rpn10, Rpn13 (61) (Fig 27).  
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The ATP-dependent proteases, that belong to the same family, are thought to form a 
pseudosymmetrical ring structure, within the highly assymetrical structure of the RP, 
forming a sort of translocation channel of the RP subunit. The substrate is retained within 
the ATPase ring where it is subjected to different processes. Indeed, the proteolysis of 
different substrates has been described to be ATP dependent, revealing a functional role 
of ATPases, moreover this subunits are thought to possess the unfoldase activity 
necessary to rapidly degrade the substrate (62).  
ATPases ring have a structural function, as well. The C-termini of the ATPase subunits 
insert into the -subunit cavities of the CP, and promote the formation of the RP-CP 
complex, favoring the alignment of the -ring with ATPases rings.      
The scaffolding subunits Rpn1, Rpn2 are the largest proteasome subunits and are 
characterized by the presence of tandem repeats elements that leads the formation of a 
particular secondary structure: a double-toroid. This toroid is able to attach to the CP, 
independently from ATPases subunits, and drives the alignment of the translocation 
channel of the RP with the channel of the CP. The model proposed is that the Rpn1/Rpn2 
subunits form part of the translocation channel, inserted within the ATPases ring, and are 
situated between the CP and the ATPases ring (168).  
Another function of Rpn1/Rpn2 complex is to function as a scaffolds for the binding of 
protesome subunits or proteasome-associated proteins. Indeed ubiquitin receptor Rpn13  
binds to Rpn2, and other ubiquitin receptors bind to Rpn1. In addition, enzymes that 
disassembled or extend ubiquitin chains interact with Rpn1 and Rpn2 proteins .  
Rpn10 and Rpn13 are the proteasome-associated ubiquitin receptors. They bind 
ubiquitinated substrates through different recognition motifs: Rpn10 has two ubiquitin 
interacting motif (UIMs), while Rpn13 has a pleckstrin-like ubiquitin receptor domain. In 
addition to these two subunits there are other ubiquitin receptors that are associated to the 
proteasome. They are called also “shuttle” receptors since recognize ubiquitinated 
substrate that are far from the proteasome and are able, through specific ubiquitin- like 
(UBL) or ubiquitin associate (UBA) domains, to engage and drive them towards the 
proteasome (186).  
 
The lid 
The lid consists of nine subunits, of which only one has been functionally characterized, 
Rpn11, as a de-ubiquitinated protein (DUB). Deubiquitination is an important step in 
proteasome activity, since before the degradation substrates need to be separated from 
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the ubiquitin groups. Ubiquitin is not degraded and is recycled within the cell. Rpn11 
activity is finely controlled and exclusively directed towards proteolytic substrates. The 
mechanism of coupling degradation with deubiquitination is still under investigation, 
however the DUBs activity is inhibited in the absence of ATP, and since all the nine 
subuinits of the lid lack ATPases activity, it is likely that the nucleotide hydrolysis of the 
base ATPases allows the lid subunits to cleave ubiquitin from the substrate. In particular 
Rpn11 cleaves the whole ubiquitin chains and in the absence of this subunit the 
proteasome does not work, probably because the ubiquitinated substrate cannot fill the CP 
channel. In addition to Rpn11 there are other DUBs, that act before the substrate is 
committed to degradation and Rpn11 activity. These DUBs, Uch37 and Ubp6, do not 
completely eliminate ubiquitin chains from the substrates but they shorten them, 
decreasing the substrate affinity for the proteasome and slowing down its degradation. 






Figure 27: 19S Regulatory particle. Subunit arrangements of the 





5.2 The ubiquitin-proteasome system (UPS) 
The UPS is the machinery involved in the regulation or life-span determination of 
intracellular proteins. In order to become proteasome substrates, the proteins need to be 
tagged with ubiquitin (Ub) molecules, even if there are rare examples of non-ubiquitinated 
substrates that are degraded by the proteasome. Ubiquitin is a small protein composed of 
76aa, and the critical residue that permit the formation of ubiquitin chain is Lys 48. 
Mutation at the level of this residues prevents the formation of poly-ubiquitin chains and 
target to the proteasome. However, recently it has been demonstrated that other residues, 
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Lys11 and Lys63, have the ability to form chains that target the proteasome degradation of 
the substrates (208). 
The process of ubiquitination consists in a very complicated mechanism, and involves 
different kind of enzymes (E1-E4). Herein the different steps of the process are described 
(93) (Fig.28): 
1. Ubiquitin activation by E1: the initial step consists in the activation of ubiquitin and is 
an ATP dependent process. The enzyme involved in this process is the E1 
“ubiquitin-activating enzyme”, that attaches to the Cys residue in its active centre 
the C-terminal end of the Ub. Different E1 enzyme are present in the cytosol and in 
the nucleus 
2. Ubiquitin-conjugation and E2 enzyme: this is an intermediate step where the E1 
enzyme transfers the activated Ub to a Cys residues of the “ubiquitin conjugation 
enzyme” E2. About several dozens of E2 enzyme exist, each interacting with a 
special set of E3 enzymes or substrates. 
3. Ubiquitin transfer to the substrate: the process that promote the transfer of ubiquitin 
to the substrate involved a third class of enzymes: the “ubiquitin ligase”E3. E3 
represent the largest group of enzymes involved in the UPS. It is supposed to exist 
at least several hundred of E3s in mammalian cells. The substrate ubiquitination 
could occur with two different ways depending on the type of E3 ligases: 
a. The E3 ligases characterized by the presence of the RING finger structure 
bind both the substrate and the Ub-E2 complex and catalyze the transfer of 
the Ub directly on the substrate. 
b. The E3ligases with the HECT structure bind both the substrate and the Ub-
E2 as well but the Ub monomer is first transfered to the E3 enzyme,binding 
to a very conserved Cys residue, and then to the substrate protein. 
How the Ub-molecules are attached to the first one to form poly-ubiquitinated chains is still 
unknown. There are models that propose repetitive cycles of ubiquitination involving E1-E3 
enzymes. However, it has been observed in yeast the existence of a fourth enzyme: 
“ubiquitin-chain elongation factor” E4 enzyme, that has a still unknown mechanism of 
action (103). 
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Figure 28: Schematic representation of substrate 
ubiquitination. Activation of the ubiquitin monomer occurs by 
E1 enzyme activity. The process need the hydrolysis of ATP 
and the ubiquitin monomer is transferred to a Cys residue of 
E1. Ubiquitin is then transfer to E2, binding to another Cys 
residues of this enzyme, and E1 is released. Ub-E2 complex 
binds the E3-substrate complex and, depending of the type of 
E3 ligase, the Ub molecule is transfered to the substrate. The 
transfer occurs directly to the Lys residues of the substate in 
the case of a RING E3 ligase (left) or throught a intermediate 
passage to the Cys residue of E3 and then to the substrate in 








5.3 The degradation process 
In order to be recognized for degradation, the substrates need to be tagged with at least 
four molecules of Ub. The recognition of the substrate is mediated by the subunit of the 
19S complex, it involves subunit Rpn1, Rpn10 and one ATPases, Rpt5. Furthermore the 
subunit Rpn1 binds to the DUB enzyme Upb6, that may function as a regulator shortening 
the Ub chains of undegradable substrates and allowing their release from the proteasome.  
After the recognition, the substrate needs to be unfolded, and inserted into the traslocation 
channel, and the mechanism of this process is still under investigation. There are two 
proposed models: 
1. Unfolding of the substrate preceeds translocation: this model proposes that the 
unfolding of the degradable substrate occurs at the surface of the ATPases ring of 
the 19S complex, and after the complete destabilization of the substrate it is 
translocated into the narrow channel of the CP (133). 
2. Unfolding occurs into the translocation channel: this model propose the direct 
interaction between the substrate and the traslocation channel. So the unfolding of 
the substrate occurs consequently to its collision into the narrow channel and 
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Once inside the CP the substrates is subjected to degradation by the -subunits proteolytic 
activity, and heterogeneous mixture of peptides are released from the machinery. In 
mammals this subset of peptides are utilized for the adaptive cell-mediated immunity.  
Ubiquitin are released during substrate degradation in the form of polyubiquitin chains that 
are subsequently decomposed in Ub monomer by the DUBs in the cytosol and recycled 
(62). 
 
5.4 UPS and virus 
The ubiquitin-proteasome system regulates different cellular process through the more 
rapid and easy degradation of cellular proteins. Indeed, apart from the elimination of 
misfolded, damaged, or unneeded proteins the UPS is involved in cell cycle regulation, 
apoptosis, antigen processing, transcriptional regulation, signals transduction, and other 
several cellular functions. Since virus replication is dependent on the activity of different 
host factors, it is not surprising that viruses have developed mechanisms to direct the 
cellular UPS activity to their own needs. A lot of studies have demonstrated that different 
type of viruses manipulate ubiquitin-proteasome pathway evading cellular response. 
Herein, are reported examples of different virus strategies in manipulating UPS. 
 
Viral proteins direct ubiquitination of cellular factors 
This mechanism is used mostly among DNA tumor virus that target cell cycle regulation 
proteins to the proteasome inducing cell transformation. This was first observed in 
papilloma virus HPV, that induces the degradation of p53 protein through the viral protein 
E6. The mechanism of HPV E6 mediated degradation consists in the recruitment and 
redirection of one cellular E3 ligase to ubiquitinate p53 (173). 
Adenovirus expresses two proteins, E1B-55K and E4orf6, able to engage another cellular 
E3 ligase in order to target p53 to proteasome degradation, as well (162).   
On the other hand, HIV-Vif protein is an important regulator of HIV infection since it drives 
the polyubiquitination and the following degradation of APOBEC3G, a potent cellular 
antiviral factor (213). 
In order to shut down the interferon response, several viruses take advantage of the 
proteasome activity and direct the degradation of cellular proteins involved in interferon 
signaling. This is the case of several paramoxyviruses, human parainfluenza virus 
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(HPIV2), and simian virus (SV5) that target to proteasome degradation STAT (signal 
trasducer and activator of transcription) proteins (164).  
And this is also the case of Rotavirus that, through its NSP1 protein, mediates the 
degradation of IRF3 protein via proteasome, preventing the activation of interferon  
response (this mechanism is extensively describe in introduction 1 page 34) (13), (14). 
Another strategy of several virus is to interfere with the retrograde translocation through 
the ER. This is a process that normally occurs in cells for misfolded proteins that enter the 
secretory pathway. These protein are finely controlled into the ER and the misfolded or 
damaged one are rapidly retrotraslocated into the cytosol for rapid proteasomal 
degradation. Some viruses express proteins able to address into this secretory pathway, 
host proteins and to induce their degradation. Citomegalovirus, US2 and US11, mediate 
the degradation of MHC class I protein using this method, which serves as an immune 
evasion mechanism (206). In the same way HIV-Vpu induces degradation of the cell 
surface receptor CD4 (175).  
 
Virus encoded ubiquitin-ligase 
Virus may encode their own E3 ligase and almost all the viral E3 ligases identified were 
classified into the RING family.  
In this classification is involved the herpes simplex virus type 1, with its ICP0 (infected cell 
protein 0). ICP0 has a RING domain with a E3 ligase activity that directs the 
ubiquitynilation and degradation of PML and SUMO-modified forms of Sp100, causing 
degradation of PML nuclear bodies and other substrates (21). 
Among the viral RING E3 ligase family, there is the RING-CH sub-family that was first 
identified in murine and human -herpesvirus and characterized by the presence of C4HC3 
Cys-His configuration in the RING (165). These are integral membrane proteins that act 
inducing ubiquitynilation and degradation of receptors. The degradation occurs both with 
the internalization of the receptor into a endolysosomal compartment, but also through 
proteasome-mediate degradation using the ERAD pathway. RING-CH ligases are involved 
in the degradation of MHC class I molecules in order to evading the viral immune response 
of the cells (165). 
For Rotavirus, it has been identified a RING structure within NSP1, that suggests a 
possible role of this protein as a E3 ligase inducing directly its own, or IRF3, ubiquitination 
and consequently proteasome degradation. (This was already discussed in introduction 
page 34) (149).  
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In addition viruses have developed different mechanisms to take advantage from the 
cellular UPS (165),(86): 
 Encode for viral ubiquitin, 
 Encode viral DUBs, 
 Interacts with cellular DUBs, 
 Interacts with ubiquitin-like modifier like SUMO, ISG15. 
All these strategies represent different ways that viruses have developed to avoid viral 
cellular responses and to enhance their own replication.   
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6 RESULTS (2) 
6.1 Intro 
The ubiquitin proteasome system, in addition to control several cellular functions, has been 
shown to be involved in different aspects of virus replication into host cells. In this study, 
which originated following an unexpected observation, we wanted to address the 
involvment of the proteasome activity during Rotavirus infection. 
6.2 The striking observation  
During our studies on Rotavirus, and in particular on the expression of NSP5 protein, we 
observed a particular effect on MG132 treated cells infected with Rotavirus. MG132 is a 
peptide aldehyde that functions as a reversible potent transition-state inhibitor of the 
chemotrypsin-like activity of the proteasome CP (111). 
The biochemical analysis performed on infected cells treated with MG132 revealed that it 
causes a decrease in the amount of rotaviral proteins that accumulate during virus 
replication. As shown in figure 29, when infected cells were treated with MG132 from the 
beginning of the infection till hour 7 post infection the accumulation of both structural (VP2) 
and non-structural (NSP5) rotaviral proteins was strongly affected. The effectiveness of 
MG132 treatment on proteasome activity was always assessed by analysis of the levels of 
p53, which increases upon proteasome inhibition.(Fig.29B) 
 
 
Figure 29: Effect of MG132 on Rotavirus infection. A) Schematic representation of the experimental steps. B) 
Western blot analysis of extracts of treated and untreated infected cells. Upon MG132 treatment there is a decrease in 
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In order to verify whether the inhibition on protein accumulation by MG132 treatment is 
related to the impairment of the first events of viral infection, we further tested its effect by 
adding the drug at three hours post infection (Fig.30A). Even in this case, we observed a 
strong reduction in both the amount of structural (VP2) and non-structural (NSP2, NSP5) 
viral proteins amount (Fig.30B). 
 
 
Figure 30: Effect of MG132 added at 3 hours post  Rotavirus infection. A) Schematic representation of the 
experimental steps. B) Western blot analysis of extracts of treated and untreated infected cells. Upon MG132 treatment 
there is a decrease in both structural e non structural viral proteins production. 
 
The effect of MG132 was evident in different rotavirus strains. Indeed we performed the 
same analysis using the porcine rotavirus strain OSU and the monkey strain SA11 and we 
observed that both strains had their infection impaired when treated with MG132 since the 
amount of rotaviral proteins was reduced compared to the controls (Fig.31B). In particular, 





























Figure 31: Effect of MG132 on different Rotavirus strains. A) Schematic representation on experimental steps. B) 
Western blot analysis of the extracts of cells infected with different Rotavirus strains, or not infected, and treated or not 
with MG132. OSU strains seems more sensitive to the treatment respect to SA11 strain. 
 
In order to characterize the effect of MG132 on Rotavirus infection from the early time post 
infection, we treated infected cells with different concentrations of the drug. MA104 cells 
were infected with Rotavirus (OSU strain) for one hour, then MG132 at different 
concentrations was added, and western blot analysis was performed at 7 h.p.i. (Fig32A). 
Figure 32B clearly shows that the accumulation of viral proteins was dependent on MG132 
concentration; in particular, with increasing concentrations of the inhibitor there is a 
decrease in the level of viral proteins, that is appreciable in NSP5 profile. Furthermore, the 
addition of the drug soon after the removal of the virus, indicated that the effect, observed 
in the previous experiments, was not due to the inhibition of the entry and the uncoating of 
the virus. Since MG132 is a widely used proteasome inhibitor, this observation suggests 
































Figure 32: OSU strain treated with different concentration of MG132. A) Schematic representation of the treatment. 
B) Western blot analysis of infected cells treated with different concentration of MG132. Increasing the concentration of 
the drug induce a concomitant decrease on viral protein accumulation, in a inverse proportion way.  
 
We then measured the amount of viral RNA accumulated upon proteasome inhibition 
treatment in the first hours post infection. Cells were infected for one hour, and then 
proteasome inhibitor MG132 (10 µM) was added at one or three hours post infection till 
seven hours. At the end of the treatment, we performed RT-PCR with primers specific for 
gene 11 (that correspond to the NSP5), and the levels of viral RNAs (both mRNA and 
dsRNA), were normalized to the amount present at 1 h.p.i.. In MG132-treated samples, 
the amount of viral RNAs was lower respect to that in the control (DMSO-treated) and is 
comparable to that at the beginning of each treatment (Fig.33). Thus, the impairment of 


























Figure 33: Effect of MG132 on viral RNA. A) Scheme of the experimental procedure. B) Total viral RNAs isolated from 
infected cells after treatment with MG132, were subjected to a real time RT-PCR analysis on NSP5 RNA. The data were 
normalized to the RNA level present at 1 hour post infection. The graphic shows the impaired viral RNA production in the 
present of MG132. Graphs report ±SEM in each column 
 
The direct implication of the reduction of viral protein and RNAs accumulation is the 
impairment of the production of infective viral particles (as described below in paragraph 
6.6, page 111), that correspond to a reduction of viral replication. 
6.3 Proteasome activity is involved in Rotavirus infection 
In order to investigate whether the effect of MG132 on Rotavirus infection was due to 
inhibition of the proteasome activity, we treated infected cells with other proteasome 
inhibitors: Bortezomib, and Epoxomycin.  
Bortezomib (PS341) is a reversible inhibitor of proteasome activity, as MG132, but is 
selective towards the proteasome over common proteases. It was approved by FDA as an 
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more active and generally used at concentrations as low as 100 nM. Epoxomycin belongs 
to the class of irreversible non-aldehydic peptide inhibitors, highly selective and potent with 
a distinct mechanism of action, with respect to MG132 (130). 
Infected cells were treated with different concentration of MG132, Bortezomib, and 
Epoxomycin, after one hour of virus absorption, and the biochemical analysis was 
performed at 7 h.p.i. (Fig.34A). All the proteasome inhibitors tested affected the 
accumulation of viral proteins, while inducing a strong inhibition of the proteasome activity 
as revealed by the accumulation of p53. Among the three inhibitors, MG132 and 
Bortezomib have the stronger effect on virus infection. Already at a concentration of 1 M, 
there was an effect, which was almost complete at 10 M. Epoxomycin showed a reduced 
effect on the amounts of viral proteins at a concentration of 10 M, which was 
nevertheless very effective in inducing accumulation of p53 (Fig 34B). This analysis 




Figure 34: Rotavirus infection depends on proteasome activity. A) Schematic representation of the experimental 
procedure. B) Western blot analysis of extracts of infected cells treated with different concentration (0,1; 1; 10 M) of 
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Since we have excluded that proteasome inhibition affects the phases of virus entry and 
uncoating (Fig.31,32), we performed different kinetic experiments in order to better define 
the time window in which the drug impairs the viral cycle. 
We let the virus infect the cell for one hour, then, after washing with serum free medium, 
the cells were treated or not with MG132 or Bortezomib for 4 hours at different time points 
post infection (Fig.35 A). The western blot analysis performed at the end of the treatments 
confirms that proteasome activity is important for viral proteins production primarly at early 
time points post infection, since its inhibition from the very beginning of infection causes a 
more clear arrest on viral protein accumulation (Fig.35 B). The effect is less evident at 5 hr 
post infection, as evidenced in the experiment of panel C (Fig.35, left panel), suggesting 
that the viral mechanism sensitive to proteasome activity takes place in the first five hours 
of infection. Indeed, when the drug was added at later time points post infection, hour 7 to 
10, the inhibition is almost null. (Fig 35C right blot). 
 
Figure 35: Time-windows treatments with proteasome inhibitors. A) Schematic representation of the kinetic. B),C) 
Western blot analysis of the cell lysates of treated and untreated infected cells as indicated in A). Treatment in the first 
five hours of infection affects virus proteins production. 
 
6.4 Proteasome inhibition affects viroplasms formation 
These results suggest that the effect is stronger in the phase when viroplasms are formed 
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to characterize the effect of proteasome inhibition on viroplasms formation during 
Rotavirus infection. For this purpose, kinetic experiments, were performed using the 
NSP5-EGFP stable cell line (previously described). 
NSP5-EGFP cells were infected for one hour and then, at different times post infection, 
were treated with MG132 or bortezomib at an effective concentration of 10M. At 9 h.p.i 
viroplasm formation was evaluated with confocal microscopy. As shown in figure 36B, 
addition of proteasome inhibitors from 1 to 5 h.p.i induces an arrest on formation of 
viroplasms that appear in reduced number and look smaller, with respect to those in 
untreated cells (DMSO-treated). On the contrary the addition of proteasome inhibitors at 7 
h.p.i did not show any effect on viroplasms which were comparable in number and 
dimension, confirming that the early/middle phases of expansion of viroplasms are the 
ones more susceptible to proteasome inhibition. The immunofluorescence analysis 
confirmed the previous observations, with a strong reduction in the number of viroplasms 
without preventing virus entry or uncoating. Moreover we confirm the observations of the 
previous kinetic analysis, since in treated infected cells the viroplasms appear smaller and 
even less in number with respect to the control cells. 




Figure 36: A) Scheme of the kinetic. B) Immunofluorescence analysis of NSP5-EGFP cell line infected with Rotavirus 3 
M.O.I and treated, or not, with proteasome inhibitors (10 M) at different time pre and post infection. Inhibition of 
proteasome activity induces the formation of small and less numerous viroplasms. 
 
6.5 Proteasome inhibition affects viroplasms growth 
According to these observations, we performed time-windows kinetic as well, to quantify 
the effect of proteasome inhibition on viroplasms formation. 
The quantification was made with an automated microscope able to identify and quantify 
defined structures in the cytoplasm of cells, such as viroplasms upon infection of the 
NSP5-EGFP stable cell line. Initial experiments were performed on untreated cells to 
follow the kinetics of viroplasms accumulation during infection at M.O.I. 3 (as shown in the 
graphic in figure 37).  
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Figure 37: Viroplasms accumulation during viral infection. Viroplasms per cell were quantified during a typical 
Rotaviral infection with an automated high content microscope (as describe in material and methods). Graphs report 
±SEM in each column. 
 
MA104 NSP5EGFP were plated on a 96 multiwell plate, infected  for one hour and, at 
different times post infection, MG132 or Bortezomib, or DMSO as control, were added for 
four hours. Each time windows was performed in triplicates, and the graphic 2 shows the 
mean of the measurements relative to the number of viroplasms per cell obtained with the 
quantification analysis. Treatment with MG132 or Bortezomib affects viroplasms formation 
when added both at the beginning of infection (starting point SP), and at 5 hours of virus 
infection. The number of viroplasms per cells in MG132 or Bortezomib treated cells is 
almost the same to that found in cells fixed at the beginning of each treatment, strongly 
suggesting that inhibition of proteasome activity affects the assembly of new viroplasm and 
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Figure 38: Time-windows treatment of NSP5-EGFP cells. Quantification of viroplasms accumulation within infected 
cells (M.O.I. 3) in a time-windows treatment with MG132 and Bortezomib at 10 M concentration. The graphic shows the 
mean of viroplasms/cell of one exemplificative experiment. Graphs report ±SEM in each column 
 
6.6 Proteasome inhibition affects production of viral particles 
Since inhibition of proteasome activity induces arrest of viral protein synthesis and 
viroplasms growth, we expect a decrease in the production of new viral particles. To 
address this point we analysed the viral progeny from treated or untreated infected cells 
titrating by IF the yield of infective particles produced. Trypsin activated particles were 
used to infect the NSP5-EGFP cell line, at different dilutions. The amount of green cells 
and viroplasms per cells, after seven hours of infection, was determined with the same 
automated microscope. As shown in the graphic of figure 39B, cells treated with 
proteasome inhibitors showed a strong reduction in viral titers. While a reduction of  75% 
of virus was observed when considering the number of cells with viroplasms (Fig 39C), a 
reduction of more than 90% was obtained considering the number of viroplasms per 
cell.(Fig 39B)  














Figure 39: Titration of Rotavirus obtained from treated cells. A) Scheme of experimental procedure. B) Graphics 
show the mean of the viroplasms per cell (left) and of the percentage of cells with viroplasms (right) of NSP5-EGFP cells 
infected (M.O.I. 3) with different amounts of supernatants derived from MA104 infected cells treated or un treated with 
proteasome inhibitors (10µM). Graphs report ±SEM in each column 
 
6.7 Viral proteins expression is not affected by proteasome inhibition 
The effect of proteasome inhibition upon infection could be due to a direct involvement of 
proteasome activity on the expression of viral proteins. Following our studies on NSP5 
and its modifications induced by the interaction with NSP2 and VP2, we investigated if 
these proteins changed their expression when proteasome functionality was impaired. For 
these purpose we transfected the cells with NSP5, NSP2, and VP2 alone or in different 
combinations and then treated with MG132 at high concentration (50 µM) for two hours. 
The Western blot analysis of cell extracts reveals that there is not differences on NSP5, or 
NSP2 or VP2 expression between treated or not treated cells, as it happens for the 
irrelevant transfected protein EGFP (Fig.40). Furthermore, in the presence of MG132, 
NSP5 modifications in the presence of  VP2 or NSP2 do not change. These observations 
suggest that proteasome activity is not directly involved in modulating the expression of 
these proteins that, are fundamental for virus replication (27), (180), (141),. Moreover it is 
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Figure 40: Proteasome inhibition does not affect viral protein expression. Western blot analysis of cells transfected 
with NSP5, NSP2, VP2 alone and in different combinations, in treated or untreated conditions.(MG132 50µM). 
Proteasome inhibition does not arrest viral protein expression. 
 
We also investigated the cytoplasmic distribution of these proteins upon treatment  with 
MG132. As previously described, NSP5 forms VLS in the presence of NSP2 or VP2, thus 
we performed immunofluorescence assays, in NSP5-EGFP cell line, to look at VLS 
formation in cells transfected with these proteins, and  treated or not with the proteasome 
inhibitors. Figure 41 shows that under these conditions, treatment with MG132 does not 
impair VLS formation, either those formed by VP2 (VLS (VP2i)) or by NSP2 (VLS 



























Figure 41: VLS formation is not impaired by proteasome inhibition. Immunofluorescence analysis of NSP5-EGFP 
cells transfected with VP2, or NSP2, or both in the presence of proteasome inhibitor MG132, 50 µM, for 2 hours before 
the cell lysis. VLS formation is not affected when proteasome activity is inhibited. 
 
Together these observations suggest that the effect observed on Rotavirus replication 
upon proteasome inhibition is not due to an effect regulating expression of NSP5, NSP2, 
VP2, nor to their capacity to interact (co-localising in VLS) and to induce NSP5 
hyperphosphorylation. Rather, this indicate that there are essential host factor(s) needed 
to be properly removed through degradation by the proteasome to allow the assembly of 
viroplasms. 
 
6.8 Proteasome inhibition does not impaired viral polymerase activities 
Alternatively, the block in viroplasms formation could be due to a direct, yet improbable, 
effect of the proteasome inhibitors on the viral polymerase activity. 
To test this hypothesis we analysed both the transcriptase and replicase activity of VP1 in 
the presence of MG132. 
Transcriptase activation was performed on purified DLPs which are well-known to have 
only trascriptase (and not replicase) activity when incubated in vitro in appropriate 
conditions. To monitor synthesis of mRNA, DLPs incubations were carried out with [32P]-
DMSO
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UTP, in the presence or not of MG132, and the products precipitated by TCA10% and 
radioactivity counted on a scintillator counter (count per minute, CPM). An additional 
control was conducted incubating DLPs without nucleotide GTP to validate the 
occurrence of transcription. Measurements were performed in triplicate and non treated 
sample was considered as the standard. The CPM mean values relative to the standard 
condition, of four independent experiments are plotted in figure 42. 
The results clearly indicate that VP1 transcriptase activity was totally unaffected by 
MG132; suggesting that the effect in vivo on virus replication is not due to a direct 
inhibition of trascription. 
 
 
Figure 42: In vitro transcription assay. Graphic of the mean of four different in vitro transcription assays. Non treated 
(NT) condition is considered as the standard, treated conditions (DMSO, MG132) measurements are relative to NT, -gtp 
is the control of the transcription assays. Graphs report ±SEM in each column 
 
To test the replicase activity we performed in vivo labeling in cell infected for five hours 
and then incubated with 32P with or without MG132 for one hour. At five hours post 
infection the VP1 replicase activity is quite high, and therefore the addition of the 
proteasome inhibitor (in this case MG132) at this phase would reveal if it directly affects 
the VP1 polymerase activity. The level of replication was visualized by purification of viral 
dsRNA and analysed by PAGE as shown in figure 43. These preliminary results suggest 
that also the activity of the polymerase is not compromised by inhibition of the 
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Figure 43: Replicase activity assay. A) Scheme of the experimental procedure. B) SDS-PAGE of radiolabeled dsRNA 
from treated and untreated infected cells. Treatment with proteasome inhibitor does not impaired viral dsRNA production 
of the VP1 polymerase. 
 
6.9 Viral infection affected by proteasome inhibitor is not due to IRF3 
amounts 
As already described in the introduction(1) (page 32), NSP1 is involved in the evasion of 
cellular antiviral response, by inducing the proteasomal degradation of IRF3 and, in this 
way, preventing the activation of interferon- response (13). Moreover, according  to 
recent observations, IRF3 disactivation by Rotavirus NSP1 is dependent on both 
Rotavirus strain and host cell (177). In particular, the porcine Rotavirus strain OSU does 
not induce the degradation of IRF3, whereas the SA11 strain does induce proteasome-
mediated degradation of IRF3 (177),(13). To investigate if the effect of MG132 on viral 
proteins was related to the accumulation of IRF3, due to the proteasome inhibition, we 
performed Western blot analysis of extracts of non infected and infected cells with both 
OSU and SA11 Rotavirus strains, treated or not with MG132. By biochemical analysis we 
confirmed that OSU strain does not induce degradation of IRF3, and that the effect of 
proteasome inhibition shown on viral protein expression is independent of IRF3 amount ( 
lane 1 and 2 fig.44). On the contrary, SA11 causes an almost complete degradation of 
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these data support the hypothesis that, even if from the last observation we cannot 
exclude that, in SA11 strain, it is the little amount of IRF3 that affects viral protein 
accumulation, the accumulation of IRF3 is not related to the decreased amount of viral 
proteins observed in the presence of MG132. This is further supported by the evidence 
that in OSU strain where IRF3 amount does not change, the effect of MG132 on viral 
protein accumulation is stronger.  Basal IRF3 expression itself is not affected by the 
inhibition of the proteasome as it is shown in non infected cells (fig.44 lane 5, 6). 
 
 
Figure 44: IRF3 amount is not related to inhibition of infection. A) Scheme of the experimental procedure. B) 
Western blot analysis of exctrats of infected cells treated or not with MG132 (10µM). IRF3 is degraded upon infection 
with SA11, but not with OSU strain, however the amount of viral protein is strong affected in both cases.
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7 DISCUSSION (2) 
 
Proteasomal degradation is involved in different cellular functions like transcription factor 
regulation, gene expression, cell differentiation, regulation of the newly synthesized 
proteins (ERAD), cell cycle regulation, immune response. In particular, it is the central 
machinery for the production of peptides to load on the MHC class I molecules for the 
antigen presentation. Viral proteins, as well as misfolded ones, are ubiquitinated, 
processed by proteasome, and the obtained peptides are presented on cell surface 
through MHC class I, in order to induce the cytotoxic T lymphocytes activation, that start 
the elimination of the infected cells (93),(80). 
Viruses have been shown to manipulate the ubiquitin-proteasome pathway at different 
stages of the virus life-cycle, to enhance viral activities and to escape the viral cellular 
response. For example, influenza virus has been shown to utilize the UPS for efficient 
trafficking to the late endosome/lysosome stages of virus entry  (99), mouse hepatitis virus 
(a coronavirus) or minute virus (a parvovirus) have been shown to use the proteasome 
machinery for their trafficking in the cytoplasm (212) or to the nucleus, (167) respectively. 
Retroviruses, like HIV, need a functional UPS for the release of mature viral particles. 
Indeed, this process involves ubiquitylation of some components of the complex that drive 
the exit of the virus from the cells, and an alteration of the store of free ubiquitin, induced 
by proteasome inhibition, prevents the budding of the virus (176),(86). Multiple members of 
the Herpesviridae family have developed different strategies to manipulate UPS, encoding 
ubiquitin ligase like proteins (39), or targeting to degradation specific host proteins (39), 
(161), (100).  
In this work we characterized the effect of proteasome inhibition on Rotavirus infection. 
Indeed, we observed that the inhibition of proteasome activity, induced mainly with two 
different proteasome inhibitors (MG132 and Bortezomib), affects Rotavirus replication, 
indicating that functional proteasome is needed during its replicative cycle.  
We first observed a decrease in the amount of both structural and non-structural viral 
proteins accumulated in virus infected cells in the presence of the MG132 inhibitor (fig.29) 
and this effect is also evident when the inhibitor is added at 3 hours post infection (fig.30). 
Moreover, the effect is appreciable in two different Rotavirus strains, a porcine OSU and a 
simian SA11 strain, in particular OSU strain results more sensitive to proteasome inhibition 
respect to the SA11, using comparable M.O.I. (Fig.31). This first indications suggest that 
 _________________________________________________________________ Discussion (2) 
119 
 
entry and uncoating of the virus were not the steps affected by proteasome inhibition. The 
timing of the Rotavirus life cycle is not well established, however, the processes of virus 
entry and uncoating likely occur in the first hour of infection (97). Thus the treatment of 
infected cells with MG132 performed one hour after the absorption of the virus on the cells 
would discriminate these first steps from the other later viral processes (transcription, 
replication, morphogenesis) (Fig.32A). Indeed, after one hour the viral particles have 
already entered the cell, and uncoated DLPs are producing mRNAs. Addition of MG132 
one hours post viral absorption still affects viral proteins production, confirming the 
hypothesis that the entry and uncoating of virus are not the processes impaired by 
proteasome inhibition (Fig.32B). Moreover, the addition of MG132 till 5 hours post 
infection, cause a moderate/appreciable decrease on the amount of viral proteins, 
whereas the treatment at later time point post infection, from 7 h.p.i. until 10, does not 
affect viral protein accumulation at all (Fig.35C). Therefore, a functional proteasome 
machinery is needed principally in the early phases of virus infection in order to allow 
Rotavirus replication into the host cells. 
The inhibition observed in the accumulation of viral proteins amount was dependent on the 
concentration of the drugs used, this is clearly demonstrated in figure 32, where increasing 
MG132 concentrations corresponded to an almost proportional decrease in viral proteins, 
visible in NSP5 profile (Fig.32B). But it is also evident when other different proteasome 
inhibitors at different concentrations were used (Fig.34). MG132, Bortezomib and 
Epoxomycin induce accumulation of p53 protein, demonstrating the effective inhibition of 
the proteasome activity, furthermore they inhibit viral protein production, strongly 
confirming the necessity of a functional proteasome during viral infection.  
The impaired viral proteins production is probably due to the concomitant impairment of 
viral RNA accumulation. RT-PCR analysis revealed that the amount of total viral RNAs 
(both mRNA and dsRNA) decreases upon treatment with MG132 at different hour post 
infection (Fig 33). However, with this technique it was not possible to discriminate the viral 
transcribed RNA (mRNA), that is continuously produced from newly synthesized DLPs and 
is source for viral proteins, from the replicated RNA (dsRNA); but, in addition to the 
previous observations, it gives indications that different viral functions are compromised 
when proteasome activity is impaired.  
An important characteristic in Rotavirus infection is the formation of viroplasms, that, as 
previously described, are cytoplasmic structures where viral replication and new DLPs 
assembly occur. Proteasome inhibition causes a reduction on viroplasms formation, as 
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well. Immunofluorescence analysis revealed that the addition of proteasome inhibitors 
from 1 till 5 hours post infection induced a decrease in viroplasms formation and their 
growth. On the contrary when the drugs were added at 7 hours post infection this effect 
was not any longer appreciable, in agreement with the observations of the biochemical 
analysis (Fig.36). The quantification analysis of this reduction was performed with an 
automated microscope, and confirms the decreased number of viroplasms per cell upon 
inhibition of proteasome. In particular the number of viroplasms measured at the beginning 
of the treatment with proteasome inhibitors is very similar to that find at the end, 
suggesting that the process of viroplasms formation is like frozen at the moment of drug 
addition and the early phase of viroplasms assembly is more susceptible to proteasome 
inhibition, as expected from the previous biochemical analysis (Fig.38). Since the 
mechanism of viroplasm formation are still obscure, even their composition and function 
have been differently characterized (55), (56),(60),(127),(180),(178), and the involvement 
of cellular components within viroplasm are under investigation, we can propose, 
according to these observations, that proteasome regulate the early step of viroplasms 
formation and growth, controlling either viral or cellular mechanisms.  
The final consequence of the proteasome inhibition is the reduction of viral particles 
production. Indeed, the treatment from 1 till 7 hour post infection allowed the recovery of 
particles that are yet functional and infective, following activation with trypsin; however the 
yield was extremely reduced since, when cells were infected with these particles for 7 
hours, only the 25% of infected cells presented viroplasms. Moreover, the amount of 
viroplasms per cells is very low and the reduction is quantified at around the 90% 
compared to the control cells (Fig 39).  
The transient expression, alone and in different combinations, of viral proteins like NSP5, 
NSP2, VP2, that have been demonstrated to be essential for viral replication 
(180),(27),(141), seemed not to be affected by proteasome inhibitor treatment (Fig.40). 
Moreover, the NSP5 profile of hyperphosphorylation induced by NSP2 or VP2 does not 
change in the presence of MG132. Nevertheless, this is only a first indication since, due to 
technical problems, the treatment was performed in a short time window, 2h, and the effect 
of proteasome inhibition, evaluated with the accumulation of p53, is not easily appreciated 
in treated sample. Further experiments are underway to improve proteasome inhibition 
and to investigate what happen to the viral proteins expression.  
As described in the first part of this thesis, transient expression of NSP5 with NSP2 or 
VP2, induces the formation of VLS in the cytosol. The structural changes and the 
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interactions that permit the formation of VLS are still under investigation, however VLS 
formation seems not to be affected by proteasome inhibition (for this assay it was possible 
to peformed the treatment 4h after the transfection, for 2h, and any differences in VLS 
formation were appreciated, not shown), first indicating that this event does not depend on 
proteasome activity, as well (Fig.41). Furthermore, the co-localization of viral proteins into 
VLS was not altered, suggesting that the interactions that allow VLS formation, take place 
even when the proteasome is inhibited. 
Since VLS are considered the model that better resembles viroplasms, the different 
sensitivity of these two structures to the proteasome inhibition would suggest that the 
similarity between them is mainly structural. Therefore, these observations would 
confirmed our previous hypothesis that, during infection, an unidentified host/viral 
mechanism/factor (different from NSP5, NSP2, VP2) rather-dependent on proteasome 
activity, is needed in order to maintain viroplasms function and growth and consequently 
viral replication; moreover the same factor is not activated by induction on VLS formation 
probably due to the lack of other different viral components. However, functional assays 
with VLS, containing also VP1 VP6 and VP3, and viral mRNAs are underway and would 
eventually lead to a better functional characterization of VLS. 
The improbable direct effect of the inhibitors on polymerase activities has also been 
investigated. The trascriptase activity was measured by counting the radiolabeled viral 
mRNA transcribed in vitro from DLPs in the presence or not of MG132. The 
measurements of the radioactivity incorporated into mRNA reveal that, there is no 
differences in mRNA amount produced in treated and untreated samples, further, no 
transcription was observed in the absence of GTP nucleotide, confirming that the 
transcription event is taking place and validating the result obtained (Fig.42). The replicase 
activity was tested in vivo when it reaches the maximal level between 5 and 9 hours post 
infection (184), through labeling of dsRNA with a pulse of radioactive inorganic phosphate 
32P. Treatment with MG132 was performed at 5 hour post infection, for one hour in order to 
limit its effect upon the whole infection and possibly concentrated it on viral replicase 
activity. Preliminary result, shown in figure 43, suggests that the replicase activity of VP1 is 
not impaired by proteasome inhibitor treatment, as well. These experiments exclude the 
possibility of a direct effect of the drug used on viral polymerase activity, and direct the 
research towards the cellular of viral mechanism that take place during the infection. 
Rotavirus NSP1 has been demonstrated to be related to the UPS, since experimental data 
and sequence analysis identified a variant of a RING finger motif, similar to E3 ligase, 
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suggesting a putative function for NSP1 as an E3 ligase. Indeed, NSP1 is able to promote 
its self-ubiquitinylation and moreover to induce the degradation of different members of 
IRF family, IRF3, IRF5, IRF7, preventing the activation of IFN, proinflammatory cytokine, 
and IFN genes, respectively (13, 14). Therefore, like many other viruses, Rotavirus 
manipulates the proteasome machinery to create an opportune environment for its 
replication.  
According to these observations, inhibition of proteasome activity during infection would 
cause an accumulation of IRF3 factor with a consequent enhanced IFN- response that 
may be responsible of the affected viral infection. Thus, the accumulation of IRF3 has 
been investigated, to understand if this was the case. The regulation of IRF3 amount 
through proteasome degradation is virus-strain specific (177). For this reason the analysis 
has been performed with two different Rotavirus strains. 
Upon infection with SA11 strain, IRF3 factor is strongly degraded, and when infected cells 
are treated with proteasome inhibitor, a very low rescue of this factor was observed, and a 
strong effect on viral protein production is still visible (Fig.44 lanes 1,2). It is possible that 
the little amount of IRF3 rescued with MG132 treatment causes a reduction of viral protein 
accumulation, possibly through IFN activation. However, the amount of IFN has not 
been measured and we do not know if at 7 h.p.i, when we performed the analysis, critical 
amounts of IFN are produced that affect viral infection. Evidences of a high gene 
expression induced by IFN production upon Rotavirus infection has been provided by 
Barro et al. (13) in FRhL2 cells at 10 h.p.i.; however there are not indications to what 
happens at 7 h.p.i in MA104 cells. 
Infection with OSU strain does not induce IRF3 degradation, as already demonstrated 
(69). When the proteasome is inhibited, despite there is not further accumulation of IRF3, 
the effect on viral proteins amount is even stronger respect to SA11 (Fig.44 lane 3,4). All 
together these observations suggest that cytosolic amount IRF3 upon inhibition of 
proteasome activity is not related to the impairment of Rotaviral infection Moreover, it has 
been recently observed that OSU strain mediates the proteasome degradation of cellular 
factors involved in NFB activation (68). Thus, it would be important for this strain to 
investigate if impairment of its replication by proteasome inhibition is related to NFB 
activation. 
NSP1 regulates its own stability through proteasome-mediated degradation, however we 
could not analyse the amount of this protein due to the lack of a specific NSP1 Ab. It has 
been demonstrated that NSP1 is not fundamental for Rotavirus infection, since infected 
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cells treated with an siRNA specific for NSP1 actively support virus replication (180). 
However, it cannot be ruled out that an accumulation of NSP1 induced by proteasome 
inhibition interferes with viral infection. Moreover its putative E3 ligase activity would be 
altered, when proteasome is impaired, affecting and destabilizing virus replication. 
The inhibition of viral infection induced by the treatment with proteasome inhibitors has 
been recently described for other dsRNA viruses like ARV (avian reovirus) (36), and IBDV 
(infectious bursal desease virus) (113). Even for these viruses, inhibition of the 
proteasome causes a decrease in viral proteins amount, a reduction in viral progeny 
production, and a diminished viral transcription. Moreover, in both cases this inhibitory 
effect is evident at early phases of the infection, suggesting that the UPS is involved in the 
early steps of viral replication. However, the mechanisms involve in the reduced viruses 
replication through proteasome inhibition has not been characterized either for ARV or 
IBDV. 
The observations collected for Rotavirus are in line with those of ARV and IBDV, 
suggesting that, in dsRNA virus infection, there are common mechanisms, that cause the 
impairment of infections followed by proteasome inhibitors, most likely related to alteration 
of UPS, or of cellular processes involving key host factors dependent on proteasome 
activity, rather than to the functions of viral proteins. 
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